(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 26 June 2003 (26.06.2003)

PCT

(10) International Publication Number WO 03/051912 A2

(51) International Patent Classification7:

C07K 14/18

(21) International Application Number: PCT/EP02/14480

(22) International Filing Date:

18 December 2002 (18.12.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10/020,510 60/418,358 18 December 2001 (18.12.2001) US 16 October 2002 (16.10.2002) US

(71) Applicant (for all designated States except US): INNO-GENETICS N.V. [BE/BE]; Technologiepark 6, B-9052 Ghent (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MAERTENS, Geert [BE/BE]; Zilversparrenstraat 64, B-8310 Brugge (BE). DEPLA, Erik [BE/BE]; Burgstraat 58, B-9070 Destelbergen (BE). BOSMAN, Fons [BE/BE]; Hulst 165, B-1745 Opwijk (BE).

(74) Common Representative: INNOGENETICS N.V.; Intellectual Property Department, Industriepark Zwijnaarde 7, Box 4, B-9052 Ghent (BE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE

(57) Abstract: The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.

WO 03/051912

PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE

Field of the invention

5

10

15

20

25

30

The present invention relates to the general fields of recombinant protein expression, purification of recombinant proteins, synthetic peptides, diagnosis of HCV infection, prophylactic treatment against HCV infection and to the prognosis/monitoring of the clinical efficiency of treatment of an individual with chronic hepatitis, or the prognosis/monitoring of natural disease.

More particularly, the present invention relates to purification methods for hepatitis C virus envelope proteins, the use in diagnosis, prophylaxis or therapy of HCV envelope proteins purified according to the methods described in the present invention, the use of single or specific oligomeric E1 and/or E2 and/or E1/E2 envelope proteins in assays for monitoring disease, and/or diagnosis of disease, and/or treatment of disease. The invention also relates to epitopes of the E1 and/or E2 envelope proteins and monoclonal antibodies thereto, as well their use in diagnosis, prophylaxis or treatment.

Background of the invention

The E2 protein purified from cell lysates according to the methods described in the present invention reacts with approximately 95% of patient sera. This reactivity is similar to the reactivity obtained with E2 secreted from CHO cells (Spaete et al., 1992). However, the intracellularly expressed form of E2 may more closely resemble the native viral envelope protein because it contains high mannose carbohydrate motifs, whereas the E2 protein secreted from CHO cells is further modified with galactose and sialic acid sugar moieties. When the aminoterminal half of E2 is expressed in the baculovirus system, only about 13 to 21% of sera from several patient groups can be detected (Inoue et al., 1992). After expression of E2 from E. coli, the reactivity of HCV sera was even lower and ranged from 14 (Yokosuka et al., 1992) to 17% (Mita et al., 1992). About 75% of HCV sera (and 95% of chronic patients) are anti-E1 positive using the purified, vaccinia-expressed recombinant E1 protein of the present invention, in sharp contrast with the results of Kohara et al. (1992) and Hsu et al. (1993). Kohara et al. used a vaccinia-virus expressed E1 protein and detected anti-E1 antibodies in 7 to 23% of patients, while Hsu et al. only detected 14/50 (28%) sera using baculovirus-expressed E1.

10

15

20

25

30

These results show that not only a good expression system but also a good purification protocol are required to reach a high reactivity of the envelope proteins with human patient sera. This can be obtained using the proper expression system and/or purification protocols of the present invention which guarantee the conservation of the natural folding of the protein and the purification protocols of the present invention which guarantee the elimination of contaminating proteins and which preserve the conformation, and thus the reactivity of the HCV envelope proteins. The amounts of purified HCV envelope protein needed for diagnostic screening assays are in the range of grams per year. For vaccine purposes, even higher amounts of envelope protein would be needed. Therefore, the vaccinia virus system may be used for selecting the best expression constructs and for limited upscaling, and large-scale expression and purification of single or specific oligomeric envelope proteins containing high-mannose carbohydrates may be achieved when expressed from several yeast strains. In the case of hepatitis B for example, manufacturing of HBsAg from mammalian cells was much more costly compared with yeast-derived hepatitis B vaccines.

Clinical importance of necro-inflammation and fibrosis in HCV infection.

The natural history of liver disease after HCV infection does vary significantly from patient to patient. About 20% of the acutely infected persons are able to resolve infection spontaneously, while 80% of infected persons progresses to a chronic infection. Chronic infection results in an ongoing inflammation and/or necrosis (=necro-inflammation) in the liver which can be diagnosed by histological analysis of a liver biopsy or which can be diagnosed using a surrogate marker such as the presence of the liver enzyme ALT in serum. This chronic infection increases the risk for development of fibrosis which can lead to development of cirrhosis and ultimately liver carcinoma. Many data suggest that the ongoing necro-inflammation drives progression to fibrosis and cirrhosis. It is estimated that up to 20% of HCV chronic carriers may develop cirrhosis over a time period of about 20 years and that of those with cirrhosis between 1 to 4%/year is at risk to develop liver carcinoma. (Lauer and Walker 2001, Shiffman 1999). Both cirrhosis and liver carcinoma are end-stage liver diseases for which the treatment options are limited to liver transplantation. Consequently, the most important aim of therapy for HCV is to reduce the risk of development of end-stage liver disease by reducing liver necro-inflammation and/or reducing fibrosis progression.

For the documentation and/or diagnosis of liver damage several scoring systems have been

developed for histological interpretation of a liver biopsy. These scoring systems may combine inflammation, necrosis and fibrosis in a single score such as the Histology Activity Index (HAI). Other scoring systems have separated the scores for necro-inflammation (=grading) from the one for fibrosis/cirrhosis (=staging). These systems include the system proposed by Ishak or the Metavir scoring system. A review of these scoring systems was published by Lefkowitch in 1997.

PCT/EP02/14480

It has been shown in several studies that treatment with interferon, and more recently treatment with interferon combined with ribavirin and most recently treatment with pegylated interferon with or without ribavirin does change the natural history of HCV and halts further progression of liver fibrosis especially in those patients with a sustained viral response (Schvarcz et al. 1999, Shiffman 1999, Reichard et al. 1999, Poynard et al. 2002). The reduction of the risk for hepatocarcinogenesis in persons with sustained virological and even with sustained biochemical response has also been documented (Takimoto et al. 2002).

For persons without sustained virological response to interferon based therapy a maintenance interferon therapy may be helpful to prevent histological progression, but this only in a subset of patients (Alric et al. 2001).

Thus, many patients who do not respond to interferon based therapies or who are excluded from these therapies for several reasons (this may mount up to 70% of patients referred to clinic, Falck-Ytter et al. 2002), remain without a therapeutic option today to reduce liver necro-inflammation and/or reduce the progression of fibrosis in order to avoid end-stage liver disease.

Aims of the invention

5

10

15

20

25

30

It is an aim of the present invention to provide a new purification method for recombinantly expressed E1 and/or E2 and/or E1/E2 proteins such that said recombinant proteins are directly usable for diagnostic and vaccine purposes as single or specific oligomeric recombinant proteins free from contaminants instead of aggregates.

It is another aim of the present invention to provide compositions comprising purified (single or specific oligomeric) recombinant E1 and/or E2 and/or E1/E2 glycoproteins comprising conformational epitopes from the E1 and/or E2 domains of HCV.

It is yet another aim of the present invention to provide novel recombinant vector constructs for recombinantly expressing E1 and/or E2 and/or E1/E2 proteins, as well as host cells transformed with said vector constructs.

10

15

20

25

30

It is also an aim of the present invention to provide a method for producing and purifying recombinant HCV E1 and/or E2 and/or E1/E2 proteins.

It is also an aim of the present invention to provide diagnostic and immunogenic uses of the recombinant HCV E1 and/or E2 and/or E1/E2 proteins of the present invention, as well as to provide kits for diagnostic use, vaccines or therapeutics comprising any of the recombinant HCV E1 and/or E2 and/or E1/E2 proteins of the present invention.

It is further an aim of the present invention to provide for a new use of E1, E2, and/or E1/E2 proteins, or suitable parts thereof, for monitoring/prognosing the response to treatment of patients (e.g. with interferon) suffering from HCV infection.

It is also an aim of the present invention to provide for the use of the recombinant E1, E2, and/or E1/E2 proteins of the present invention in HCV screening and confirmatory antibody tests.

It is also an aim of the present invention to provide E1 and/or E2 peptides which can be used for diagnosis of HCV infection and for raising antibodies. Such peptides may also be used to isolate human monoclonal antibodies.

It is also an aim of the present invention to provide monoclonal antibodies, more particularly human monoclonal antibodies or mouse monoclonal antibodies which are humanized, which react specifically with E1 and/or E2 epitopes, either comprised in peptides or conformational epitopes comprised in recombinant proteins.

It is also an aim of the present invention to provide possible uses of anti-E1 or anti-E2 monoclonal antibodies for HCV antigen detection or for therapy of chronic HCV infection.

It is also an aim of the present invention to provide kits for monitoring/prognosing the response to treatment (e.g. with interferon) of patients suffering from HCV infection or monitoring/prognosing the outcome of the disease.

All the aims of the present invention are considered to have been met by the embodiments as set out below.

Definitions

The following definitions serve to illustrate the different terms and expressions used in the present invention.

The term 'hepatitis C virus single envelope protein' refers to a polypeptide or an analogue thereof (e.g. mimotopes) comprising an amino acid sequence (and/or amino acid analogues) defining at least one HCV epitope of either the E1 or the E2 region. These single

10

15

20

25

30

envelope proteins in the broad sense of the word may be both monomeric or homooligomeric forms of recombinantly expressed envelope proteins. Typically, the sequences defining the epitope correspond to the amino acid sequence of either the E1 or the E2 region of HCV (either identically or via substitution of analogues of the native amino acid residue that do not destroy the epitope). In general, the epitope-defining sequence will be 3 or more amino acids in length, more typically, 5 or more amino acids in length, more typically 8 or more amino acids in length, and even more typically 10 or more amino acids in length. With respect to conformational epitopes, the length of the epitope-defining sequence can be subject to wide variations, since it is believed that these epitopes are formed by the three-dimensional shape of the antigen (e.g. folding). Thus, the amino acids defining the epitope can be relatively few in number, but widely dispersed along the length of the molecule being brought into the correct epitope conformation via folding. The portions of the antigen between the residues defining the epitope may not be critical to the conformational structure of the epitope. For example, deletion or substitution of these intervening sequences may not affect the conformational epitope provided sequences critical to epitope conformation are maintained (e.g. cysteines involved in disulfide bonding, glycosylation sites, etc.). A conformational epitope may also be formed by 2 or more essential regions of subunits of a homooligomer or heterooligomer.

The HCV antigens of the present invention comprise conformational epitopes from the E1 and/or E2 (envelope) domains of HCV. The E1 domain, which is believed to correspond to the viral envelope protein, is currently estimated to span amino acids 192-383 of the HCV polyprotein (Hijikata et al., 1991). Upon expression in a mammalian system (glycosylated), it is believed to have an approximate molecular weight of 35 kDa as determined via SDS-PAGE. The E2 protein, previously called NS1, is believed to span amino acids 384-809 or 384-746 (Grakoui et al., 1993) of the HCV polyprotein and to also be an envelope protein. Upon expression in a vaccinia system (glycosylated), it is believed to have an apparent gel molecular weight of about 72 kDa. It is understood that these protein endpoints are approximations (e.g. the carboxy terminal end of E2 could lie somewhere in the 730-820 amino acid region, e.g. ending at amino acid 730, 735, 740, 742, 744, 745, preferably 746, 747, 748, 750, 760, 770, 780, 790, 800, 809, 810, 820). The E2 protein may also be expressed together with the E1, P7 (aa 747-809), NS2 (aa 810-1026), NS4A (aa 1658-1711) or NS4B (aa 1712-1972). Expression together with these other HCV proteins may be important for obtaining the correct protein folding.

It is also understood that the isolates used in the examples section of the present invention were not intended to limit the scope of the invention and that any HCV isolate from type 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or any other new genotype of HCV is a suitable source of E1 and/or E2 sequence for the practice of the present invention.

5

10

15

20

25

30

The E1 and E2 antigens used in the present invention may be full-length viral proteins, substantially full-length versions thereof, or functional fragments thereof (e.g. fragments which are not missing sequence essential to the formation or retention of an epitope). Furthermore, the HCV antigens of the present invention can also include other sequences that do not block or prevent the formation of the conformational epitope of interest. The presence or absence of a conformational epitope can be readily determined though screening the antigen of interest with an antibody (polyclonal serum or monoclonal to the conformational epitope) and comparing its reactivity to that of a denatured version of the antigen which retains only linear epitopes (if any). In such screening using polyclonal antibodies, it may be advantageous to adsorb the polyclonal serum first with the denatured antigen and see if it retains antibodies to the antigen of interest.

The HCV antigens of the present invention can be made by any recombinant method that provides the epitope of intrest. For example, recombinant intracellular expression in mammalian or insect cells is a preferred method to provide glycosylated E1 and/or E2 antigens in 'native' conformation as is the case for the natural HCV antigens. Yeast cells and mutant yeast strains (e.g. mnn 9 mutant (Kniskern et al., 1994) or glycosylation mutants derived by means of vanadate resistence selection (Ballou et al., 1991)) may be ideally suited for production of secreted high-mannose-type sugars; whereas proteins secreted from mammalian cells may contain modifications including galactose or sialic acids which may be undesirable for certain diagnostic or vaccine applications. However, it may also be possible and sufficient for certain applications, as it is known for proteins, to express the antigen in other recombinant hosts (such as *E. coli*) and renature the protein after recovery.

The term 'fusion polypeptide' intends a polypeptide in which the HCV antigen(s) are part of a single continuous chain of amino acids, which chain does not occur in nature. The HCV antigens may be connected directly to each other by peptide bonds or be separated by intervening amino acid sequences. The fusion polypeptides may also contain amino acid sequences exogenous to HCV.

The term 'solid phase' intends a solid body to which the individual HCV antigens or the fusion polypeptide comprised of HCV antigens are bound covalently or by noncovalent means such as hydrophobic adsorption.

5

10

15

20

25

30

The term 'biological sample' intends a fluid or tissue of a mammalian individual (e.g. an anthropoid, a human) that commonly contains antibodies produced by the individual, more particularly antibodies against HCV. The fluid or tissue may also contain HCV antigen. Such components are known in the art and include, without limitation, blood, plasma, serum, urine, spinal fluid, lymph fluid, secretions of the respiratory, intestinal or genitourinary tracts, tears, saliva, milk, white blood cells and myelomas. Body components include biological liquids. The term 'biological liquid' refers to a fluid obtained from an organism. Some biological fluids are used as a source of other products, such as clotting factors (e.g. Factor VIII;C), serum albumin, growth hormone and the like. In such cases, it is important that the source of biological fluid be free of contamination by virus such as HCV.

The term 'immunologically reactive' means that the antigen in question will react specifically with anti-HCV antibodies present in a body component from an HCV infected individual.

The term 'immune complex' intends the combination formed when an antibody binds to an epitope on an antigen.

'E1' as used herein refers to a protein or polypeptide expressed within the first 400 amino acids of an HCV polyprotein, sometimes referred to as the E, ENV or S protein. In its natural form it is a 35 kDa glycoprotein which is found in strong association with membranes. In most natural HCV strains, the E1 protein is encoded in the viral polyprotein following the C (core) protein. The E1 protein extends from approximately amino acid (aa) 192 to about aa 383 of the full-length polyprotein.

The term 'E1' as used herein also includes analogs and truncated forms that are immunologically cross-reactive with natural E1, and includes E1 proteins of genotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or any other newly identified HCV type or subtype.

'E2' as used herein refers to a protein or polypeptide expressed within the first 900 amino acids of an HCV polyprotein, sometimes referred to as the NS1 protein. In its natural form it is a 72 kDa glycoprotein that is found in strong association with membranes. In most natural HCV strains, the E2 protein is encoded in the viral polyprotein following the E1 protein. The E2 protein extends from approximately amino acid position 384 to amino acid position 746, another form of E2 extends to amino acid position 809. The term 'E2' as used herein also includes analogs and truncated forms that are immunologically cross-reactive with natural E2. For example, insertions of multiple codons between codon 383 and 384, as

well as deletions of amino acids 384-387 have been reported by Kato et al. (1992).

5

10

15

20

25

30

'E1/E2' as used herein refers to an oligomeric form of envelope proteins containing at least one E1 component and at least one E2 component.

The term 'specific oligomeric' E1 and/or E2 and/or E1/E2 envelope proteins refers to all possible oligomeric forms of recombinantly expressed E1 and/or E2 envelope proteins which are not aggregates. E1 and/or E2 specific oligomeric envelope proteins are also referred to as homo-oligomeric E1 or E2 envelope proteins (see below).

The term 'single or specific oligomeric' E1 and/or E2 and/or E1/E2 envelope proteins refers to single monomeric E1 or E2 proteins (single in the strict sense of the word) as well as specific oligomeric E1 and/or E2 and/or E1/E2 recombinantly expressed proteins. These single or specific oligomeric envelope proteins according to the present invention can be further defined by the following formula $(E1)_x(E2)_y$ wherein x can be a number between 0 and 100, and y can be a number between o and 100, provided that x and y are not both 0. With x=1 and y=0 said envelope proteins include monomeric E1.

The term 'homo-oligomer' as used herein refers to a complex of E1 and/or E2 containing more than one E1 or E2 monomer, e.g. E1/E1 dimers, E1/E1/E1 trimers or E1/E1/E1/E1 tetramers and E2/E2 dimers, E2/E2/E2 trimers or E2/E2/E2/E2 tetramers, E1 pentamers and hexamers, E2 pentamers and hexamers or any higher-order homo-oligomers of E1 or E2 are all 'homo-oligomers' within the scope of this definition. The oligomers may contain one, two, or several different monomers of E1 or E2 obtained from different types or subtypes of hepatitis C virus including for example those described in an international application published under WO 94/25601 and European application No. 94870166.9 both by the present applicants. Such mixed oligomers are still homo-oligomers within the scope of this invention, and may allow more universal diagnosis, prophylaxis or treatment of HCV.

The term 'purified' as applied to proteins herein refers to a composition wherein the desired protein comprises at least 35% of the total protein component in the composition. The desired protein preferably comprises at least 40%, more preferably at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, even more preferably at least about 80%, even more preferably at least about 90%, and most preferably at least about 95% of the total protein component. The composition may contain other compounds such as carbohydrates, salts, lipids, solvents, and the like, withouth affecting the determination of the percentage purity as used herein. An 'isolated' HCV protein intends an HCV protein composition that is at least 35% pure.

10

15

20

25

30

The term 'essentially purified proteins' refers to proteins purified such that they can be used for in vitro diagnostic methods and as a therapeutic compound. These proteins are substantially free from cellular proteins, vector-derived proteins or other HCV viral components. Usually these proteins are purified to homogeneity (at least 80% pure, preferably, 90%, more preferably 95%, more preferably 97%, more preferably 98%, more preferably 99%, even more preferably 99.5%, and most preferably the contaminating proteins should be undetectable by conventional methods like SDS-PAGE and silver staining.

The term 'recombinantly expressed' used within the context of the present invention refers to the fact that the proteins of the present invention are produced by recombinant expression methods be it in prokaryotes, or lower or higher eukaryotes as discussed in detail below.

The term 'lower eukaryote' refers to host cells such as yeast, fungi and the like. Lower eukaryotes are generally (but not necessarily) unicellular. Preferred lower eukaryotes are yeasts, particularly species within Saccharomyces, Schizosaccharomyces, Kluyveromyces, Pichia (e.g. Pichia pastoris), Hansenula (e.g. Hansenula polymorpha), Yarowia, Schwaniomyces, Schizosaccharomyces, Zygosaccharomyces and the like. Saccharomyces cerevisiae, S. carlsbergensis and K. lactis are the most commonly used yeast hosts, and are convenient fungal hosts.

The term 'prokaryotes' refers to hosts such as *E. coli*, *Lactobacillus*, *Lactococcus*, *Salmonella*, *Streptococcus*, *Bacillus subtilis* or *Streptomyces*. Also these hosts are contemplated within the present invention.

The term 'higher eukaryote' refers to host cells derived from higher animals, such as mammals, reptiles, insects, and the like. Presently preferred higher eukaryote host cells are derived from Chinese hamster (e.g. CHO), monkey (e.g. COS and Vero cells), baby hamster kidney (BHK), pig kidney (PK15), rabbit kidney 13 cells (RK13), the human osteosarcoma cell line 143 B, the human cell line HeLa and human hepatoma cell lines like Hep G2, and insect cell lines (e.g. *Spodoptera frugiperda*). The host cells may be provided in suspension or flask cultures, tissue cultures, organ cultures and the like. Alternatively the host cells may also be transgenic animals.

The term 'polypeptide' refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations

10

15

20

25

30

10

and the like. Included within the definition are, for example, polypeptides containing one or more analogues of an amino acid (including, for example, unnatural amino acids, PNA, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

The term 'recombinant polynucleotide or nucleic acid' intends a polynucleotide or nucleic acid of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, or (3) does not occur in nature.

The term 'recombinant host cells', 'host cells', 'cells', 'cell lines', 'cell cultures', and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refer to cells which can be or have been, used as recipients for a recombinant vector or other transfer polynucleotide, and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.

The term 'replicon' is any genetic element, e.g., a plasmid, a chromosome, a virus, a cosmid, etc., that behaves as an autonomous unit of polynucleotide replication within a cell; i.e., capable of replication under its own control.

The term 'vector' is a replicon further comprising sequences providing replication and/or expression of a desired open reading frame.

The term 'control sequence' refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and terminators; in eukaryotes, generally, such control sequences include promoters, terminators and, in some instances, enhancers. The term 'control sequences' is intended to include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences which govern secretion.

The term 'promoter' is a nucleotide sequence which is comprised of consensus sequences which allow the binding of RNA polymerase to the DNA template in a manner such that mRNA production initiates at the normal transcription initiation site for the adjacent structural gene.

The expression 'operably linked' refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence 'operably linked' to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

5

10

15

20

25

30

An 'open reading frame' (ORF) is a region of a polynucleotide sequence which encodes a polypeptide and does not contain stop codons; this region may represent a portion of a coding sequence or a total coding sequence.

A 'coding sequence' is a polynucleotide sequence which is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop codon at the 3'-terminus. A coding sequence can include but is not limited to mRNA, DNA (including cDNA), and recombinant polynucleotide sequences.

As used herein, 'epitope' or 'antigenic determinant' means an amino acid sequence that is immunoreactive. Generally an epitope consists of at least 3 to 4 amino acids, and more usually, consists of at least 5 or 6 amino acids, sometimes the epitope consists of about 7 to 8, or even about 10 amino acids. As used herein, an epitope of a designated polypeptide denotes epitopes with the same amino acid sequence as the epitope in the designated polypeptide, and immunologic equivalents thereof. Such equivalents also include strain, subtype (=genotype), or type(group)-specific variants, e.g. of the currently known sequences or strains belonging to genotypes 1a, 1b, 1c, 1d, 1e, 1f, 2a, 2b, 2c, 2d, 2e, 2f, 2g, 2h, 2i, 3a, 3b, 3c, 3d, 3e, 3f, 3g, 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j, 4k, 4l, 5a, 5b, 6a, 6b, 6c, 7a, 7b, 7c, 8a, 8b, 9a, 9b, 10a, or any other newly defined HCV (sub)type. It is to be understood that the amino acids constituting the epitope need not be part of a linear sequence, but may be interspersed by any number of amino acids, thus forming a conformational epitope.

The term 'immunogenic' refers to the ability of a substance to cause a humoral and/or cellular response, whether alone or when linked to a carrier, in the presence or absence of an adjuvant. 'Neutralization' refers to an immune response that blocks the infectivity, either partially or fully, of an infectious agent. A 'vaccine' is an immunogenic composition capable of eliciting protection against HCV, whether partial or complete. A vaccine may also be useful for treatment of an individual, in which case it is called a therapeutic vaccine.

The term 'therapeutic' refers to a composition capable of treating HCV infection.

The term 'effective amount' refers to an amount of epitope-bearing polypeptide sufficient to induce an immunogenic response in the individual to which it is administered, or to otherwise detectably immunoreact in its intended system (e.g., immunoassay). Preferably, the effective amount is sufficient to effect treatment, as defined above. The exact amount necessary will vary according to the application. For vaccine applications or for the generation of polyclonal antiserum / antibodies, for example, the effective amount may vary depending on the species, age, and general condition of the individual, the severity of the condition being treated, the particular polypeptide selected and its mode of administration, etc. It is also believed that effective amounts will be found within a relatively large, non-critical range. An appropriate effective amount can be readily determined using only routine experimentation. Preferred ranges of E1 and/or E2 and/or E1/E2 single or specific oligometric envelope proteins for prophylaxis of HCV disease are 0.01 to 100 µg/dose, preferably 0.1 to 50 µg/dose. Several doses may be needed per individual in order to achieve a sufficient immune response and subsequent protection against HCV disease.

15

10

5

Detailed description of the invention

More particularly, the present invention contemplates a method for isolating or purifying recombinant HCV single or specific oligomeric envelope protein selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disculphide bond cleaving agent.

The essence of these 'single or specific oligomeric' envelope proteins of the invention is that they are free from contaminating proteins and that they are not disulphide bond linked with contaminants.

25

20

The proteins according to the present invention are recombinantly expressed in lower or higher eukaryotic cells or in prokaryotes. The recombinant proteins of the present invention are preferably glycosylated and may contain high-mannose-type, hybrid, or complex glycosylations. Preferentially said proteins are expressed from mammalian cell lines as discussed in detail in the Examples section, or in yeast such as in mutant yeast strains also as detailed in the Examples section.

30

The proteins according to the present-invention may be secreted or expressed within components of the cell, such as the ER or the Golgi Apparatus. Preferably, however, the proteins of the present invention bear high-mannose-type glycosylations and are retained in

- 5

10

15

20

25

30

the ER or Golgi Apparatus of mammalian cells or are retained in or secreted from yeast cells, preferably secreted from yeast mutant strains such as the mnn9 mutant (Kniskern et al., 1994), or from mutants that have been selected by means of vanadate resistence (Ballou et al., 1991).

Upon expression of HCV envelope proteins, the present inventors could show that some of the free thiol groups of cysteines not involved in intra- or inter-molecular disulphide bridges, react with cysteines of host or expression-system-derived (e.g. vaccinia) proteins or of other HCV envelope proteins (single or oligomeric), and form aspecific intermolecular bridges. This results in the formation of 'aggregates' of HCV envelope proteins together with contaminating proteins. It was also shown in WO 92/08734 that 'aggregates' were obtained after purification, but it was not described which protein interactions were involved. In patent application WO 92/08734, recombinant E1/E2 protein expressed with the vaccinia virus system were partially purified as aggregates and only found to be 70% pure, rendering the purified aggregates not useful for diagnostic, prophylactic or therapeutic purposes.

Therefore, a major aim of the present invention resides in the separation of single or specific-oligomeric HCV envelope proteins from contaminating proteins, and to use the purified proteins (> 95% pure) for diagnostic, prophylactic and therapeutic purposes. To those purposes, the present inventors have been able to provide evidence that aggregated protein complexes ('aggregates') are formed on the basis of disulphide bridges and non-covalent protein-protein interactions. The present invention thus provides a means for selectively cleaving the disulphide bonds under specific conditions and for separating the cleaved proteins from contaminating proteins which greatly interfere with diagnostic, prophylactic and therapeutic applications. The free thiol groups may be blocked (reversibly or irreversibly) in order to prevent the reformation of disulphide bridges, or may be left to oxidize and oligomerize with other envelope proteins (see definition homo-oligomer). It is to be understood that such protein oligomers are essentially different from the 'aggregates' described in WO 92/08734 and WO 94/01778, since the level of contaminating proteins is undetectable.

Said disuphide bond cleavage may also be achieved by:

- (1) performic acid oxidation by means of cysteic acid in which case the cysteine residues are modified into cysteic acid (Moore et al., 1963).
- (2) Sulfitolysis (R-S-S-R \rightarrow 2 R-SO₃) for example by means of sulphite (SO₃) together with a proper oxidant such as Cu²⁺ in which case the cysteine is modified into S-sulpho-cysteine

(Bailey and Cole, 1959).

5

10

15

20

25

30

(3) Reduction by means of mercaptans, such as dithiotreitol (DDT), \(\beta\)-mercapto-ethanol, cysteine, glutathione Red, \(\epsilon\)-mercapto-ethylamine, or thioglycollic acid, of which DTT and \(\beta\)-mercapto-ethanol are commonly used (Cleland, 1964), is the preferred method of this invention because the method can be performed in a water environment and because the cysteine remains unmodified.

PCT/EP02/14480

(4) Reduction by means of a phosphine (e.g. Bu₃P) (Ruegg and Rudinger, 1977).

All these compounds are thus to be regarded as agents or means for cleaving disulphide bonds according to the present invention.

Said disulphide bond cleavage (or reducing) step of the present invention is preferably a partial disulphide bond cleavage (reducing) step (carried out under partial cleavage or reducing conditions).

A preferred disulphide bond cleavage or reducing agent according to the present invention is dithiothreitol (DTT). Partial reduction is obtained by using a low concentration of said reducing agent, i.e. for DTT for example in the concentration range of about 0.1 to about 50 mM, preferably about 0.1 to about 20 mM, preferably about 0.5 to about 10 mM, preferably more than 1 mM, more than 2 mM or more than 5 mM, more preferably about 1.5 mM, about 2.0 mM, about 2.5 mM, about 5 mM or about 7.5 mM.

Said disulphide bond cleavage step may also be carried out in the presence of a suitable detergent (as an example of a means for cleaving disulphide bonds or in combination with a cleaving agent) able to dissociate the expressed proteins, such as DecylPEG, EMPIGEN-BB, NP-40, sodium cholate, Triton X-100.

Said reduction or cleavage step (preferably a partial reduction or cleavage step) is carried out preferably in in the presence of (with) a detergent. A preferred detergent according to the present invention is Empigen-BB. The amount of detergent used is preferably in the range of 1 to 10 %, preferably more than 3%, more preferably about 3.5% of a detergent such as Empigen-BB.

A particularly preferred method for obtaining disulphide bond cleavage employs a combination of a classical disulphide bond cleavage agent as detailed above and a detergent (also as detailed above). As contemplated in the Examples section, the particular combination of a low concentration of DTT (1.5 to 7.5 mM) and about 3.5 % of Empigen-BB is proven to be a particularly preferred combination of reducing agent and detergent for the purification of recombinantly expressed E1 and E2 proteins. Upon gelfiltration chromatography, said partial

10

15

20

reduction is shown to result in the production of possibly dimeric E1 protein and separation of this E1 protein from contaminating proteins that cause false reactivity upon use in immunoassays.

It is, however, to be understood that also any other combination of any reducing agent known in the art with any detergent or other means known in the art to make the cysteines better accessible is also within the scope of the present invention, insofar as said combination reaches the same goal of disulphide bridge cleavage as the preferred combination examplified in the present invention.

Apart from reducing the disulphide bonds, a disulphide bond cleaving means according to the present invention may also include any disulphide bridge exchanging agents (competitive agent being either organic or proteinaeous, see for instance Creighton, 1988) known in the art which allows the following type of reaction to occur:

$$R1 S - S R2 + R3 SH \rightarrow R1 S - S R3 + R2 SH$$

- * R1, R2: compounds of protein aggregates
- * R3 SH: competitive agent (organic, proteinaeous)

The term 'disulphide bridge exchanging agent' is to be interpretated as including disulphide bond reforming as well as disulphide bond blocking agents.

The present invention also relates to methods for purifying or isolating HCV single or specific oligomeric envelope proteins as set out above further including the use of any SH group blocking or binding reagent known in the art such as chosen from the following list:

- Glutathion
- 5,5'-dithiobis-(2-nitrobenzoic acid) or bis-(3-carboxy-4-nitrophenyl)-disulphide (DTNB or Ellman's reagent) (Elmann, 1959)
- N-ethylmaleimide (NEM; Benesch et al., 1956)
- N-(4-dimethylamino-3,5-dinitrophenyl) maleimide or Tuppy's maleimide which provides a color to the protein
 - P-chloromercuribenzoate (Grassetti et al., 1969)
 - 4-vinylpyridine (Friedman and Krull, 1969) can be liberated after reaction by acid hydrolysis
- acrylonitrile, can be liberated after reaction by acid hydrolysis (Weil and Seibles, 1961)
 - NEM-biotin (e.g. obtained from Sigma B1267)
 - 2,2'-dithiopyridine (Grassetti and Murray, 1967)

- 4,4'-dithiopyridine (Grassetti and Murray, 1967)

5

10

15

20

25

30

- 6,6'-dithiodinicontinic acid (DTDNA; Brown and Cunnigham, 1970)
- 2,2'-dithiobis-(5'-nitropyridine) (DTNP; US patent 3597160) or other dithiobis (heterocyclic derivative) compounds (Grassetti and Murray, 1969)

A survey of the publications cited shows that often different reagents for sulphydryl groups will react with varying numbers of thiol groups of the same protein or enzyme molecule. One may conclude that this variation in reactivity of the thiol groups is due to the steric environment of these groups, such as the shape of the molecule and the surrounding groups of atoms and their charges, as well as to the size, shape and charge of the reagent molecule or ion. Frequently the presence of adequate concentrations of denaturants such as sodium dodecylsulfate, urea or guanidine hydrochoride will cause sufficient unfolding of the protein molecule to permit equal access to all of the reagents for thiol groups. By varying the concentration of denaturant, the degree of unfolding can be controlled and in this way thiol groups with different degrees of reactivity may be revealed. Although up to date most of the work reported has been done with p-chloromercuribenzoate, N-ethylmaleimide and DTNB, it is likely that the other more recently developed reagents may prove equally useful. Because of their varying structures, it seems likely, in fact, that they may respond differently to changes in the steric environment of the thiol groups.

Alternatively, conditions such as low pH (preferably lower than pH 6) for preventing free SH groups from oxidizing and thus preventing the formation of large intermolecular aggregates upon recombinant expression and purification of E1 and E2 (envelope) proteins are also within the scope of the present invention.

A preferred SH group blocking reagent according to the present invention is N-ethylmaleimide (NEM). Said SH group blocking reagent may be administrated during lysis of the recombinant host cells and after the above-mentioned partial reduction process or after any other process for cleaving disulphide bridges. Said SH group blocking reagent may also be modified with any group capable of providing a detectable label and/or any group aiding in the immobilization of said recombinant protein to a solid substrate, e.g. biotinylated NEM.

Methods for cleaving cysteine bridges and blocking free cysteines have also been described in Darbre (1987), Means and Feeney (1971), and by Wong (1993).

A method to purify single or specific oligomeric recombinant E1 and/or E2 and/or E1/E2 proteins according to the present invention as defined above is further characterized as comprising the following steps:

10

15

20

25

30

WO 03/051912 PCT/EP02/14480

- lysing recombinant E1 and/or E2 and/or E1/E2 expressing host cells, preferably in the presence of an SH group blocking agent, such as N-ethylmaleimide (NEM), and possibly a suitable detergent, preferably Empigen-BB,

17

- recovering said HCV envelope protein by affinity purification for instance by means lectin-chromatography, such as lentil-lectin chromatography, or immunoaffinity chromatography using anti-E1 and/or anti-E2 specific monoclonal antibodies, followed by,
- reduction or cleavage of disulphide bonds with a disulphide bond cleaving agent, such as DTT, preferably also in the presence of an SH group blocking agent, such as NEM or Biotin-NEM, and,
- recovering the reduced HCV E1 and/or E2 and/or E1/E2 envelope proteins for instance by gelfiltration (size exclusion chromatography or molecular sieving) and possibly also by an additional Ni²⁺-IMAC chromatography and desalting step.

It is to be understood that the above-mentioned recovery steps may also be carried out using any other suitable technique known by the person skilled in the art.

Preferred lectin-chromatography systems include *Galanthus nivalis* agglutinin (GNA) - chromatography, or *Lens culinaris* agglutinin (LCA) (lentil) lectin chromatography as illustrated in the Examples section. Other useful lectins include those recognizing highmannose type sugars, such as *Narcissus pseudonarcissus* agglutinin (NPA), *Pisum sativum* agglutinin (PSA), or *Allium ursinum* agglutinin (AUA).

Preferably said method is usable to purify single or specific oligomeric HCV envelope protein produced intracellularly as detailed above.

For secreted E1 or E2 or E1/E2 oligomers, lectins binding complex sugars such as *Ricinus communis* agglutinin I (RCA I), are preferred lectins.

The present invention more particularly contemplates essentially purified recombinant HCV single or specific oligomeric envelope proteins, selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized as being isolated or purified by a method as defined above.

The present invention more particularly relates to the purification or isolation of recombinant envelope proteins which are expressed from recombinant mammalian cells such as vaccinia.

The present invention also relates to the purification or isolation of recombinant envelope proteins which are expressed from recombinant yeast cells.

The present invention equally relates to the purification or isolation of recombinant envelope proteins which are expressed from recombinant bacterial (prokaryotic) cells.

The present invention also contemplates a recombinant vector comprising a vector sequence, an appropriate prokaryotic, eukaryotic or viral or synthetic promoter sequence followed by a nucleotide sequence allowing the expression of the single or specific oligomeric E1 and/or E2 and/or E1/E2 of the invention.

5

10

15

20

25

30

Particularly, the present invention contemplates a recombinant vector comprising a vector sequence, an appropriate prokaryotic, eukaryotic or viral or synthetic promoter sequence followed by a nucleotide sequence allowing the expression of the single E1 or E1 of the invention.

Particularly, the present invention contemplates a recombinant vector comprising a vector sequence, an appropriate prokaryotic, eukaryotic or viral or synthetic promoter sequence followed by a nucleotide sequence allowing the expression of the single E1 or E2 of the invention.

The segment of the HCV cDNA encoding the desired E1 and/or E2 sequence inserted into the vector sequence may be attached to a signal sequence. Said signal sequence may be that from a non-HCV source, e.g. the IgG or tissue plasminogen activator (tpa) leader sequence for expression in mammalian cells, or the α-mating factor sequence for expression into yeast cells, but particularly preferred constructs according to the present invention contain signal sequences appearing in the HCV genome before the respective start points of the E1 and E2 proteins. The segment of the HCV cDNA encoding the desired E1 and/or E2 sequence inserted into the vector may also include deletions e.g. of the hydrophobic domain(s) as illustrated in the examples section, or of the E2 hypervariable region I.

More particularly, the recombinant vectors according to the present invention encompass a nucleic acid having an HCV cDNA segment encoding the polyprotein starting in the region between amino acid positions 1 and 192 and ending in the region between positions 250 and 400 of the HCV polyprotein, more preferably ending in the region between positions 250 and 341, even more preferably ending in the region between positions 290 and 341 for expression of the HCV single E1 protein. Most preferably, the present recombinant vector encompasses a recombinant nucleic acid having a HCV cDNA sequent encoding part of the HCV polyprotein starting in the region between positions 117 and 192, and ending at any position in the region between positions 263 and 326, for expression of HCV single E1 protein. Also within the scope of the present invention are forms that have the first

10

15

20

25

30

hydrophobic domain deleted (positions 264 to 293 plus or minus 8 amino acids), or forms to which a 5'-terminal ATG codon and a 3'-terminal stop codon has been added, or forms which have a factor Xa cleavage site and/or 3 to 10, preferably 6 Histidine codons have been added.

More particularly, the recombinant vectors according to the present invention encompass a nucleic acid having an HCV cDNA segment encoding the polyprotein starting in the region between amino acid positions 290 and 406 and ending in the region between positions 600 and 820 of the HCV polyprotein, more preferably starting in the region between positions 322 and 406, even more preferably starting in the region between positions 347 and 406, even still more preferably starting in the region between positions 364 and 406 for expression of the HCV single E2 protein. Most preferably, the present recombinant vector encompasses a recombinant nucleic acid having a HCV cDNA segment encoding the polyprotein starting in the region between positions 290 and 406, and ending at any position of positions 623, 650, 661, 673, 710, 715, 720, 746 or 809, for expression of HCV single E2 protein. Also within the scope of the present invention are forms to which a 5'-terminal ATG codon and a 3'-terminal stop codon has been added, or forms which have a factor Xa cleavage site and/or 3 to 10, preferably 6 Histidine codons have been added.

A variety of vectors may be used to obtain recombinant expression of HCV single or specific oligomeric envelope proteins of the present invention. Lower eukaryotes such as yeasts and glycosylation mutant strains are typically transformed with plasmids, or are transformed with a recombinant virus. The vectors may replicate within the host independently, or may integrate into the host cell genome.

Higher eukaryotes may be transformed with vectors, or may be infected with a recombinant virus, for example a recombinant vaccinia virus. Techniques and vectors for the insertion of foreign DNA into vaccinia virus are well known in the art, and utilize, for example homologous recombination. A wide variety of viral promoter sequences, possibly terminator sequences and poly(A)-addition sequences, possibly enhancer sequences and possibly amplification sequences, all required for the mammalian expression, are available in the art. Vaccinia is particularly preferred since vaccinia halts the expression of host cell proteins. Vaccinia is also very much preferred since it allows the expression of E1 and E2 proteins of HCV in cells or individuals which are immunized with the live recombinant vaccinia virus. For vaccination of humans the avipox and Ankara Modified Virus (AMV) are particularly useful vectors.

Also known are insect expression transfer vectors derived from baculovirus

Autographa californica nuclear polyhedrosis virus (AcNPV), which is a helper-independent viral expression vector. Expression vectors derived from this system usually use the strong viral polyhedrin gene promoter to drive the expression of heterologous genes. Different vectors as well as methods for the introduction of heterologous DNA into the desired site of baculovirus are available to the man skilled in the art for baculovirus expression. Also different signals for posttranslational modification recognized by insect cells are known in the art.

5

10

15

20

25

30

Also included within the scope of the present invention is a method for producing purified recombinant single or specific oligomeric HCV E1 or E2 or E1/E2 proteins, wherein the cysteine residues involved in aggregates formation are replaced at the level of the nucleic acid sequence by other residues such that aggregate formation is prevented. The recombinant proteins expressed by recombinant vectors caarying such a mutated E1 and/or E2 protein encoding nucleic acid are also within the scope of the present invention.

The present invention also relates to recombinant E1 and/or E2 and/or E1/E2 proteins characterized in that at least one of their glycosylation sites has been removed and are consequently termed glycosylation mutants. As explained in the Examples section, different glycosylation mutants may be desired to diagnose (screening, confirmation, prognosis, etc.) and prevent HCV disease according to the patient in question. An E2 protein glycosylation mutant lacking the GLY4 has for instance been found to improve the reactivity of certain sera in diagnosis. These glycosylation mutants are preferably purified according to the method disclosed in the present invention. Also contemplated within the present invention are recombinant vectors carrying the nucleic acid insert encoding such a E1 and/or E2 and/or E1/E2 glycosylation mutant as well as host cells tranformed with such a recombinant vector.

The present invention also relates to recombinant vectors including a polynucleotide which also forms part of the present invention. The present invention relates more particularly to the recombinant nucleic acids as represented in SEQ ID NO 3, 5, 7, 9, 11, 13, 21, 23, 25, 27, 29, 31, 35, 37, 39, 41, 43, 45, 47 and 49, or parts thereof.

The present invention also contemplates host cells transformed with a recombinant vector as defined above, wherein said vector comprises a nucleotide sequence encoding HCV E1 and/or E2 and/or E1/E2 protein as defined above in addition to a regulatory sequence operably linked to said HCV E1 and/or E2 and/or E1/E2 sequence and capable of regulating the expression of said HCV E1 and/or E2 and/or E1/E2 protein.

Eukaryotic hosts include lower and higher eukaryotic hosts as described in the definitions section. Lower eukaryotic hosts include yeast cells well known in the art. Higher eukaryotic hosts mainly include mammalian cell lines known in the art and include many immortalized cell lines available from the ATCC, inluding HeLa cells, Chinese hamster ovary (CHO) cells, Baby hamster kidney (BHK) cells, PK15, RK13 and a number of other cell lines.

5

10

15

20

30

The present invention relates particularly to a recombinant E1 and/or E2 and/or E1/E2 protein expressed by a host cell as defined above containing a recombinant vector as defined above. These recombinant proteins are particularly purified according to the method of the present invention.

A preferred method for isolating or purifying HCV envelope proteins as defined above is further characterized as comprising at least the following steps:

- growing a host cell as defined above transformed with a recombinant vector according to the present invention or with a known recombinant vector expressing E1 and/or E2 and/or E1/E2 HCV envelope proteins in a suitable culture medium,
- causing expression of said vector sequence as defined above under suitable conditions, and,
- lysing said transformed host cells, preferably in the presence of a SH group blocking agent, such as N-ethylmaleimide (NEM), and possibly a suitable detergent, preferably Empigen-BB,
- recovering said HCV envelope protein by affinity purification such as by means of lectin-chromatography or immunoaffinity chromatography using anti-E1 and/or anti-E2 specific monoclonal antibodies, with said lectin being preferably lentil-lectin or GNA, followed by,
- incubation of the eluate of the previous step with a disulphide bond cleavage means,
 such as DTT, preferably followed by incubation with an SH group blocking agent,
 such as NEM or Biotin-NEM, and,
 - isolating the HCV single or specific oligomeric E1 and/or E2 and/or E1/E2 proteins such as by means of gelfiltration and possibly also by a subsequent Ni²⁺-IMAC chromatography followed by a desalting step.

As a result of the above-mentioned proces, E1 and/or E2 and/or E1/E2 proteins may be produced in a form which elute differently from the large aggregates containing vectorderived components and/or cell components in the void volume of the gelfiltration column or

10

15

25

30

the IMAC column as illustrated in the Examples section. The disulphide bridge cleavage step advantageously also eliminates the false reactivity due to the presence of host and/or expression-system-derived proteins. The presence of NEM and a suitable detergent during lysis of the cells may already partly or even completely prevent the aggregation between the HCV envelope proteins and contaminants.

Ni²⁺-IMAC chromatography followed by a desalting step is preferably used for contructs bearing a (His)₆ as described by Janknecht et al., 1991, and Hochuli et al., 1988.

The present invention also relates to a method for producing monoclonal antibodies in small animals such as mice or rats, as well as a method for screening and isolating human B-cells that recognize anti-HCV antibodies, using the HCV single or specific oligomeric envelope proteins of the present invention.

The present invention further relates to a composition comprising at least one of the following E1 peptides as listed in Table 3 and described elsewhere herein:

E1-31 (SEQ ID NO:56) spanning amino acids 181 to 200 of the Core/E1 V1 region,

E1-33 (SEQ ID NO:57) spanning amino acids 193 to 212 of the E1 region,

E1-35 (SEQ ID NO:58) spanning amino acids 205 to 224 of the E1 V2 region (epitope B),

E1-35A (SEQ ID NO:59) spanning amino acids 208 to 227 of the E1 V2 region (epitope B),

20 1bE1 (SEQ ID NO:53) spanning amino acids 192 to 228 of E1 regions (V1, C1, and V2 regions (containing epitope B)),

E1-51 (SEQ ID NO:66) spanning amino acids 301 to 320 of the E1 region,

E1-53 (SEQ ID NO:67) spanning amino acids 313 to 332 of the E1 C4 region (epitope A),

E1-55 (SEQ ID NO:68) spanning amino acids 325 to 344 of the E1 region,

The present invention also relates to a composition comprising at least one of the following E2 peptides as listed in Table 3:

Env 67 or E2-67 (SEQ ID NO:72) spanning amino acid positions 397 to 416 of the E2 region (epitope A, recognized by monoclonal antibody 2F10H10, see Figure 19),

Env 69 or E2-69 (SEQ ID NO:73) spanning amino acid positions 409 to 428 of the E2 region (epitope A),

Env 23 or E2-23 (SEQ ID NO:86) spanning positions 583 to 602 of the E2 region (epitope E),

10

15

20

25

30

Env 25 or E2-25 (SEQ ID NO:87) spanning positions 595 to 614 of the E2 region (epitope E),

Env 27 or E2-27 (SEQ ID NO:88) spanning positions 607 to 626 of the E2 region (epitope E),

Env 17B or E2-17B (SEQ ID NO:83) spanning positions 547 to 566 of the E2 region (epitope D),

Env 13B or E2-13B (SEQ ID NO:82) spanning positions 523 to 542 of the E2 region (epitope C; recognized by monoclonal antibody 16A6E7, see Figure 19).

The present invention also relates to a composition comprising at least one of the following E2 conformational epitopes:

epitope F recognized by monoclonal antibodies 15C8C1, 12D11F1 and 8G10D1H9, epitope G recognized by monoclonal antibody 9G3E6,

epitope H (or C) recognized by monoclonal antibody 10D3C4 and 4H6B2, or, epitope I recognized by monoclonal antibody 17F2C2.

The present invention also relates to an E1 or E2 specific antibody raised upon immunization with a peptide or protein composition, with said antibody being specifically reactive with any of the polypeptides or peptides as defined above, and with said antibody being preferably a monoclonal antibody.

The present invention also relates to an E1 or E2 specific antibody screened from a variable chain library in plasmids or phages or from a population of human B-cells by means of a process known in the art, with said antibody being reactive with any of the polypeptides or peptides as defined above, and with said antibody being preferably a monoclonal antibody.

The E1 or E2 specific monoclonal antibodies of the invention can be produced by any hybridoma liable to be formed according to classical methods from splenic cells of an animal, particularly from a mouse or rat, immunized against the HCV polypeptides or peptides according to the invention, as defined above on the one hand, and of cells of a myeloma cell line on the other hand, and to be selected by the ability of the hybridoma to produce the monoclonal antibodies recognizing the polypeptides which has been initially used for the immunization of the animals.

The antibodies involved in the invention can be labelled by an appropriate label of the enzymatic, fluorescent, or radioactive type.

The monoclonal antibodies according to this preferred embodiment of the invention may be humanized versions of mouse monoclonal antibodies made by means of recombinant

15

20

25

30

DNA technology, departing from parts of mouse and/or human genomic DNA sequences coding for H and L chains from cDNA or genomic clones coding for H and L chains.

Alternatively the monoclonal antibodies according to this preferred embodiment of the invention may be human monoclonal antibodies. These antibodies according to the present embodiment of the invention can also be derived from human peripheral blood lymphocytes of patients infected with HCV, or vaccinated against HCV. Such human monoclonal antibodies are prepared, for instance, by means of human peripheral blood lymphocytes (PBL) repopulation of severe combined immune deficiency (SCID) mice (for recent review, see Duchosal et al., 1992).

The invention also relates to the use of the proteins or peptides of the invention, for the selection of recombinant antibodies by the process of repertoire cloning (Persson et al., 1991).

Antibodies directed to peptides or single or specific oligomeric envelope proteins derived from a certain genotype may be used as a medicament, more particularly for incorporation into an immunoassay for the detection of HCV genotypes (for detecting the presence of HCV E1 or E2 antigen), for prognosing/monitoring of HCV disease, or as therapeutic agents.

Alternatively, the present invention also relates to the use of any of the above-specified E1 or E2 specific monoclonal antibodies for the preparation of an immunoassay kit for detecting the presence of E1 or E2 antigen in a biological sample, for the preparation of a kit for prognosing/monitoring of HCV disease or for the preparation of a HCV medicament.

The present invention also relates to the a method for *in vitro* diagnosis or detection of HCV antigen present in a biological sample, comprising at least the following steps:

- contacting said biological sample with any of the E1 and/or E2 specific monoclonal antibodies as defined above, preferably in an immobilized form under appropriate conditions which allow the formation of an immune complex,
- (ii) removing unbound components,
- (iii) incubating the immune complexes formed with heterologous antibodies, which specifically bind to the antibodies present in the sample to be analyzed, with said heterologous antibodies having conjugated to a detectable label under appropriate conditions,
- (iv) detecting the presence of said immune complexes visually or mechanically

20

25

30

(e.g. by means of densitometry, fluorimetry, colorimetry).

The present invention also relates to a kit for in vitro diagnosis of HCV antigen present in a biological sample, comprising:

- at least one monoclonal antibody as defined above, with said antibody being preferentially immobilized on a solid substrate,
- a buffer or components necessary for producing the buffer enabling binding reaction between these antibodies and the HCV antigens present in the biological sample,
- a means for detecting the immune complexes formed in the preceding binding reaction.
- possibly also including an automated scanning and interpretation device for inferring the HCV antigens present in the sample from the observed binding pattern.

The present invention also relates to a composition comprising E1 and/or E2 and/or E1/E2 recombinant HCV proteins purified according to the method of the present invention or a composition comprising at least one peptides as specified above for use as a medicament.

The present invention more particularly relates to a composition comprising at least one of the above-specified envelope peptides or a recombinant envelope protein composition as defined above, for use as a vaccine for immunizing a mammal, preferably humans, against HCV, comprising administering a sufficient amount of the composition possibly accompanied by pharmaceutically acceptable adjuvant(s), to produce an immune response.

More particularly, the present invention relates to the use of any of the compositions as described here above for the preparation of a vaccine as described above.

Also, the present invention relates to a vaccine composition for immunizing a mammal, preferably humans, against HCV, comprising HCV single or specific oligomeric proteins or peptides derived from the E1 and/or the E2 region as described above.

Immunogenic compositions can be prepared according to methods known in the art. The present compositions comprise an immunogenic amount of a recombinant E1 and/or E2 and/or E1/E2 single or specific oligomeric proteins as defined above or E1 or E2 peptides as defined above, usually combined with a pharmaceutically acceptable carrier, preferably further comprising an adjuvant.

The single or specific oligomeric envelope proteins of the present invention, either E1

and/or E2 and/or E1/E2, are expected to provide a particularly useful vaccine antigen, since the formation of antibodies to either E1 or E2 may be more desirable than to the other envelope protein, and since the E2 protein is cross-reactive between HCV types and the E1 protein is type-specific. Cocktails including type 1 E2 protein and E1 proteins derived from several genotypes may be particularly advantageous. Cocktails containing a molar excess of E1 versus E2 or E2 versus E1 may also be particularly useful. Immunogenic compositions may be administered to animals to induce production of antibodies, either to provide a source of antibodies or to induce protective immunity in the animal.

5

10

15

20

25

30

Pharmaceutically acceptable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers; and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: aluminim hydroxide (alum), N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP) as found in U.S. Patent No. 4,606,918, N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE) and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate, and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion. Any of the 3 components MPL, TDM or CWS may also be used alone or combined 2 by 2. Additionally, adjuvants such as Stimulon (Cambridge Bioscience, Worcester, MA) or SAF-1 (Syntex) may be used. Further, Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA) may be used for non-human applications and research purposes.

The immunogenic compositions typically will contain pharmaceutically acceptable vehicles, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, preservatives, and the like, may be included in such vehicles.

Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect. The E1 and E2 proteins may also be

incorporated into Immune Stimulating Complexes together with saponins, for example Quil A (ISCOMS).

5

10

15

20

25

30

Immunogenic compositions used as vaccines comprise a 'sufficient amount' or 'an immunologically effective amount' of the envelope proteins of the present invention, as well as any other of the above mentioned components, as needed. 'Immunologically effective amount', means that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment, as defined above. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (e.g. nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, the strain of infecting HCV, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Usually, the amount will vary from 0.01 to 1000 $\mu g/dose$, more particularly from 0.1 to 100 $\mu g/dose$.

The single or specific oligomeric envelope proteins may also serve as vaccine carriers to present homologous (e.g. T cell epitopes or B cell epitopes from the core, NS2, NS3, NS4 or NS5 regions) or heterologous (non-HCV) haptens, in the same manner as Hepatitis B surface antigen (see European Patent Application 174,444). In this use, envelope proteins provide an immunogenic carrier capable of stimulating an immune response to haptens or antigens conjugated to the aggregate. The antigen may be conjugated either by conventional chemical methods, or may be cloned into the gene encoding E1 and/or E2 at a location corresponding to a hydrophilic region of the protein. Such hydrophylic regions include the V1 region (encompassing amino acid positions 191 to 202), the V2 region (encompassing amino acid positions 213 to 223), the V3 region (encompassing amino acid positions 230 to 242), the V4 region (encompassing amino acid positions 230 to 242), the V5 region (encompassing amino acid positions 294 to 303) and the V6 region (encompassing amino acid positions 329 to 336). Another useful location for insertion of haptens is the hydrophobic region (encompassing approximately amino acid positions 264 to 293). It is shown in the present invention that this region can be deleted without affecting the reactivity of the deleted E1 protein with antisera. Therefore, haptens may be inserted at the site of the deletion.

The immunogenic compositions are conventionally administered parenterally,

PCT/EP02/14480 WO 03/051912 28

typically by injection, for example, subcutaneously or intramuscularly. Additional formulations suitable for other methods of administration include oral formulations and suppositories. Dosage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.

The present invention also relates to a composition comprising peptides or polypeptides as described above, for in vitro detection of HCV antibodies present in a biological sample.

The present invention also relates to the use of a composition as described above for the preparation of an immunoassay kit for detecting HCV antibodies present in a biological sample.

The present invention also relates to a method for in vitro diagnosis of HCV antibodies present in a biological sample, comprising at least the following steps:

- (i) contacting said biological sample with a composition comprising any of the envelope peptide or proteins as defined above, preferably in an immobilized form under appropriate conditions which allow the formation of an immune complex, wherein said peptide or protein can be a biotinylated peptide or protein which is covalently bound to a solid substrate by means of streptavidin or avidin complexes,
- (ii) removing unbound components,

5

10

15

20

25

30

- incubating the immune complexes formed with heterologous antibodies, with (iii) said heterologous antibodies having conjugated to a detectable label under appropriate conditions,
- detecting the presence of said immune complexes visually or mechanically (iv) (e.g. by means of densitometry, fluorimetry, colorimetry).

Alternatively, the present invention also relates to competition immunoassay formats in which recombinantly produced purified single or specific oligomeric protein E1 and/or E2 and/or E1/E2 proteins as disclosed above are used in combination with E1 and/or E2 peptides in order to compete for HCV antibodies present in a biological sample.

The present invention also relates to a kit for determining the presence of HCV antibodies, in a biological sample, comprising:

> at least one peptide or protein composition as defined above, possibly in combination with other polypeptides or peptides from HCV or other types of HCV, with said peptides or proteins being preferentially immobilized on a

15

20

25

30

solid substrate, more preferably on different microwells of the same ELISA plate, and even more preferentially on one and the same membrane strip,

- a buffer or components necessary for producing the buffer enabling binding reaction between these polypeptides or peptides and the antibodies against HCV present in the biological sample,
- means for detecting the immune complexes formed in the preceding binding reaction,
- possibly also including an automated scanning and interpretation device for inferring the HCV genotypes present in the sample from the observed binding pattern.

The immunoassay methods according to the present invention utilize single or specific oligomeric antigens from the E1 and/or E2 domains that maintain linear (in case of peptides) and conformational epitopes (single or specific oligomeric proteins) recognized by antibodies in the sera from individuals infected with HCV. It is within the scope of the invention to use for instance single or specific oligomeric antigens, dimeric antigens, as well as combinations of single or specific oligomeric antigens. The HCV E1 and E2 antigens of the present invention may be employed in virtually any assay format that employs a known antigen to detect antibodies. Of course, a format that denatures the HCV conformational epitope should be avoided or adapted. A common feature of all of these assays is that the antigen is contacted with the body component suspected of containing HCV antibodies under conditions that permit the antigen to bind to any such antibody present in the component. Such conditions will typically be physiologic temperature, pH and ionic strength using an excess of antigen. The incubation of the antigen with the specimen is followed by detection of immune complexes comprised of the antigen.

Design of the immunoassays is subject to a great deal of variation, and many formats are known in the art. Protocols may, for example, use solid supports, or immunoprecipitation. Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, enzymatic, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify the signals from the immune complex are also known; examples of which are assays which utilize biotin and avidin or streptavidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.

The immunoassay may be, without limitation, in a heterogeneous or in a homogeneous format, and of a standard or competitive type. In a heterogeneous format, the

20

25

30

WO 03/051912 PCT/EP02/14480

30

polypeptide is typically bound to a solid matrix or support to facilitate separation of the sample from the polypeptide after incubation. Examples of solid supports that can be used are nitrocellulose (e.g., in membrane or microtiter well form), polyvinyl chloride (e.g., in sheets or microtiter wells), polystyrene latex (e.g., in beads or microtiter plates, polyvinylidine fluoride (known as ImmunolonTM), diazotized paper, nylon membranes, activated beads, and Protein A beads. For example, Dynatech ImmunolonTM 1 or ImmunolonTM 2 microtiter plates or 0.25 inch polystyrene beads (Precision Plastic Ball) can be used in the heterogeneous format. The solid support containing the antigenic polypeptides is typically washed after separating it from the test sample, and prior to detection of bound antibodies. Both standard and competitive formats are know in the art.

In a homogeneous format, the test sample is incubated with the combination of antigens in solution. For example, it may be under conditions that will precipitate any antigen-antibody complexes which are formed. Both standard and competitive formats for these assays are known in the art.

In a standard format, the amount of HCV antibodies in the antibody-antigen complexes is directly monitored. This may be accomplished by determining whether labeled anti-xenogeneic (e.g. anti-human) antibodies which recognize an epitope on anti-HCV antibodies will bind due to complex formation. In a competitive format, the amount of HCV antibodies in the sample is deduced by monitoring the competitive effect on the binding of a known amount of labeled antibody (or other competing ligand) in the complex.

Complexes formed comprising anti-HCV antibody (or in the case of competitive assays, the amount of competing antibody) are detected by any of a number of known techniques, depending on the format. For example, unlabeled HCV antibodies in the complex may be detected using a conjugate of anti-xenogeneic Ig complexed with a label (e.g. an enzyme label).

In an immunoprecipitation or agglutination assay format the reaction between the HCV antigens and the antibody forms a network that precipitates from the solution or suspension and forms a visible layer or film of precipitate. If no anti-HCV antibody is present in the test specimen, no visible precipitate is formed.

There currently exist three specific types of particle agglutination (PA) assays. These assays are used for the detection of antibodies to various antigens when coated to a support. One type of this assay is the hemagglutination assay using red blood cells (RBCs) that are sensitized by passively adsorbing antigen (or antibody) to the RBC. The addition of specific

15

20

25

30

antigen antibodies present in the body component, if any, causes the RBCs coated with the purified antigen to agglutinate.

To eliminate potential non-specific reactions in the hemagglutination assay, two artificial carriers may be used instead of RBC in the PA. The most common of these are latex particles. However, gelatin particles may also be used. The assays utilizing either of these carriers are based on passive agglutination of the particles coated with purified antigens.

The HCV single or specific oligomeric E1 and/or E2 and/or E1/E2 antigens of the present invention comprised of conformational epitopes will typically be packaged in the form of a kit for use in these immunoassays. The kit will normally contain in separate containers the native HCV antigen, control antibody formulations (positive and/or negative), labeled antibody when the assay format requires the same and signal generating reagents (e.g. enzyme substrate) if the label does not generate a signal directly. The native HCV antigen may be already bound to a solid matrix or separate with reagents for binding it to the matrix. Instructions (e.g. written, tape, CD-ROM, etc.) for carrying out the assay usually will be included in the kit.

Immunoassays that utilize the native HCV antigen are useful in screening blood for the preparation of a supply from which potentially infective HCV is lacking. The method for the preparation of the blood supply comprises the following steps. Reacting a body component, preferably blood or a blood component, from the individual donating blood with HCV E1 and/or E2 proteins of the present invention to allow an immunological reaction between HCV antibodies, if any, and the HCV antigen. Detecting whether anti-HCV antibody - HCV antigen complexes are formed as a result of the reacting. Blood contributed to the blood supply is from donors that do not exhibit antibodies to the native HCV antigens, E1 or E2.

In cases of a positive reactivity to the HCV antigen, it is preferable to repeat the immunoassay to lessen the possibility of false positives. For example, in the large scale screening of blood for the production of blood products (e.g. blood transfusion, plasma, Factor VIII, immunoglobulin, etc.) 'screening' tests are typically formatted to increase sensitivity (to insure no contaminated blood passes) at the expense of specificity; i.e. the false-positive rate is increased. Thus, it is typical to only defer for further testing those donors who are 'repeatedly reactive'; i.e. positive in two or more runs of the immunoassay on the donated sample. However, for confirmation of HCV-positivity, the 'confirmation' tests are typically formatted to increase specificity (to insure that no false-positive samples are

confirmed) at the expense of sensitivity. Therefore the purification method described in the present invention for E1 and E2 will be very advantageous for including single or specific oligomeric envelope proteins into HCV diagnostic assays.

The solid phase selected can include polymeric or glass beads, nitrocellulose, microparticles, microwells of a reaction tray, test tubes and magnetic beads. The signal generating compound can include an enzyme, a luminescent compound, a chromogen, a radioactive element and a chemiluminescent compound. Examples of enzymes include alkaline phosphatase, horseradish peroxidase and beta-galactosidase. Examples of enhancer compounds include biotin, anti-biotin and avidin. Examples of enhancer compounds binding members include biotin, anti-biotin and avidin. In order to block the effects of rheumatoid factor-like substances, the test sample is subjected to conditions sufficient to block the effect of rheumatoid factor-like substances. These conditions comprise contacting the test sample with a quantity of anti-human IgG to form a mixture, and incubating the mixture for a time and under conditions sufficient to form a reaction mixture product substantially free of rheumatoid factor-like substance.

The present invention further contemplates the use of E1 proteins, or parts thereof, more particularly HCV single or specific oligomeric E1 proteins as defined above, for *in vitro* monitoring HCV disease or prognosing the response to treatment (for instance with Interferon) of patients suffering from HCV infection comprising:

20

30

5

10

15

- incubating a biological sample from a patient with hepatitis C infection with an E1 protein or a suitable part thereof under conditions allowing the formation of an immunological complex,
- removing unbound components,
- calculating the anti-E1 titers present in said sample (for example at the start of and/or during the course of (interferon) therapy),
 - monitoring the natural course of HCV disease, or prognosing the response to treatment of said patient on the basis of the amount anti-E1 titers found in said sample at the start of treatment and/or during the course of treatment.

Patients who show a decrease of 2, 3, 4, 5, 7, 10, 15, or preferably more than 20 times of the initial anti-E1 titers could be concluded to be long-term, sustained responders to HCV therapy, more particularly to interferon therapy. It is illustrated in the Examples section, that an anti-E1 assay may be very useful for prognosing long-term response to IFN treatment, or to treatment of Hepatitis C virus disease in general.

25

30

More particularly the following E1 peptides as listed in Table 3 were found to be useful for *in vitro* monitoring HCV disease or prognosing the response to interferon treatment of patients suffering from HCV infection:

E1-31 (SEQ ID NO:56) spanning amino acids 181 to 200 of the Core/E1 V1 region,

E1-33 (SEQ ID NO:57) spanning amino acids 193 to 212 of the E1 region,

E1-35 (SEQ ID NO:58) spanning amino acids 205 to 224 of the E1 V2 region (epitope B),

E1-35A (SEQ ID NO:59) spanning amino acids 208 to 227 of the E1 V2 region (epitope B),

1bE1 (SEQ ID NO:53) spanning amino acids 192 to 228 of E1 regions (V1, C1, and V2 regions (containing epitope B)),

E1-51 (SEQ ID NO:66) spanning amino acids 301 to 320 of the E1 region,

E1-53 (SEQ ID NO:67) spanning amino acids 313 to 332 of the E1 C4 region (epitope A),

15 E1-55 (SEQ ID NO:68) spanning amino acids 325 to 344 of the E1 region.

It is to be understood that smaller fragments of the above-mentioned peptides also fall within the scope of the present invention. Said smaller fragments can be easily prepared by chemical synthesis and can be tested for their ability to be used in an assay as detailed above and in the Examples section.

The present invention also relates to a kit for monitoring HCV disease or prognosing the response to treatment (for instance to interferon) of patients suffering from HCV infection comprising:

- at least one E1 protein or E1 peptide, more particularly an E1 protein or E1 peptide as defined above,
- a buffer or components necessary for producing the buffer enabling the binding reaction between these proteins or peptides and the anti-E1 antibodies present in a biological sample,
- means for detecting the immune complexes formed in the preceding binding reaction,
- possibly also an automated scanning and interpretation device for inferring a decrease of anti-E1 titers during the progression of treatment.

It is to be understood that also E2 protein and peptides according to the present invention can be used to a certain degree to monitor/prognose HCV treatment as indicated

above for the E1 proteins or peptides because also the anti-E2 levels decrease in comparison to antibodies to the other HCV antigens. It is to be understood, however, that it might be possible to determine certain epitopes in the E2 region which would also be suited for use in an test for monitoring/prognosing HCV disease.

5

The present invention also relates to a serotyping assay for detecting one or more serological types of HCV present in a biological sample, more particularly for detecting antibodies of the different types of HCV to be detected combined in one assay format, comprising at least the following steps:

1 (

- (i) contacting the biological sample to be analyzed for the presence of HCV antibodies of one or more serological types, with at least one of the E1 and/or E2 and/or E1/E2 protein compositions or at least one of the E1 or E2 peptide compositions as defined above, preferantially in an immobilized form under appropriate conditions which allow the formation of an immune complex,
- (ii) removing unbound components,

15

(iii) incubating the immune complexes formed with heterologous antibodies, with said heterologous antibodies being conjugated to a detectable label under appropriate conditions,

20

(iv) detecting the presence of said immune complexes visually or mechanically (e.g. by means of densitometry, fluorimetry, colorimetry) and inferring the presence of one or more HCV serological types present from the observed binding pattern.

It is to be understood that the compositions of proteins or peptides used in this method are recombinantly expressed type-specific envelope proteins or type-specific peptides.

25

- The present invention further relates to a kit for serotyping one or more serological types of HCV present in a biological sample, more particularly for detecting the antibodies to these serological types of HCV comprising:
 - at least one E1 and/or E2 and/or E1/E2 protein or E1 or E2 peptide, as defined above,

30

- a buffer or components necessary for producing the buffer enabling the binding reaction between these proteins or peptides and the anti-E1-antibodies present in a biological sample,
- means for detecting the immune complexes formed in the preceding binding

15

20

25

30

reaction,

possibly also an automated scanning and interpretation device for detecting the presence of one or more serological types present from the observed binding pattern.

The present invention also relates to the use of a peptide or protein composition as defined above, for immobilization on a solid substrate and incorporation into a reversed phase hybridization assay, preferably for immobilization as parallel lines onto a solid support such as a membrane strip, for determining the presence or the genotype of HCV according to a method as defined above. Combination with other type-specific antigens from other HCV polyprotein regions also lies within the scope of the present invention.

The present invention provides a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from E1 and/or E2 and/or E1/E2 proteins which have been produced by a recombinant process comprising contacting said proteins with a disulphide bond cleavage or reducing agent. The contacting of the method of the invention may be carried out under partial cleavage or reducing conditions. Preferably, the disulphide bond cleavage agent is dithiothreitol (DTT), preferably in a concentration range of 0.1 to 50 mM, preferably 0.1 to 20 mM, more preferably 0.5 to 10 mM. Alternatively, the disulphide bond cleavage agent may be a detergent, such as Empigen-BB (which is a mixture containing N-Docecyl-N,N-dimethylglycine as a major component), preferably at a concentration of 1 to 10%, more preferably at a concentration of 3.5%. Mixtures of detergents, disulphide bond cleavage agents and/or reducing agents may also be used. In one embodiment, disulphide bond reformation is prevented with an SH group blocking agent, such as N-ethylmaleimide (NEM) or a derivative thereof. In a preferred embodiment, the disulphide bond reformation is blocked by use of low pH conditions.

The present invention further provides a method as described herein, further involving the following steps: lysing recombinant E1 and/or E2 and/or E1/E2 expressing host cells, optionally in the presence of an SH blocking agent such as N-ethylmaleimide (NEM); recovering said HCV envelope proteins by affinity purification such as by means of lectin-chromatography, such as lentil-lectin chromatography, or by means of immunoaffinity using anti-E1 and/or anti-E2 specific monoclonal antibodies; reducing or cleaving of the disulfide bonds with a disulphide bond cleaving agent, such as DTT, preferably also in the presence of an SH blocking agent, such as NEM or Biotin-NEM; and, recovering the reduced E1 and/or E2 and/or E1/E2 envelope proteins by gelfiltration

and optionally additionally by a subsequent Ni²⁺-IMAC chromatography and desalting step.

The present invention provides a composition containing substantially isolated and/or purified, and/or isolated and/or purified recombinant HCV single or specific oligomeric recombinant envelope proteins selected from E1 and/or E2 and/or E1/E2, which have preferably been isolated from the methods described herein. In a preferred embodiment, the recombinant HCV envelope proteins of the invention have been expressed in recombinant mammalian cells, such as vaccinia, recombinant yeast cells.

10

15

20

25

30

The present invention provides a recombinant vector containing a vector sequence. a prokaryotic, eukaryotic or viral promoter sequence and a nucleotide sequence allowing the expression of a single or specific oligomeric E1 and/or E2 and/or E1/E2 protein, in operable combination. In one embodiment, the nucleotide sequence of the vector encodes a single HCV E1 protein starting in the region between amino acid positions 1 and 192 and ending in the region between amino acid positions 250 and 400, more particularly ending in the region between positions 250 and 341, even more preferably ending in the region between position 290 and 341. In another embodiment, the nucleotide sequence of the vector encodes a single HCV E1 protein starting in the region between amino acid positions 117 and 192 and ending in the region between amino acid positions 263 and 400, more particularly ending in the region between positions 250 and 326. In yet another embodiment, the nucleotide sequence of the vector encodes a single HCV E1 protein bearing a deletion of the first hydrophobic domain between positions 264 to 293, plus or minus 8 amino acids. In a further embodiment, the nucleotide sequence of the vector encodes a single HCV E2 protein starting in the region between amino acid positions 290 and 406 and ending in the region between amino acid positions 600 and 820, more particularly starting in the region between positions 322 and 406, even more preferably starting in the region between position 347 and 406 and most preferably starting in the region between positions 364 and 406; and preferably ending at any of amino acid positions 623, 650, 661, 673, 710, 715, 720, 746 or 809. The vector of the present invention, in one embodiment, contains a 5'-terminal ATG codon and a 3'-terminal stop codon operably linked to the nucleotide sequence. The vector further contains, in one embodiment, a nucleotide sequence further containing at a factor Xa cleavage site and/or 3 to 10, preferably 6, histidine codons added 3'-terminally to the coding region. The vector of the present invention optionally contains a nucleotide sequence wherein at least one of

10

15

20

25

30

PCT/EP02/14480

the glycosylation sites present in the E1 or E2 proteins has been removed at the nucleic acid level.

The present invention provides a nucleic acid containing any one of SEQ ID Nos: 3, 5, 7, 9, 11, 13, 21, 23, 25, 27, 29, 31, 35, 37, 39, 41, 43, 45, 47 and 49, or parts thereof. The vector of the invention may preferably contain a nucleotide sequence containing a nucleic acid containing any one of SEQ ID Nos: 3, 5, 7, 9, 11, 13, 21, 23, 25, 27, 29, 31, 35, 37, 39, 41, 43, 45, 47 and 49, or parts thereof.

The composition of the present invention further contains recombinant HCV envelope proteins which have been expressed or are the expression product of a vector described herein.

The present invention provides a host cell transformed with at least one recombinant vector as described herein, wherein the vector contains a nucleotide sequence encoding HCV E1 and/or E2 and/or E1/E2 protein as described herein in addition to a regulatory sequence operable in the host cell and capable of regulating expression of the HCV E1 and/or E2 and/or E1/E2 protein. Moreover, the present invention provides a ecombinant E1 and/or E2 and/or E1/E2 protein expressed by a host cell of the invention.

The present invention further provides a method as described herein and containing the following steps: growing a host cell as described herein which has been transformed with a recombinant vector as described herein in a suitable culture medium; causing expression of the vector nucleotide sequence of the vector, as described herein under suitable conditions; lysing the transformed host cells, preferably in the presence of an SH group blocking agent, such as N-ethylmaleimide (NEM); recovering the HCV envelope protein by affinity purification by means of for instance lectin-chromatography or immunoaffinity chromatography using anti-E1 and/or anti-E2 specific monoclonal antibodies, with said lectin being preferably lentil-lectin, followed by, incubation of the eluate of the previous step with a disulphide bond cleavage agent, such as DTT, preferably also in the presence of an SH group blocking agent, such as NEM or Biotin-NEM; and, isolating the HCV single or specific oligomeric E1 and/or E2 and/or E1/E2 proteins by means of gelfiltration and possibly also by means of an additional Ni²⁺-IMAC chromatography and desalting step.

The present invention provides a composition containing at least one of the following E1 and/or E2 peptides:

E1-31 (SEQ ID NO:56) spanning amino acids 181 to 200 of the Core/E1

V1 region,

E1-33 (SEQ ID NO:57) spanning amino acids 193 to 212 of the E1 region, E1-35 (SEQ ID NO:58) spanning amino acids 205 to 224 of the E1 V2 region (epitope B),

5

E1-35A (SEQ ID NO:59) spanning amino acids 208 to 227 of the E1 V2 region (epitope B),

1bE1 (SEQ ID NO:53) spanning amino acids 192 to 228 of E1 regions (V1, C1, and V2 regions (containing epitope B),

10

E1-51 (SEQ ID NO:66) spanning amino acids 301 to 320 of the E1 region, E1-53 (SEQ ID NO:67) spanning amino acids 313 to 332 of the E1 C4 region (epitope A),

E1-55 (SEQ ID NO:68) spanning amino acids 325 to 344 of the E1 region.

Env 67 or E2-67 (SEQ ID NO:72) spanning amino acid positions 397 to 416 of the E2 region (epitope A),

15

20

Env 69 or E2-69 (SEQ ID NO:73) spanning amino acid positions 409 to 428 of the E2 region (epitope A),

Env 23 or E2-23 (SEQ ID NO:86) spanning positions 583 to 602 of the E2 region (epitope E),

Env 25 or E2-25 (SEQ ID NO:87) spanning positions 595 to 614 of the E2 region (epitope E),

Env 27 or E2-27 (SEQ ID NO:88) spanning positions 607 to 626 of the E2 region (epitope E),

Env 17B or E2-17B (SEQ ID NO:83) spanning positions 547 to 566 of the E2 region (epitope D),

25

Env 13B or E2-13B (SEQ ID NO:82) spanning positions 523 to 542 of the E2 region (epitope C).

The present invention provides a composition containing at least one of the following E2 conformational epitopes:

epitope F recognized by monoclonal antibodies 15C8C1, 12D11F1, and 30 8G10D1H9,

epitope G recognized by monoclonal antibody 9G3E6, epitope H (or C) recognized by monoclonal antibodies 10D3C4 and 4H6B2, epitope I recognized by monoclonal antibody 17F2C2.

10

15

20

25

30

The present invention provides an E1 and/or E2 specific monoclonal antibody raised upon immunization with a composition as described herein. The antibodies of the present invention may be used, for example, as a medicament, for incorporation into an immunoassay kit for detecting the presence of HCV E1 or E2 antigen, for prognosis/monitoring of disease or for HCV therapy. The present invention provides for the use of an E1 and/or E2 specific monoclonal antibody as described herein for the preparation of an immunoassay kit for detecting HCV E1 or E2 antigens, for the preparation of a kit for prognosing/monitoring of HCV disease or for the preparation of a HCV medicament.

The present invention provides a method for in vitro diagnosis of HCV antigen present in a biological sample, containing at least the following steps:

- (i) contacting said biological sample with an E1 and/or E2 specific monoclonal antibody as described herein, preferably in an immobilized form under appropriate conditions which allow the formation of an immune complex,
 - (ii) removing unbound components,
- (iii) incubating the immune complexes formed with heterologous antibodies, with the heterologous antibodies being conjugated to a detectable label under appropriate conditions.
 - (iv) detecting the presence of the immune complexes visually or mechanically.

The present invention provides a kit for determining the presence of HCV antigens present in a biological sample, which includes at least the following: at least one E1 and/or E2 specific monoclonal antibody as described herein, preferably in an immobilized form on a solid substrate, a buffer or components necessary for producing the buffer enabling binding reaction between these antibdodies and the HCV antigens present in a biological sample, and optionally a means for detecting the immune complexes formed in the preceding binding reaction.

The composition of the present invention may be provided in the form of a medicament.

The present invention provides a composition, as described herein for use as a vaccine for immunizing a mammal, preferably humans, against HCV, comprising administrating an effective amount of said composition being optionally accompanied by pharmaceutically acceptable adjuvants, to produce an immune response.

The present invention provides a method of using the composition, as described

herein, for the preparation of a vaccine for immunizing a mammal, preferably humans, against HCV, comprising administrating an effective amount of said composition, optionally accompanied by pharmaceutically acceptable adjuvants, to produce an immune response.

The present invention provides a vaccine composition for immunzing a mammal, preferably humans, against HCV, which contains an effective amount of a composition containing an E1 and/or E2 containing composition as described herein, optionally also accompanied by pharmaceutically acceptable adjuvants.

The composition of the present invention may be provided in a form for *in vitro* detection of HCV antibodies present in a biological sample. The present invention also provides a method of preparing an immunoassay kit for detecting HCV antibodies present in a biological sample and a method of detecting HCV antibodies present in a biological sample using the kit of the invention to diagnose HCV antibodies present in a biological sample. Such a method of the present invention includes at least the following steps:

- (i) contacting said biological sample with a composition as described herein, preferably in an immobilized form under appropriate conditions which allow the formation of an immune complex with HCV antibodies present in the biological sample,
 - (ii) removing unbound components,

5

15

20

25

30

- (iii) incubating the immune complexes formed with heterologous antibodies, with the heterologous antibodies being conjugated to a detectable label under appropriate conditions,
 - (iv) detecting the presence of the immune complexes visually or mechanically.

The present invention provides a kit for determining the presence of HCV antibodies present in a biological sample, containing: at least one peptide or protein composition as described herein, preferably in an immobilized form on a solid substrate; a buffer or components necessary for producing the buffer enabling binding reaction between these proteins or peptides and the antibodies against HCV present in the biological sample; and, optionally, a means for detecting the immune complexes formed in the preceding binding reaction.

The present invention provides a method of *in vitro* monitoring HCV disease or diagnosing the response of a patient suffering from HCV infection to treatment, preferably with interferon, the method including: incubating a biological sample from the patient with HCV infection with an E1 protein or a suitable part thereof under conditions allowing the

formation of an immunological complex; removing unbound components; calculating the anti-E1 titers present in the sample at the start of and during the course of treatment; monitoring the natural course of HCV disease, or diagnosing the response to treatment of the patient on the basis of the amount anti-E1 titers found in the sample at the start of treatment and/or during the course of treatment.

5

10

15

20

25

30

The present invention provides a kit for monitoring HCV disease or prognosing the response to treatment, particularly with interferon, of patients suffering from HCV infection, wherein the kit contains: at least one E1 protein or E1 peptide, more particularly an E1 protein or E1 peptide as described herein; a buffer or components necessary for producing the buffer enabling the binding reaction between these proteins or peptides and the anti-E1 antibodies present in a biological sample; and optionally, means for detetecting the immune complexes formed in the preceding binding reaction, optionally, also an automated scanning and interpretation device for inferring a decrease of anti-E1 titers during the progression of treatment.

The present invention provides a serotyping assay for detecting one or more serological types of HCV present in a biological sample, more particularly for detecting antibodies of the different types of HCV to be detected combined in one assay format, including at least the following steps: (i) contacting the biological sample to be analyzed for the presence of HCV antibodies of one or more serological types, with at least one of the E1 and/or E2 and/or E1/E2 protein compositions as described herein or at least one of the E1 or E2 peptide compositions described herein, preferentially in an immobilized form under appropriate conditions which allow the formation of an immune complex; (ii) removing unbound components; (iii) incubating the immune complexes formed with heterologous antibodies, with the heterologous antibodies being conjugated to a detectable label under appropriate conditions; and optionally, (iv) detecting the presence of said immune complexes visually or mechanically (e.g. by means of densitometry, fluorimetry, colorimetry) and inferring the presence of one or more HCV serological types present from the observed binding pattern.

The present invention provides a kit for serotyping one or more serological types of HCV present in a biological sample, more particularly for detecting the antibodies to these serological types of HCV containing: at least one E1 and/or E2 and/or E1/E2 protein as described herein or an E1 or E2 peptide as described herein; a buffer or components necessary for producing the buffer enabling the binding reaction between these proteins or

peptides and the anti-E1 antibodies present in a biological sample; optionally, means for detecting the immune complexes formed in the preceding binding reaction, optionally, also an automated scanning and interpretation device for detecting the presence of one or more serological types present from the observed binding pattern.

5

The present invention provides a peptide or protein composition as described herein, for immobilization on a solid substrate and incorporation into a reversed phase hybridization assay, preferably for immobilization as parallel lines onto a solid support such as a membrane strip, for determining the presence or the genotype of HCV according to a method as described herein.

10

15

The present invention provides a therapeutic vaccine composition, such as a therapeutic HCV vaccine composition, containing or comprising a therapeutically effective amount of: a composition containing at least one purified recombinant HCV single or specific oligomeric recombinant envelope proteins selected from the group consisting of an E1 protein, an E2 protein, a part of said E1 and E2 proteins, an E1/E2 protein complex formed from purified HCV single or specific oligomeric recombinant E1 or E2 proteins or parts thereof; and optionally a pharmaceutically acceptable adjuvant. Another therapeutic vaccine composition, such as a therapeutic HCV vaccine composition, of the invention may be comprising a therapeutically effective amount of a combination of at least two purified HCV single or specific oligomeric recombinant envelope proteins selected from the group consisting of E1 proteins derived from different HCV genotypes or subtypes, E2 proteins derived from different HCV genotypes or subtypes, parts of said E1 and E2 proteins, and E1/E2 protein complexes formed from purified HCV single or specific oligomeric recombinant E1 or E2 proteins, or parts thereof, derived from different HCV genotypes or subtypes; and optionally a pharmaceutically acceptable adjuvant.

25

20

The HCV envelope proteins of the vaccine, or more particularly the HCV vaccine, of the present invention are optionally produced by recombinant mammalian cells, by recombinant yeast cells, or by or via a recombinant virus. The invention provides a therapeutic vaccine composition, such as a therapeutic HCV vaccine composition, containing or comprising a therapeutically effective amount of a composition comprising at least one of the following E1 and E2 peptides:

30

E1-31 (SEQ ID NO:56) spanning amino acids 181 to 200 of the Core/E1 V1 region, E1-33 (SEQ ID NO:57) spanning amino acids 193 to 212 of the E1 region, E1-35 (SEQ ID NO:58) spanning amino acids 205 to 224 of the E1 V2 region (epitope B),

5

15

30

E1-35A (SEQ ID NO:59) spanning amino acids 208 to 227 of the E1 V2 region (epitope B),

1bE1 (SEQ ID NO:53) spanning amino acids 192 to 228 of E1 regions V1, C1, and V2 regions (containing epitope B),

E1-51 (SEQ ID NO:66) spanning amino acids 301 to 320 of the E1 region,

E1-53 (SEQ ID NO:67) spanning amino acids 313 to 332 of the E1 C4 region (epitope A),

E1-55 (SEQ ID NO:68) spanning amino acids 325 to 344 of the E1 region,

Env 67 or E2-67 (SEQ ID NO:72) spanning amino acid positions 397 to 418 of the E2 region (epitope A),

Env 69 or E2-69 (SEQ ID NO:73) spanning amino acid positions 409 to 428 of the E2 region (epitope A),

Env 23 or E2-23 (SEQ ID NO:86) spanning positions 583 to 602 of the E2 region (epitope E),

Env 25 or E2-25 (SEQ ID NO:87) spanning positions 595 to 614 of the E2 region (epitope E),

Env 27 or E2-27 (SEQ ID NO:88) spanning positions 607 to 626 of the E2 region (epitope E),

Env 17B or E2-17B (SEQ ID NO:83) spanning positions 547 to 586 of the E2 region (epitope D),

Env 13B or E2-13B (SEQ ID NO:82) spanning positions 523 to 542 of the E2 region (epitope C),

IGP 1626 spanning positions 192-211 of the E1 region (SEQ ID NO:112),

25 IGP 1627 spanning positions 204-223 of the E1 region (SEQ ID NO:113),

IGP 1628 spanning positions 216-235 of the E1 region (SEQ ID NO:114),

IGP 1629 spanning positions 228-247 of the E1 region (SEQ ID NO:115),

IGP 1630 spanning positions 240-259 of the E1 region (SEQ ID NO:116),

IGP 1631 spanning positions 252-271 of the E1 region (SEQ ID NO:117),

IGP 1632 spanning positions 264-283 of the E1 region (SEQ ID NO:118),

IGP 1633 spanning positions 276-295 of the E1 region (SEQ ID NO:119),

IGP 1634 spanning positions 288-307 of the E1 region (SEQ ID NO:120),

IGP 1635 spanning positions 300-319 of the E1 region (SEQ ID NO:121) and

15

20

IGP 1636 spanning positions 312-331 of the E1 region (SEQ ID NO:122); and wherein said peptides may be of recombinant or synthetic origin, and optionally combined with a pharmaceutically acceptable adjuvant.

Any of the above mentioned therapeutic vaccine compositions may also be considered or regarded as therapeutic HCV vaccine compositions, or as therapeutic compositions or therapeutic HCV compositions, or as compositions or HCV compositions.

The present invention provides a method of treating a mammal, such as a human, infected with HCV comprising administering an effective amount of a composition as described herein, such as the above described vaccines or therapeutic compositions, and optionally, a pharmaceutically acceptable adjuvant. In one embodiment, the composition of the invention is administered in combination with or at a time in conjunction with antiviral therapy, either soon prior to or subsequent to or with administration of the composition of the invention. It will be clear that any of the compositions of the invention, e.g. a therapeutic HCV vaccine composition, can be used for treating a mammal chronically infected with HCV (a "chronic HCV-infected mammal").

The present invention provides a composition, such as a therapeutic HCV composition or a HCV composition, containing or comprising at least one purified recombinant HCV recombinant envelope proteins selected from the group consisting of an E1 protein and an E2 protein, and optionally an adjuvant. In a preferred embodiment, the composition contains at least one of the following E1 and E2 peptides:

E1-31 (SEQ ID NO:56) spanning amino acids 181 to 200 of the Core/E1 V1 region, E1-33 (SEQ ID NO:57) spanning amino acids 193 to 212 of the E1 region, E1-35 (SEQ ID NO:58) spanning amino acids 205 to 224 of the E1 V2 region (epitope B),

E1-35A (SEQ ID NO:59) spanning amino acids 208 to 227 of the E1 V2 region (epitope B),

1bE1 (SEQ ID NO:53) spanning amino acids 192 to 228 of E1 regions V1, C1, and V2 regions (containing epitope B),

E1-51 (SEQ ID NO:66) spanning amino acids 301 to 320 of the E1 region,

E1-53 (SEQ ID NO:67) spanning amino acids 313 to 332 of the E1 C4 region (epitope A),

E1-55 (SEQ ID NO:68) spanning amino acids 325 to 344 of the E1 region, Env 67 or E2-67 (SEQ ID NO:72) spanning amino acid positions 397 to 418 of the E2

20

25

30

region (epitope A),

Env 69 or E2-69 (SEQ ID NO:73) spanning amino acid positions 409 to 428 of the E2 region (epitope A),

Env 23 or E2-23 (SEQ ID NO:86) spanning positions 583 to 602 of the E2 region (epitope E),

Env 25 or E2-25 (SEQ ID NO:87) spanning positions 595 to 614 of the E2 region (epitope E),

Env 27 or E2-27 (SEQ ID NO:88) spanning positions 607 to 626 of the E2 region (epitope E),

Env 17B or E2-17B (SEQ ID NO:83) spanning positions 547 to 586 of the E2 region (epitope D),

Env 13B or E2-13B (SEQ ID NO:82) spanning positions 523 to 542 of the E2 region (epitope C),

IGP 1626 spanning positions 192-211 of the E1 region (SEQ ID NO:112),

15 IGP 1627 spanning positions 204-223 of the E1 region (SEQ ID NO:113),

IGP 1628 spanning positions 216-235 of the E1 region (SEQ ID NO:114),

IGP 1629 spanning positions 228-247 of the E1 region (SEQ ID NO:115),

IGP 1630 spanning positions 240-259 of the E1 region (SEQ ID NO:116),

IGP 1631 spanning positions 252-271 of the E1 region (SEQ ID NO:117),

IGP 1632 spanning positions 264-283 of the E1 region (SEO ID NO:118).

IGP 1633 spanning positions 276-295 of the E1 region (SEQ ID NO:119),

IGP 1634 spanning positions 288-307 of the E1 region (SEQ ID NO:120),

IGP 1635 spanning positions 300-319 of the E1 region (SEQ ID NO:121) and

IGP 1636 spanning positions 312-331 of the E1 region (SEQ ID NO:122),

and wherein said peptides may be of recombinant or synthetic origin, and optionally combined with a pharmaceutically acceptable adjuvant.

Another composition, such as a therapeutic HCV composition or HCV composition, of the invention may be comprising a therapeutically effective amount of a combination of at least two purified HCV single or specific oligomeric recombinant envelope proteins selected from the group consisting of E1 proteins derived from different HCV genotypes or subtypes, E2 proteins derived from different HCV genotypes or subtypes, parts of said E1 and E2 proteins, and E1/E2 protein complexes formed from purified HCV single or specific oligomeric recombinant E1 or E2 proteins, or parts thereof,

15

20

25

30

derived from different HCV genotypes or subtypes; and optionally a pharmaceutically acceptable adjuvant.

The present invention provides a therapeutic composition or therapeutic vaccine composition or composition for inducing HCV-specific antibodies or for stimulating T-cell activity or for stimulating cytokine secretion or cytokine production. The present invention provides a therapeutic HCV composition or therapeutic HCV vaccine composition or HCV composition for inducing HCV-specific antibodies or for stimulating T-cell activity or for stimulating cytokine secretion or cytokine production.

The therapeutic composition according to the present invention, such as a therapeutic HCV vaccine composition or therapeutic HCV composition, may also be therapeutically effective in a HCV carrier infected with a HCV genotype different from the HCV genotype or HCV genotypes from which said E1, E2, or E1/E2 protein complexes are derived.

The recombinant HCV envelope proteins may be produced by recombinant mammalian cells, recombinant HCV envelope proteins are produced by recombinant yeast cells, or recombinant HCV envelope proteins are produced by or via a recombinant virus. The present invention provides a method of treating a mammal, such as a human, infected with HCV including administering an effective amount of a composition described herein, such as a therapeutic HCV vaccine composition, and, optionally, a pharmaceutically acceptable adjuvant. It will be clear that any of the compositions of the invention, such as a therapeutic HCV vaccine composition, can be used for treating a chronic HCV-infected mammal. The present invention provides a therapeutic composition for inducing HCV-specific antibodies, for stimulating T-cell activity or for stimulating cytokine secretion or cytokine production, said composition containing a therapeutic effective amount of a composition containing at least one purified recombinant HCV single or specific oligomeric recombinant envelope protein selected from the group consisting of an E1 protein and an E2 protein; and optionally a pharmaceutically acceptable adjuvant.

In particular, any of the compositions according to this invention (including the vaccine compositions and therapeutic compositions) may comprise recombinant HCV envelope proteins wherein the cysteines of said recombinant HCV envelope proteins are blocked, or may comprise E1 and/or E2 peptides wherein the cysteines of said E1 or E2 peptides are blocked.

In another embodiment of the invention, the compositions (including the vaccine

10

15

20

25

30

PCT/EP02/14480

compositions and therapeutic compositions) according to the invention may comprise recombinant HCV envelope proteins which are added to said compositions as viral-like particles (VLPs).

In a further embodiment, a composition of the invention such as a therapeutic HCV vaccine composition may comprise as recombinant HCV E1 envelope protein an E1s protein. More particularly, said E1s protein is defined by SEQ ID NO:123.

Another aspect of the invention relates to an immunogenic composition, in particular a HCV immunogenic composition, comprising a recombinant virus allowing expression of at least one HCV recombinant envelope protein chosen from an E1 protein and/or an E2 protein, and parts of said E1 and E2 proteins; and, optionally, a pharmaceutically acceptable adjuvant.

In yet a further aspect, the invention is envisaging a vaccine composition such as a HCV vaccine composition comprising a recombinant virus allowing expression of at least one HCV recombinant envelope protein chosen from an E1 protein and/or an E2 protein, and parts of said E1 and E2 proteins; and, optionally, a pharmaceutically acceptable adjuvant.

In one embodiment, the above recombinant virus compositions may be effective against a HCV genotype or subtype different from the HCV genotype or subtype from which said E1 protein and/or E2 protein, or said parts thereof, are derived.

In another embodiment, the above recombinant virus compositions may be used for inducing HCV-specific antibodies or for stimulating T-cell activity or for stimulating cytokine secretion or cytokine production.

In another embodiment to the recombinant virus compositions, said recombinant virus is a vaccinia virus, a recombinant avipox virus or a recombinant Ankara Modified Virus.

Another aspect of the invention relates to a method of treating a mammal infected with HCV comprising administering an effective amount of a recombinant vaccine composition as described above.

The mammal in any of the above aspects of the invention may in particular be a human.

One further aspect of the present invention relates to a method to reduce liver disease in a chronic HCV-infected mammal or human comprising administering a therapeutic vaccine to said mammal or human.

In another aspect, a method to reduce liver fibrosis progression in a chronic HCV-

infected mammal or human comprising administering a therapeutic vaccine to said mammal or human is covered.

A further aspect relates to a method to reduce liver fibrosis in a chronic HCV-infected mammal or human comprising administering a therapeutic vaccine to said mammal or human.

5

10

15

20

25

30

A further aspect relates to a method to reduce liver steatosis in a chronic HCV-infected mammal or human comprising administering a therapeutic vaccine to said mammal or human.

Yet another aspect of the invention embodies a method to reduce liver disease by at least 2 points according to the overall Ishak score or Ishak activity score in a chronic HCV-infected mammal or human comprising administering a therapeutic vaccine to said mammal or human.

Another further aspect relates to a method to reduce liver disease or liver fibrosis by at least 1 point according to the Ishak fibrosis score in a chronic HCV-infected mammal or human comprising administering a therapeutic vaccine to said mammal or human.

A further aspect of the invention provides a method to reduce serum ALT levels in a chronic HCV-infected mammal or human comprising administering a therapeutic vaccine to said mammal or human.

Yet another aspect of the invention relates to a method to reduce anti-E1 and/or anti-E2 immunoreactivity in the liver of a chronic HCV-infected mammal or human comprising administering a therapeutic vaccine to said mammal or human.

Furthermore included in the invention is a method for treating a chronic HCV-infected mammal or human wherein said method is comprising administration of multiple doses of any of the compositions of the invention, such as a therapeutic HCV vaccine composition, to said mammal or human and wherein said multiple doses are administrated to said mammal or human separated by a specified time interval. Thus, said plurality of administrations of a composition of the invention to treat a chronic HCV-infected carrier may be separated, e.g., by a time-interval of 4 weeks or less. Thus, said time intervals could be 1 or 1.5 or 2 or 2.5 or 3 or 3.5 or 4 weeks, or could be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or 28 days. In particular, said method of treating a chronic HCV-infected mammal or human comprises a plurality of administrations of a composition of the invention, such as a therapeutic HCV vaccine composition, to said mammal or human wherein said administrations are separated by a

time interval of 3 weeks. In a further embodiment, said plurality of administrations consists of a first series of at least 5 administrations followed by an administration-free period of at least 12 weeks followed by a second series of at least 3 administrations. In particular, a series of administrations may comprise at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more administrations. The administration-free period may be at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or more weeks.

It will furthermore be clear that any of the compositions of the invention, such as a therapeutic HCV vaccine composition, can be used for obtaining any of the effects aimed at in the various methods as described above. Said therapeutic vaccine as applied in the methods described above may be any composition of the current invention, such as a therapeutic HCV vaccine composition.

The use of the HCV E1/E2 proteins or parts thereof or E1/E2 peptides as outlined throughout the above description for the manufacture of a composition, HCV composition, vaccine, HCV vaccine, therapeutic vaccine or therapeutic HCV vaccine for use in any of the methods outlined above or used for obtaining any of the effects aimed at in the various methods outlined above is also envisaged by the current invention.

15

20

25

30

In any of these methods said therapeutic vaccine comprises at least one HCV antigen and, optionally, a pharmaceutically acceptable adjuvant such as alum. In one embodiment thereto said HCV antigen is an E1 or E2 antigen, or an immunogenic part of an E1 or E2 antigen. When referring to the HCV antigen as being an E1s antigen, the E1s antigen may be defined by SEQ ID NO:123.

With the term "liver disease" is meant in this context any abnormal liver condition caused by infection with the hepatitis C virus including inflammation, fibrosis, cirrhosis, necrosis, necro-inflammation and hepatocellular carcinoma.

With "steatosis" is meant a histological feature of lipid accumulation in the hepatocytes that is indicative of liver involvement in a wide variety of systemic disorders, toxic or drug-induced liver injury, as well as of various specific liver diseases, including hepatitis C infection, Wilson's disease, and galactosemia.

With "reducing liver disease" is meant any stabilization or reduction of the liver disease status. Liver disease can be determined, e.g., by the Knodell scoring system or the Knodell scoring system adapted by Ishak. A reduction of this score by two points is accepted as therapeutically beneficial effect in several studies (see, e.g., studies published after 1996 as indicated in Table 2 of Shiffman 1999).

WO 03/051912 PCT/EP02/14480

With "reducing liver fibrosis progression" is meant any slowing down, halting or reverting of the normally expected progression of liver fibrosis. Liver fibrosis progression can be determined, e.g., by the Metavir scoring system. Normal expected progression of liver fibrosis according to this system was published to be an increase of the Metavir score of an untreated chronic HCV patient of approximately 0.133 per year (Poynard et al. 1997). Fibrosis is considered to include any form of fibrosis, e.g. as scored by the Metavir or Ishak system, including perisinusoidal fibrosis.

With the term "HCV antigen" is meant any HCV protein or fragment thereof comprising at least one T cell epitope or B cell epitope.

A further aspect of the current invention provides a method to predict changes in liver disease in a chronic HCV-infected mammal or human, said method comprising:

- (i) determining the level of serum anti-E1 antibody level prior to therapeutic vaccination with a HCV vaccine composition comprising an E1 antigen;
- (ii) determining the level of serum anti-E1 antibody level after therapeutic vaccination with a HCV vaccine composition comprising an E1 antigen;
- (iii) inferring the difference in level of serum anti-E1 antibody level determined in(i) and (ii) and, therefrom, predicting the change in liver disease.

It will be clear to the skilled artisan that a significantly high and positive difference in level of serum anti-E1 antibody, calculated as the value measured in (ii) minus the value measured in (i), would tip the balance in favor of a positive prediction, i.e., a prediction that the degree of liver disease will decrease. It will also be clear that a sustained significantly high and positive difference would add to the positive character of the prediction of decreased liver disease. When said difference is, however, not significantly high, is zero, is negative, or is significantly high and positive at one point in time but is not sustained, this would then tip the balance in favor of a negative prediction, i.e., a prediction that the degree of liver disease will remain unchanged or will increase. A sustained high level of serum anti-E1 antibody could be reached trough additional immunizations either by administering a new series of immunizations after an administration free period or by repeating immunizations with a larger time interval, e.g. 6 weeks, after an initial priming series consisting of administrations with a short time interval, e.g. 3 weeks.

Figure and Table legends

Figure 1:	Restriction map of plasmid pgpt ATA 18
Figure 2:	Restriction map of plasmid pgs ATA 18
Figure 3:	Restriction map of plasmid pMS 66
Figure 4:	Restriction map of plasmid pv HCV-11A
Figure 5:	Anti-E1 levels in non-responders to IFN treatment
Figure 6:	Anti-E1 levels in responders to IFN treatment
Figure 7:	Anti-E1 levels in patients with complete response to IFN treatment
Figure 8:	Anti-E1 levels in incomplete responders to IFN treatment
Figure 9:	Anti-E2 levels in non-responders to IFN treatment
Figure 10:	Anti-E2 levels in responders to IFN treatment
Figure 11:	Anti-E2 levels in incomplete responders to IFN treatment
Figure 12:	Anti-E2 levels in complete responders to IFN treatment
Figure 13:	Human anti-E1 reactivity competed with peptides
Figure 14:	Competition of reactivity of anti-E1 monoclonal antibodies with peptides
Figure 15:	Anti-E1 (epitope 1) levels in non-responders to IFN treatment
Figure 16:	Anti-E1 (epitope 1) levels in responders to IFN treatment
Figure 17:	Anti-E1 (epitope 2) levels in non-responders to IFN treatment
Figure 18:	Anti-E1 (epitope 2) levels in responders to IFN treatment
Figure 19:	Competition of reactivity of anti-E2 monoclonal antibodies with peptides
Figure 20:	Human anti-E2 reactivity competed with peptides
Figure 21:	Nucleic acid sequences of the present invention. The nucleic acid sequences
	encoding an E1 or E2 protein according to the present invention may be
• • •	translated (SEQ ID NO 3 to 13, 21-31, 35 and 41-49 are translated in a
	reading frame starting from residue number 1, SEQ ID NO 37-39 are
	translated in a reading frame starting from residue number 2), into the amino
	acid sequences of the respective E1 or E2 proteins as shown in the sequence
·	listing.
Figure 22:	ELISA results obtained from lentil lectin chromatography eluate fractions of
	4 different E1 purifications of cell lysates infected with vvHCV39 (type 1b),
_	vvHCV40 (type 1b), vvHCV62 (type 3a), and vvHCV63 (type 5a).
Figure 23:	Elution profiles obtained from the lentil lectin chromatography of the 4
	Figure 2: Figure 3: Figure 4: Figure 5: Figure 6: Figure 7: Figure 8: Figure 9: Figure 10: Figure 13: Figure 15: Figure 15: Figure 16: Figure 17: Figure 19: Figure 20: Figure 21:

PCT/EP02/14480

different E1 constructs on the basis of the values as shown in Figure 22.

Figure 24: ELISA results obtained from fractions obtained after gelfiltration chromatography of 4 different E1 purifications of cell lysates infected with vvHCV39 (type 1b), vvHCV40 (type 1b), vvHCV62 (type 3a), and vvHCV63

(type 5a).

Figure 25: Profiles obtained from purifications of E1 proteins of type 1b (1), type 3a (2),

and type 5a (3) (from RK13 cells infected with vvHCV39, vvHCV62, and vvHCV63, respectively; purified on lentil lectin and reduced as in example

5.2 - 5.3) and a standard (4). The peaks indicated with '1', '2', and '3', represent

pure E1 protein peaks (see Figure 24, E1 reactivity mainly in fractions 26 to

30).

Figure 26: Silver staining of an SDS-PAGE as described in example 4 of a raw lysate of

E1 vvHCV40 (type 1b) (lane 1), pool 1 of the gelfiltration of vvHCV40 representing fractions 10 to 17 as shown in Figure 25 (lane 2), pool 2 of the

gelfiltration of vvHCV40 representing fractions 18 to 25 as shown in Figure

germation of vitte vito representing fluctions to to 25 as shown in t

25 (lane 3), and E1 pool (fractions 26 to 30) (lane 4).

Figure 27: Streptavidine-alkaline phosphatase blot of the fractions of the gelfiltration of

E1 constructs 39 (type 1b) and 62 (type 3a). The proteins were labelled with

NEM-biotin. Lane 1: start gelfiltration construct 39, lane 2: fraction 26

construct 39, lane 3: fraction 27 construct 39, lane 4: fraction 28 construct 39,

lane 5: fraction 29 construct 39, lane 6: fraction 30 construct 39, lane 7

fraction 31 construct 39, lane 8: molecular weight marker, lane 9: start

gelfiltration construct 62, lane 10: fraction 26 construct 62, lane 11: fraction

27 construct 62, lane 12: fraction 28 construct 62, lane 13: fraction 29

construct 62, lane 14: fraction 30 construct 62, lane 15: fraction 31 construct

62.

Figure 28: Siver staining of an SDS-PAGE gel of the gelfiltration fractions of vvHCV-

39 (E1s, type 1b) and vvHCV-62 (E1s, type 3a) run under identical conditions

as Figure 26. Lane 1: start gelfiltration construct 39, lane 2: fraction 26

construct 39, lane 3: fraction 27 construct 39, lane 4: fraction 28 construct 39,

lane 5: fraction-29 construct 39, lane 6: fraction 30 construct 39, lane 7

fraction 31 construct 39, lane 8: molecular weight marker, lane 9: start

gelfiltration construct 62, lane 10: fraction 26 construct 62, lane 11: fraction

5

15

20

25

30

WO 03/051912 PCT/EP02/14480

27 construct 62, lane 12: fraction 28 construct 62, lane 13: fraction 29 construct 62, lane 14: fraction 30 construct 62, lane 15: fraction 31 construct 62.

Figure 29:

Western Blot analysis with anti-E1 mouse monoclonal antibody 5E1A10 giving a complete overview of the purification procedure. Lane 1: crude lysate, Lane 2: flow through of lentil chromagtography, Lane 3: wash with Empigen BB after lentil chromatography, Lane 4: Eluate of lentil chromatography, Lane 5: Flow through during concentration of the lentil eluate, Lane 6: Pool of E1 after Size Exclusion Chromatography (gelfiltration).

10

15

5

Figure 30: OD₂₈₀ profile (continuous line) of the lentil lectin chromatography of E2 protein from RK13 cells infected with vvHCV44. The dotted line represents the E2 reactivity as detected by ELISA (as in example 6).

Figure 31A:

Figure 31B:

OD₂₈₀ profile (continuous line) of the lentil-lectin gelfiltration chromatography E2 protein pool from RK13 cells infected with vvHCV44 in which the E2 pool is applied immediately on the gelfiltration column (non-reduced conditions). The dotted line represents the E2 reactivity as detected by ELISA (as in example 6).

20

25

OD₂₈₀ profile (continuous line) of the lentil-lectin gelfiltration chromatography E2 protein pool from RK13 cells infected with vvHCV44 in which the E2 pool was reduced and blocked according to Example 5.3 (reduced conditions). The dotted line represents the E2 reactivity as detected by ELISA (as in example 6).

Figure 32:

Ni²⁺-IMAC chromatography and ELISA reactivity of the E2 protein as expressed from vvHCV44 after gelfiltration under reducing conditions as shown in Figure 31B.

Figure 33:

Silver staining of an SDS-PAGE of 0.5 μ g of purified E2 protein recovered by a 200 mM imidazole elution step (lane 2) and a 30mM imidazole wash (lane 1) of the Ni²⁺-IMAC chromatography as shown in Figure 32.

30 Figure 34:

OD profiles of a desalting step of the purified E2 protein recovered by 200 mM imidazole as shown in Figure 33, intended to remove imidazole.

Figure 35A:

Antibody levels to the different HCV antigens (Core 1, Core 2, E2HCVR, NS3) for NR and LTR followed during treatment and over a period of 6 to 12

months after treatment determined by means of the LIAscan method. The average values are indicated by the curves with the open squares.

Figure 35B: Antibody levels to the different HCV antigens (NS4, NS5, E1 and E2) for NR and LTR followed during treatment and over a period of 6 to 12 months after treatment determined by means of the LIAscan method. The average values are indicated by the curve with the open squares.

Figure 36: Average E1 antibody (E1Ab) and E2 antibody (E2Ab) levels in the LTR and NR

LO groups.

20

25

30

Figure 37: Averages E1 antibody (E1Ab) levels for non-responders (NR) and long term responders (LTR) for type 1b and type 3a.

Figure 38: Relative map positions of the anti-E2 monoclonal antibodies.

Figure 39: Partial deglycosylation of HCV E1 envelope protein. The lysate of vvHCV10A-infected RK13 cells were incubated with different concentrations of glycosidases according to the manufacturer's instructions. Right panel: Glycopeptidase F (PNGase F). Left panel: Endoglycosidase H (Endo H).

Figure 40: Partial deglycosylation of HCV E2 envelope proteins. The lysate of vvHCV64-infected (E2) and vvHCV41-infected (E2s)RK13 cells were incubated with different concentrations of Glycopeptidase F (PNGase F) according to the manufacturer's instructions.

Figure 41: In vitro mutagenesis of HCV E1 glycoproteins. Map of the mutated sequences and the creation of new restriction sites.

Figure 42A: In vitro mutagenesis of HCV E1 glycoprotein (part 1). First step of PCR amplification.

Figure 42B: In vitro mutagensis of HCV E1 glycoprotein (part 2). Overlap extension and nested PCR.

Figure 43: In vitro mutagesesis of HCV E1 glycoproteins. Map of the PCR mutated fragments (GLY-# and OVR-#) synthesized during the first step of amplification.

Figure 44A: Analysis of E1 glycoprotein mutants by Western blot expressed in HeLa (left) and RK13 (right) cells. Lane 1: wild type VV (vaccinia virus), Lane 2: original E1 protein (vvHCV-10A), Lane 3: E1 mutant Gly-1 (vvHCV-81),

Lane 4: E1 mutant Gly-2 (vvHCV-82), Lane 5: E1 mutant Gly-3 (vvHCV-83), Lane 6: E1 mutant Gly-4 (vvHCV-84), Lane 7: E1 mutant Gly-5 (vvHCV-85), Lane 8: E1 mutant Gly-6 (vvHCV-86).

Figure 44B:

Analysis of E1 glycosylation mutant vaccinia viruses by PCR amplification/restriction. Lane 1: E1 (vvHCV-10A), BspE I, Lane 2: E1.GLY-1 (vvHCV-81), BspE I, Lane 4: E1 (vvHCV-10A), Sac I, Lane 5: E1.GLY-2 (vvHCV-82), Sac I, Lane 7: E1 (vvHCV-10A), Sac I, Lane 8: E1.GLY-3 (vvHCV-83), Sac I, Lane 10: E1 (vvHCV-10A), Stu I, Lane 11: E1.GLY-4 (vvHCV-84), Stu I, Lane 13: E1 (vvHCV-10A), Sma I, Lane 14: E1.GLY-5 (vvHCV-85), Sma I, Lane 16: E1 (vvHCV-10A), Stu I, Lane 17: E1.GLY-6 (vvHCV-86), Stu I, Lane 3 - 6 - 9 - 12 - 15: Low Molecular Weight Marker, pBluescript SK+, Msp I.

U

15

5

Figure 45:

SDS polyacrylamide gel electrophoresis of recombinant E2 expressed in S. cerevisiae. Innoculates were grown in leucine selective medium for 72 hrs. and diluted 1/15 in complete medium. After 10 days of culture at 28° C, medium samples were taken. The equivalent of $200 \, \mu l$ of culture supernatant concentrated by speedvac was loaded on the gel. Two independent transformants were analysed.

Figure 46:

20

SDS polyacrylamide gel electrophoresis of recombinant E2 expressed in a glycosylation deficient *S. cerevisiae* mutant. Innoculae were grown in leucine selective medium for 72 hrs. and diluted 1/15 in complete medium. After 10 days of culture at 28° C, medium samples were taken. The equivalent of 350 μ l of culture supernatant, concentrated by ion exchange chromatography, was loaded on the gel.

25 Figure 47:

Profile of chimpanzees and immunization schedule.

Figure 48:

Cellular response after 3 immunizations.

Figure 49:

Evolution of cellular response upon repeated E1 immunizations.

Figure 50:

Cellular response upon NS3 immunizations.

Figure 51:

30

Stimulation index through week 28. The stimulation index (SI; cellular immune response) was obtained by culturing PBMC (10⁵ cells), drawn from the individuals before immunization (week 0), two weeks after the third immunization (week 8), before the booster immunization (week 26) and two weeks after the booster immunization (week 28), in the presence or absence

of 3 µg of recombinant E1s or 2 µg tetanos toxoid and determining the amount of tritiated thymidine incorporated in these cells during a pulse of 18 hours after 5 days of culture. The stimulation index is the ratio of thymidine incorporated in the cells cultured with envelope antigen versus the ones cultured without antigen. Samples of week 0 and 8 were determined in a first assay (A), while the samples of week 26 and 28 were determined in a second assay (B) in which the samples of week 0 were reanalyzed. Results are expressed as the geometric mean stimulation index of all 20 (A, experiment) or 19 (B, experiment) volunteers.

Cytokine production of PBMCs. PBMC (10^5 cells), drawn from the individuals before the booster immunization (week 26) and two weeks after the booster immunization (week 28), were cultured in the presence of 3 μ g of recombinant E1s (E1) or 2 μ g of tetanos toxoid (TT) or no antigen (Bl). Cytokines were measured in the supernatant taken after 24 hours

(interleukin-5) or after 120 hours (interferon-gamma) by means of ELISA. The stimulation index is the ratio of cytokine measured in the supernatants of cells cultured with envelope antigen versus the ones cultured without antigen. Results are expressed as the geometric mean of pg cytokine/ml secreted of all 19 volunteers. Samples with a cytokine amount below

detection limit were assigned the value of the detection limit. Similarly samples with extremely high concentrations of cytokine out of the linear range of the assay were assigned the value of the limit of the linear range of

. Fi 50.

_,

15

20

Figure 53:

the assay.

25

30

Thymidine incorporation results. The stimulation index (cellular immune response) was obtained by culturing PBMC (3 x10⁵ cells), in the presence or absence of peptides and determining the amount of tritiated thymidine incorporated in these cells during a pulse after 5-6 days of culture. The stimulation index is the ratio of thymidine incorporated in the cells cultured with peptide versus the ones cultured without peptide. Results are expressed as individual values for vaccinated persons (top panel) or non vaccinated or controls (lower panel).

-

Figure 54:

Three-dimensional graph showing for the individual patients (each represented by a dot) the % change in ALT-levels (absolute change from

WO 03/051912 PCT/EP02/14480

57

baseline) on the X-axis, the change in serum anti-E1 antibody levels (in mU/mL) on the Y-axis, and the change in Ishak fibrosis score on the Z-axis.

Figure 55: Three-dimensional graph showing for the individual patients (each represented by a dot) the % change in ALT-levels (absolute change from baseline) on the X-axis, the change in serum anti-E1 antibody levels (in mU/mL) on the Y-axis, and the change in Metavir fibrosis score on the Z-

axis.

Figure 56: For each individual patient (represented by a dot or a "*"), the Ishak

fibrosis score (on the X-axis) and the ALT values (on the Y-axis) are given.

In panel A (top), the baseline (pre-vaccination) situation is given whereas panel B (bottom) is illustrating the situation at the time of taking of liver biopsies. The seven patients with the highest increase in serum anti-E1

antibody level are represented by a "★".

Figure 57: The influence of the age (on the X-axis) of each individual patient (represented by a dot or a "*") on the Ishak fibrosis score (on the Y-axis) is given. In panel A (top), the baseline (pre-vaccination) situation is given whereas panel B (bottom) is illustrating the situation at the time of taking of liver biopsies. The seven patients with the highest increase in serum anti-E1

antibody level are represented by a "*".

20

15

Table 1: Features of the respective clones and primers used for amplification for constructing the different forms of the E1 protein as despected in Example 1.

Table 2: Summary of Anti-E1 tests

Table 3: Synthetic peptides for competition studies

25 Table 4: Changes of envelope antibody levels over time.

Table 5: Difference between LTR and NR

Table 6: Competition experiments between murine E2 monoclonal antibodies

Table 7: Primers for construction of E1 glycosylation mutants

Table 8: Analysis of E1 glycosylation mutants by ELISA

30 Table 9: Profile of adjuvanted E1 Balb/c mice.

Table 10: Humoral responses: No. of immunizations required for different E1-antibodies levels.

Table 11: Chimpanzee antibody titers.

WO 03/051912 PCT/EP02/14480 58

Table 12: Human antibody titers.

Table 13: Human antibody titers (8-28 weeks).

Table 14: Stimulation index (SI) of cultured PBMC, drawn from the individuals four weeks (W16) after the fourth immunization and two weeks (W26) after the

fifth immunization in the presence or absence of 3 µg of E1s. A stimulation

index of >3 is considered a positive signal.

Ishak grading of necro-inflammatory intensities for periportal hepatitis, Table 15: confluent necrosis, focal inflammation, portal inflammation and the overall total inflammation grading. Scores are indicated as the change from baseline (mean and 95 % confidence interval) and the mean baseline- to

end-values.

Overview of frequencies (given as number of patients) of changes of a Table 16:

given baseline Metavir score (given in top row; Baseline 0 to 4) to a given

Metavir score at the end of the second course of therapeutic E1s vaccination

(given in left row; EOT 0 to 4). For instance, the "5" marked with a "*"

(i.e., "5*") means that 5 patients had a baseline Metavir score of 1 and a

Metavir score of 0 at the end of the second course treatment (EOT = end of

treatment).

15

20

Table 17: Correlation between serum anti-E1 antibody levels induced by therapeutic

Els vaccination and change in overall Ishak scores. Given are the number

of patients corresponding to the possible criteria as outlined in the Table.

Example 1: Cloning and expression of the hepatitis C virus E1 protein

1. Construction of vaccinia virus recombination vectors

The pgptATA18 vaccinia recombination plasmid is a modified version of pATA18 (Stunnenberg et al, 1988) with an additional insertion containing the *E. coli* xanthine guanine phosphoribosyl transferase gene under the control of the vaccinia virus I3 intermediate promoter (Figure 1). The plasmid pgsATA18 was constructed by inserting an oligonucleotide linker with SEQ ID NO 1/94, containing stop codons in the three reading frames, into the *Pst* I and *Hin*dIII-cut pATA18 vector. This created an extra *Pac* I restriction site (Figure 2). The original *Hin*dIII site was not restored.

Oligonucleotide linker with SEQ ID NO 1/94:

In order to facilitate rapid and efficient purification by means of Ni²⁺ chelation of engineered histidine stretches fused to the recombinant proteins, the vaccinia recombination vector pMS66 was designed to express secreted proteins with an additional carboxy-terminal histidine tag. An oligonucleotide linker with SEQ ID NO 2/95, containing unique sites for 3 restriction enzymes generating blunt ends (*Sma* I, *Stu* I and *Pml* I/*Bbr* PI) was synthesized in such a way that the carboxy-terminal end of any cDNA could be inserted in frame with a sequence encoding the protease factor Xa cleavage site followed by a nucleotide sequence encoding 6 histidines and 2 stop codons (a new *Pac* I restriction site was also created downstream the 3'end). This oligonucleotide with SEQ ID NO 2/95 was introduced between the *Xma* I and *Psi* I sites of pgptATA18 (Figure 3).

Oligonucleotide linker with SEQ ID NO 2/95:

```
5'-CCGGG GAGGCCTGCACGTGATCGAGGGCAGACACCATCACCACA/

3'-C CTCCGGACGTGCACTAGCTCCCGTCTGTGGTAGTGGTGGT/

XmaI

7TCACTAATAGTTAATTAA CTGCA-3' (SEQ ID

NO:2)

/AGTGATTATCAATTAATT G-5' (SEQ ID

NO:95)
```

PstI

5

10

15

20

25

Plasmid pgptATA-18 contained within *Escherichia coli* MC1061 (lambda) has been deposited under the terms of the Budapest Treaty at BCCM/LMBP (Belgian Coordinated Collections of microorganisms/Laboratorium voor Moleculaire Biologie - Plasmidencollectie, Universiteit Gent, K.L. Ledeganckstraat 35, B-9000 Ghent, Belgium), and bears accession number LMBP4486. Said deposit was made on January 9, 2002.

Example 2. Construction of HCV recombinant plasmids

2.1. Constructs encoding different forms of the E1 protein

10

15

20

25

30

Polymerase Chain Reaction (PCR) products were derived from the serum samples by RNA preparation and subsequent reverse-transcription and PCR as described previously (Stuyver et al., 1993b). Table 1 shows the features of the respective clones and the primers used for amplification. The PCR fragments were cloned into the Sma I-cut pSP72 (Promega) plasmids. The following clones were selected for insertion into vaccinia reombination vectors: HCCl9A (SEQ ID NO:3), HCCl10A (SEQ ID NO:5), HCCl11A (SEQ ID NO:7), HCCl12A (SEQ ID NO:9), HCCl13A (SEQ ID NO:11), and HCCl17A (SEQ ID NO:13) as depicted in Figure 21. cDNA fragments containing the E1-coding regions were cleaved by EcoRI and HindIII restriction from the respective pSP72 plasmids and inserted into the EcoRI/HindIII-cut pgptATA-18 vaccinia recombination vector (described in example 1), downstream of the 11K vaccinia virus late promoter. The respective plasmids were designated pvHCV-9A, pvHCV-10A, pvHCV-11A, pvHCV-12A, pvHCV-13A and pvHCV-17A, of which pvHCV-11A is shown in Figure 4.

2.2. Hydrophobic region E1 deletion mutants

Clone HCCl37, containing a deletion of codons Asp264 to Val287 (nucleotides 790 to 861, region encoding hydrophobic domain I) was generated as follows: 2 PCR fragments were generated from clone HCCl10A with primer sets HCPr52 (SEQ ID NO:16)/HCPr107 (SEQ ID NO:19) and HCPr108 (SEQ ID NO:20)/HCPR54 (SEQ ID NO:18). These primers are shown in Figure 21. The two PCR fragments were purified from agarose gel after electrophoresis and 1 ng of each fragment was used together as template for PCR by means of primers HCPr52 (SEQ ID NO:16) and HCPr54 (SEQ ID NO:18). The resulting fragment was cloned into the Sma I-cut pSP72 vector and clones containing the deletion were readily identified because of the deletion of 24 codons (72 base pairs). Plasmid pSP72HCCl37

containing clone HCCl37 (SEQ ID 15) was selected. A recombinant vaccinia plasmid containing the full-length E1 cDNA lacking hydrophobic domain I was constructed by inserting the HCV sequence surrounding the deletion (fragment cleaved by Xma I and BamH I from the vector pSP72-HCCl37) into the Xma I-Bam H I sites of the vaccinia plasmid pvHCV-10A. The resulting plasmid was named pvHCV-37. After confirmatory sequencing, the amino-terminal region containing the internal deletion was isolated from this vector pvHCV-37 (cleavage by EcoR I and BstE II) and reinserted into the Eco RI and Bst EII-cut pvHCV-11A plasmid. This construct was expected to express an E1 protein with both hydrophobic domains deleted and was named pvHCV-38. The E1-coding region of clone HCCl38 is represented by SEO ID NO:23.

As the hydrophilic region at the E1 carboxyterminus (theoretically extending to around amino acids 337-340) was not completely included in construct pvHCV-38, a larger E1 region lacking hydrophobic domain I was isolated from the pvHCV-37 plasmid by EcoR I/Bam HI cleavage and cloned into an EcoRI/BamHI-cut pgsATA-18 vector. The resulting plasmid was named pvHCV-39 and contained clone HCCl39 (SEQ ID NO:25). The same fragment was cleaved from the pvHCV-37 vector by BamH I (of which the sticky ends were filled with Klenow DNA Polymerase I (Boehringer)) and subsequently by EcoR I (5' cohesive end). This sequence was inserted into the EcoRI and Bbr PI-cut vector pMS-66. This resulted in clone HCCl40 (SEQ ID NO:27) in plasmid pvHCV-40, containing a 6 histidine tail at its carboxy-terminal end.

2.3. E1 of other genotypes

10

15

20

25

30

Clone HCCl62 (SEQ ID NO:29) was derived from a type 3a-infected patient with chronic hepatitis C (serum BR36, clone BR36-9-13, SEQ ID NO:19 in WO 94/25601, and see also Stuyver et al. 1993a) and HCCl63 (SEQ ID NO:31) was derived from a type 5ainfected child with post-transfusion hepatitis (serum BE95, clone PC-4-1, SEQ ID NO:45 in WO 94/25601).

2.4. E2 constructs

The HCV E2 PCR fragment 22 was obtained from serum BE11 (genotype 1b) by means of primers HCPr109 (SEQ ID NO:33) and HCPr72 (SEQ ID NO:34) using techniques of RNA preparation, reverse-transcription and PCR, as described in Stuyver et al., 1993b, and the fragment was cloned into the Sma I-cut pSP72 vector. Clone HCCl22A (SEO ID

NO:35) was cut with NcoI/AlwNI or by BamHI/AlwNI and the sticky ends of the fragments were blunted (NcoI and BamHI sites with Klenow DNA Polymerase I (Boehringer), and AlwNI with T4 DNA polymerase (Boehringer)). The BamHI/AlwNI cDNA fragment was then inserted into the vaccinia pgsATA-18 vector that had been linearized by EcoR I and Hind III cleavage and of which the cohesive ends had been filled with Klenow DNA Polymerase (Boehringer). The resulting plasmid was named pvHCV-41 and encoded the E2 region from amino acids Met347 to Gln673, including 37 amino acids (from Met347 to Gly383) of the E1 protein that can serve as signal sequence. The same HCV cDNA was inserted into the EcoR I and Bbr PI-cut vector pMS66, that had subsequently been blunt ended with Klenow DNA Polymerase. The resulting plasmid was named pvHCV-42 and also encoded amino acids 347 to 683. The NcoI/AlwNI fragment was inserted in a similar way into the same sites of pgsATA-18 (pvHCV-43) or pMS-66 vaccinia vectors (pvHCV-44). pvHCV-43 and pvHCV-44 encoded amino acids 364 to 673 of the HCV polyprotein, of which amino acids 364 to 383 were derived from the natural carboxyterminal region of the E1 protein encoding the signal sequence for E2, and amino acids 384 to 673 of the mature E2 protein.

2.5. Generation of recombinant HCV-vaccinia viruses

10

15

20

25

30

Rabbit kidney RK13 cells (ATCC CCL 37), human osteosarcoma 143B thymidine kinase deficient (TK) (ATCC CRL 8303), HeLa (ATCC CCL 2), and Hep G2 (ATCC HB 8065) cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, Md, USA). The cells were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10 % foetal calf serum, and with Earle's salts (EMEM) for RK13 and 143 B (TK-), and with glucose (4 g/l) for Hep G2. The vaccinia virus WR strain (Western Reserve, ATTC VR119) was routinely propagated in either 143B or RK13 cells, as described previously (Panicali & Paoletti, 1982; Piccini et al., 1987; Mackett et al., 1982, 1984, and 1986). A confluent monolayer of 143B cells was infected with wild type vaccinia virus at a multiplicity of infection (m.o.i.) of 0.1 (= 0.1 plaque forming unit (PFU) per cell). Two hours later, the vaccinia recombination plasmid was transfected into the infected cells in the form of a calcium phosphate coprecipitate containing 500 ng of the plasmid DNA to allow homologous recombination (Graham & van der Eb, 1973; Mackett et al., 1985). Recombinant viruses expressing the *E.coli* xanthine-guanine phosphoribosyl transferase (gpt) protein were selected on rabbit kidney RK13 cells incubated in selection medium (EMEM

containing 25 µg/ml mycophenolic acid (MPA), 250 µg/ml xanthine, and 15 µg/ml hypoxanthine; Falkner and Moss, 1988; Janknecht et al, 1991). Single recombinant viruses were purified on fresh monolayers of RK13 cells under a 0.9% agarose overlay in selection medium. Thymidine kinase deficient (TK') recombinant viruses were selected and then plaque purified on fresh monolayers of human 143B cells (TK-) in the presence of 25 µg/ml 5-bromo-2'-deoxyuridine. Stocks of purified recombinant HCV-vaccinia viruses were prepared by infecting either human 143 B or rabbit RK13 cells at an m.o.i. of 0.05 (Mackett et al, 1988). The insertion of the HCV cDNA fragment in the recombinant vaccinia viruses was confirmed on an aliquot (50 ul) of the cell lysate after the MPA selection by means of PCR with the primers used to clone the respective HCV fragments (see Table 1). The recombinant vaccinia-HCV viruses were named according to the vaccinia recombination plasmid number, e.g. the recombinant vaccinia virus vvHCV-10A was derived from recombining the wild type WR strain with the pvHCV-10A plasmid.

Example 3: infection of cells with recombinant vaccinia viruses

15

20

25

30

A confluent monolayer of RK13 cells was infected at a m.o.i. of 3 with the recombinant HCV-vaccinia viruses as described in example 2. For infection, the cell monolayer was washed twice with phosphate-buffered saline pH 7.4 (PBS) and the recombinant vaccinia virus stock was diluted in MEM medium. Two hundred ul of the virus. solution was added per 10⁶ cells such that the m.o.i. was 3, and incubated for 45 min at 24°C. The virus solution was aspirated and 2 ml of complete growth medium (see example 2) was added per 106 cells. The cells were incubated for 24 hr at 37°C during which expression of the HCV proteins took place.

Example 4: Analysis of recombinant proteins by means of western blotting

The infected cells were washed two times with PBS, directly lysed with lysis buffer (50 mM Tris.HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 5 mM MgCl₂, 1 µg/ml aprotinin (Sigma, Bornem, Belgium)) or detached from the flasks by incubation in 50 mM Tris.HCL pH 7.5/ 10 mM EDTA/ 150 mM NaCl for 5 min, and collected by centrifugation (5 min at 1000g). The cell pellet was then resuspended in 200 ul lysis buffer (50 mM Tris.HCL pH 8.0, 2 mM EDTA, 150 mM NaCl, 5 mM MgCl₂ aprotinin, 1% Triton X-100) per 10⁶ cells.

The cell lysates were cleared for 5 min at 14,000 rpm in an Eppendorf centrifuge to remove the insoluble debris. Proteins of 20 ul lysate were separated by means of sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were then electro-transferred from the gel to a nitrocellulose sheet (Amersham) using a Hoefer HSI transfer unit cooled to 4°C for 2 hr at 100 V constant voltage, in transfer buffer (25 mM Tris.HCl pH 8.0, 192 mM glycine, 20% (v/v) methanol). Nitrocellulose filters were blocked with Blotto (5 % (w/v) fat-free instant milk powder in PBS; Johnson et al., 1981) and incubated with primary antibodies diluted in Blotto/0.1 % Tween 20. Usually, a human negative control serum or serum of a patient infected with HCV were 200 times diluted and preincubated for 1 hour at room temperature with 200 times diluted wild type vaccinia virusinfected cell lysate in order to decrease the non-specific binding. After washing with Blotto/0.1% Tween 20, the nitrocellulose filters were incubated with alkaline phosphatase substrate solution diluted in Blotto/0.1 % Tween 20. After washing with 0.1% Tween 20 in PBS, the filters were incubated with alkaline phosphatase substrate solution (100 mM Tris.HCl pH 9.5, 100 mM NaCl, 5 mM MgCl₂, 0,38 µg/ml nitroblue tetrazolium, 0.165 µg/ml 5-bromo-4-chloro-3-indolylphosphate). All steps, except the electrotransfer, were performed at room temperature.

Example 5: Purification of recombinant E1 or E2 protein

5.1. Lysis

10

15

20

25

30

Infected RK13 cells (carrying E1 or E2 constructs) were washed 2 times with phosphate-buffered saline (PBS) and detached from the culture recipients by incubation in PBS containing 10 mM EDTA. The detached cells were washed twice with PBS and 1 ml of lysis buffer (50 mM Tris.HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 5 mM MgCl₂, 1 μg/ml aprotinin (Sigma, Bornem, Belgium) containing 2 mM biotinylated N-ethylmaleimide (biotin-NEM) (Sigma) was added per 10⁵ cells at 4°C. This lysate was homogenized with a type B douncer and left at room temperature for 0.5 hours. Another 5 volumes of lysis buffer containing 10 mM N-ethylmaleimide (NEM, Aldrich, Bornem, Belgium) was added to the primary lysate and the mixture was left at room temperature for 15 min. Insoluble cell debris was cleared from the solution by centrifugation in a Beckman JA-14 rotor at 14,000 rpm $(30100 \text{ g at } r_{\text{max}})$ for 1 hour at 4°C.

5.2. Lectin Chromatography

The cleared cell lysate was loaded at a rate of 1ml/min on a 0.8 by 10 cm Lentil-lectin

Sepharose 4B column (Pharmacia) that had been equilibrated with 5 column volumes of lysis buffer at a rate of 1ml/min. The lentil-lectin column was washed with 5 to 10 column volumes of buffer 1 (0.1M potassium phosphate pH 7.3, 500 mM KCl, 5% glycerol, 1 mM 6-NH₂-hexanoic acid, 1 mM MgCl₂, and 1% DecylPEG (KWANT, Bedum, The Netherlands). In some experiments, the column was subsequently washed with 10 column volumes of buffer 1 containing 0.5% Empigen-BB (Calbiochem, San Diego, CA, USA) instead of 1% DecylPEG. The bound material was eluted by applying elution buffer (10 mM potassium phosphate pH 7.3, 5% glycerol, 1 mM hexanoic acid, 1mM MgCl₂, 0.5% Empigen-BB, and 0.5 M α-methyl-mannopyranoside). The eluted material was fractionated and fractions were screened for the presence of E1 or E2 protein by means of ELISA as described in example 6. Figure 22 shows ELISA results obtained from lentil lectin eluate fractions of 4 different E1 purifications of cell lysates infected with vvHCV39 (type 1b), vvHCV40 (type 1b), vvHCV62 (type 3a), and vvHCV63 (type 5a). Figure 23 shows the profiles obtained from the values shown in Figure 22. These results show that the lectin affinity column can be employed for envelope proteins of the different types of HCV.

5.3. Concentration and partial reduction

15

20

25

30

The E1- or E2-positive fractions were pooled and concentrated on a Centricon 30 kDa (Amicon) by centrifugation for 3 hours at 5,000 rpm in a Beckman JA-20 rotor at 4°C. In some experiments the E1- or E2-positive fractions were pooled and concentrated by nitrogen evaporation. An equivalent of 3.10⁸ cells was concentrated to approximately 200 μl. For partial reduction, 30% Empigen-BB (Calbiochem, San Diego, CA, USA) was added to this 200 μl to a final concentration of 3.5 %, and 1M DTT in H₂O was subsequently added to a final concentration of 1.5 to 7.5 mM and incubated for 30 min at 37 °C. NEM (1M in dimethylsulphoxide) was subsequently added to a final concentration of 50 mM and left to react for another 30 min at 37°C to block the free sulphydryl groups.

5.4. Gel filtration chromatography

A Superdex-200 HR 10/20 column (Pharmacia) was equilibrated with 3 column volumes PBS/3% Empigen-BB. The reduced mixture was injected in a 500 μ l sample loop of the Smart System (Pharmacia) and PBS/3% Empigen-BB buffer was added for gelfiltration. Fractions of 250 μ l were collected from V_0 to V_t . The fractions were screened for the

presence of E1 or E2 protein as described in example 6.

15

20

25

30

Figure 24 shows ELISA results obtained from fractions obtained after gelfiltration chromatography of 4 different E1 purifications of cell lysates infected with vvHCV39 (type 1b), vvHCV40 (type 1b), vvHCV62 (type 3a), and vvHCV63 (type 5a). Figure 25 shows the profiles obtained from purifications of E1 proteins of types 1b, 3a, and 5a (from RK13 cells infected with vvHCV39, vvHCV62, and vvHCV63, respectively; purified on lentil lectin and reduced as in the previous examples). The peaks indicated with '1', '2', and '3', represent pure E1 protein peaks (E1 reactivity mainly in fractions 26 to 30). These peaks show very similar molecular weights of approximately 70 kDa, corresponding to dimeric E1 protein. Other peaks in the three profiles represent vaccinia virus and/or cellular proteins which could be separated from E1 only because of the reduction step as outlined in example 5.3. and because of the subsequent gelfiltration step in the presence of the proper detergent. As shown in Figure 26 pool 1 (representing fractions 10 to 17) and pool 2 (representing fractions 18 to 25) contain contaminating proteins not present in the E1 pool (fractions 26 to 30). The E1 peak fractions were ran on SDS/PAGE and blotted as described in example 4. Proteins labelled with NEM-biotin were detected by streptavidin-alkaline phosphatase as shown in Figure 27. It can be readily observed that, amongst others, the 29 kDa and 45kDa contaminating proteins present before the gelfiltration chromatography (lane 1) are only present at very low levels in the fractions 26 to 30. The band at approximately 65kDa represents the E1 dimeric form that could not be entirely disrupted into the monomeric E1 form. Similar results were obtained for the type 3a E1 protein (lanes 10 to 15), which shows a faster mobility on SDS/PAGE because of the presence of only 5 carbohydrates instead of 6. Figure 28 shows a silver stain of an SDS/PAGE gel run in identical conditions as in Figure 26. A complete overview of the purification procedure is given in Figure 29.

The presence of purified E1 protein was further confirmed by means of western blotting as described in example 4. The dimeric E1 protein appeared to be non-aggregated and free of contaminants. The subtype 1b E1 protein purified from vvHCV40-infected cells according to the above scheme was aminoterminally sequenced on an 477 Perkin-Elmer sequencer and appeared to contain a tyrosine as first residue. This confirmed that the E1 protein had been cleaved by the signal peptidase at the correct position (between A191 and Y192) from its signal sequence. This confirms the finding of Hijikata et al. (1991) that the aminoterminus of the mature E1 protein starts at amino acid position 192.

5.5. Purification of the E2 protein

15

20

25

30

The E2 protein (amino acids 384 to 673) was purified from RK13 cells infected with vvHCV44 as indicated in Examples 5.1 to 5.4. Figure 30 shows the OD₂₈₀ profile (continuous line) of the lentil lectin chromatography. The dotted line represents the E2 reactivity as detected by ELISA (see example 6). Figure 31 shows the same profiles obtained from gelfiltration chromatography of the lentil-lectin E2 pool (see Figure 30), part of which was reduced and blocked according to the methods as set out in example 5.3., and part of which was immediately applied to the column. Both parts of the E2 pool were run on separate gelfiltration columns. It could be demonstrated that E2 forms covalently-linked aggregates with contaminating proteins if no reduction has been performed. After reduction and blocking, the majority of contaminating proteins segregated into the V₀ fraction. Other contaminating proteins copurified with the E2 protein, were not covalently linked to the E2 protein any more because these contaminants could be removed in a subsequent step. Figure 32 shows an additional Ni²⁺-IMAC purification step carried out for the E2 protein purification. This affinity purification step employs the 6 histidine residues added to the E2 protein as expressed from vvHCV44. Contaminating proteins either run through the column or can be removed by a 30 mM imidazole wash. Figure 33 shows a silver-stained SDS/PAGE of 0.5 µg of purified E2 protein and a 30 mM imidazole wash. The pure E2 protein could be easily recovered by a 200 mM imidazole elution step. Figure 34 shows an additional desalting step intended to remove imidazole and to be able to switch to the desired buffer, e.g. PBS, carbonate buffer, saline.

Starting from about 50,000 cm² of RK13 cells infected with vvHCV11A (or vvHCV40) for the production of E1 or vvHCV41, vvHCV42, vvHCV43, or vvHCV44 for production of E2 protein, the procedures described in examples 5.1 to 5.5 allow the purification of approximately 1.3 mg of E1 protein and 0.6 mg of E2 protein.

It should also be remarked that secreted E2 protein (constituting approximately 30-40%, 60-70% being in the intracellular form) is characterized by aggregate formation (contrary to expectations). The same problem is thus posed to purify secreted E2. The secreted E2 can be purified as disclosed above.

Example 6: ELISA for the detection of anti-E1 or anti-E2 antibodies or for the detection of E1 or E2 proteins

Maxisorb microwell plates (Nunc, Roskilde, Denmark) were coated with 1 volume

(e.g. 50 ul or 100 ul or 200 ul) per well of a 5 ug/ml solution of Streptavidin (Boehringer Mannheim) in PBS for 16 hours at 4°C or for 1 hour at 37°C. Alternatively, the wells were coated with 1 volume of 5 ug/ml of Galanthus nivalis agglutinin (GNA) in 50 mM sodium carbonate buffer pH 9.6 for 16 hours at 4°C or for 1 hour at 37°C. In the case of coating with GNA, the plates were washed 2 times with 400 ul of Washing Solution of the Innotest HCV Ab III kit (Innogenetics, Belgium). Unbound coating surfaces were blocked with 1.5 to 2 volumes of blocking solution (0.1% casein and 0.1% NaN, in PBS) for 1 hour at 37°C or for 16 hours at 4°C. Blocking solution was aspirated. Purified E1 or E2 was diluted to 100-1000 ng/ml (concentration measured at A = 280 nm) or column fractions to be screened for E1 or E2 (see example 5), or E1 or E2 in non-purified cell lysates (example 5.1.) were diluted 20 times in blocking solution, and 1 volume of the E1 or E2 solution was added to each well and incubated for 1 hour at 37°C on the Streptavidin- or GNA-coated plates. The microwells were washed 3 times with 1 volume of Washing Solution of the Innotest HCV Ab III kit (Innogenetics, Belgium). Serum samples were diluted 20 times or monoclonal anti-E1 or anti-E2 antibodies were diluted to a concentration of 20 ng/ml in Sample Diluent of the Innotest HCV Ab III kit and 1 volume of the solution was left to react with the E1 or E2 protein for 1 hour at 37°C. The microwells were washed 5 times with 400 ul of Washing Solution of the Innotest HCV Ab III kit (Innogenetics, Belgium). The bound antibodies were detected by incubating each well for 1 hour at 37°C with a goat anti-human or anti-mouse IgG, peroxidase-conjugated secondary antibody (DAKO, Glostrup, Denmark) diluted 1/80,000 in 1 volume of Conjugate Diluent of the Innotest HCV Ab III kit (Innogenetics, Belgium), and color development was obtained by addition of substrate of the Innotest HCV Ab III kit (Innogenetics, Belgium) diluted 100 times in 1 volume of Substrate Solution of the Innotest HCV Ab III kit (Innogenetics, Belgium) for 30 min at 24°C after washing of the plates 3 times with 400 µl of Washing Solution of the Innotest HCV Ab III kit (Innogenetics, Belgium).

Example 7: Follow up of patient groups with different clinical profiles

30 7.1. Monitoring of anti-E1 and anti-E2 antibodies

15

20

25

The current hepatitis C virus (HCV) diagnostic assays have been developed for screening and confirmation of the presence of HCV antibodies. Such assays do not seem to provide information useful for monitoring of treatment or for prognosis of the outcome of disease. However, as is the case for hepatitis B, detection and quantification of anti-envelope antibodies may prove more useful in a clinical setting. To investigate the possibility of the use of anti-E1 antibody titer and anti-E2 antibody titer as prognostic markers for outcome of hepatitis C disease, a series of IFN- α treated patients with long-term sustained response (defined as patients with normal transaminase levels and negative HCV-RNA test (PCR in the 5' non-coding region) in the blood for a period of at least 1 year after treatment) was

69

compared with patients showing no response or showing biochemical response with relapse

at the end of treatment.

A group of 8 IFN-\alpha treated patients with long-term sustained response (LTR, follow 1 to 3.5 years, 3 type 3a and 5 type 1b) was compared with 9 patients showing noncomplete responses to treatment (NR, follow up 1 to 4 years, 6 type 1b and 3 type 3a). Type 1b (vvHCV-39, see example 2.5.) and 3a E1 (vvHCV-62, see example 2.5.) proteins were expressed by the vaccinia virus system (see examples 3 and 4) and purified to homogeneity (example 5). The samples derived from patients infected with a type 1b hepatitis C virus were tested for reactivity with purified type 1b E1 protein, while samples of a type 3a infection were tested for reactivity of anti-type 3a E1 antibodies in an ELISA as desribed in example 6. The genotypes of hepatitis C viruses infecting the different patients were determined by means of the Inno-LiPA genotyping assay (Innogenetics, Belgium). Figure 5 shows the anti-E1 signal-to-noise ratios of these patients followed during the course of interferon treatment and during the follow-up period after treatment. LTR cases consistently showed rapidly declining anti-E1 levels (with complete negativation in 3 cases), while anti-El levels of NR cases remained approximately constant. Some of the obtained anti-El data are shown in Table 2 as average S/N ratios ± SD (mean anti-E1 titer). The anti-E1 titer could be deduced from the signal to noise ratio as show in Figures 5, 6, 7, and 8.

25

15

20

Already at the end of treatment, marked differences could be observed between the 2 groups. Anti-E1 antibody titers had decreased 6.9 times in LTR but only 1.5 times in NR. At the end of follow up, the anti-E1 titers had declined by a factor of 22.5 in the patients with sustained response and even slightly increased in NR. Therefore, based on these data, decrease of anti-E1 antibody levels during monitoring of IFN- α therapy correlates with long-term, sustained response to treatment. The anti-E1 assay may be very useful for prognosis of long-term response to IFN treatment, or to treatment of the hepatitis C disease in general.

30

This finding was not expected. On the contrary, the inventors had expected the anti-E1 antibody levels to increase during the course of IFN treatment in patients with long term response. As is the case for hepatitis B, the virus is cleared as a consequence of the seroconversion for anti-HBsAg antibodies. Also in many other virus infections, the virus is eliminated when anti-envelope antibodies are raised. However, in the experiments of the present invention, anti-E1 antibodies clearly decreased in patients with a long-term response to treatment, while the antibody-level remained approximately at the same level in non-responding patients. Although the outcome of these experiments was not expected, this non-obvious finding may be very important and useful for clinical diagnosis of HCV infections. As shown in Figures 9, 10, 11, and 12, anti-E2 levels behaved very differently in the same patients studied and no obvious decline in titers was observed as for anti-E1 antibodies. Figure 35 gives a complete overview of the pilot study.

PCT/EP02/14480

As can be deduced from Table 2, the anti-E1 titers were on average at least 2 times higher at the start of treatment in long term responders compared with incomplete responders to treatment. Therefore, measuring the titer of anti-E1 antibodies at the start of treatment, or monitoring the patient during the course of infection and measuring the anti-E1 titer, may become a useful marker for clinical diagnosis of hepatitis C. Furthermore, the use of more defined regions of the E1 or E2 proteins may become desirable, as shown in example 7.3.

7.2. Analysis of E1 and E2 antibodies in a larger patient cohort

10

15

20

25

30

The pilot study lead the inventors to conclude that, in case infection was completely cleared, antibodies to the HCV envelope proteins changed more rapidly than antibodies to the more conventionally studied HCV antigens, with E1 antibodies changing most vigorously. We therefore included more type 1b and 3a-infected LTR and further supplemented the cohort with a matched series of NR, such that both groups included 14 patients each. Some partial responders (PR) and responders with relapse (RR) were also analyzed.

Figure 36 depicts average E1 antibody (E1Ab) and E2 antibody (E2Ab) levels in the LTR and NR groups and Tables 4 and 5 show the statistical analyses. In this larger cohort, higher E1 antibody levels before IFN- α therapy were associated with LTR (P < 0.03). Since much higher E1 antibody levels were observed in type 3a-infected patients compared with type 1b-infected patients (Figure 37), the genotype was taken into account (Table 4). Within the type 1b-infected group, LTR also had higher E1 antibody levels than NR at the initiation of treatment [P < 0.05]; the limited number of type 3a-infected NR did not allow statistical analysis.

Of antibody levels monitored in LTR during the 1.5-year follow up period, only E1

antibodies cleared rapidly compared with levels measured at initiation of treatment [P = 0.0058, end of therapy; P = 0.0047 and P = 0.0051 at 6 and 12 months after therapy, respectively]. This clearance remained significant within type 1- or type 3-infected LTR (average P values < 0.05). These data confirmed the initial finding that E1Ab levels decrease rapidly in the early phase of resolvement. This feature seems to be independent of viral genotype. In NR, PR, or RR, no changes in any of the antibodies measured were observed throughout the follow up period. In patients who responded favourably to treatment with normalization of ÂLT levels and HCV-RNA negative during treatment, there was a marked difference between sustained responders (LTR) and responders with a relapse (RR). In contrast to LTR, RR did not show any decreasing E1 antibody levels, indicating the presence of occult HCV infection that could neither be demonstrated by PCR or other classical techniques for detection of HCV-RNA, nor by raised ALT levels. The minute quantities of viral RNA, still present in the RR group during treatment, seemed to be capable of anti-E1 B cell stimulation. Anti-E1 monitoring may therefore not only be able to discriminate LTR from NR, but also from RR.

7.3. Monitoring of antibodies of defined regions of the E1 protein

5

10

15

20

25

30

Although the molecular biological approach of identifying HCV antigens resulted in unprecedented breakthrough in the development of viral diagnostics, the method of immune screening of $\lambda gt11$ libraries predominantly yielded linear epitopes dispersed throughout the core and non-structural regions, and analysis of the envelope regions had to await cloning and expression of the E1/E2 region in mammalian cells. This approach sharply contrasts with many other viral infections of which epitopes to the envelope regions had already been mapped long before the deciphering of the genomic structure. Such epitopes and corresponding antibodies often had neutralizing activity useful for vaccine development and/or allowed the development of diagnostic assays with clinical or prognostic significance (e.g. antibodies to hepatitis B surface antigen).

As no HCV vaccines or tests allowing clinical diagnosis and prognosis of hepatitis C disease are available today, the characterization of viral envelope regions exposed to immune surveillance may significantly contribute to new directions in HCV diagnosis and prophylaxis.

Several 20-mer peptides (Table 3) that overlapped each other by 8 amino acids, were synthesized according to a previously described method (EP-A-0 489 968) based on the HC-

J1 sequence (Okamoto et al., 1990). None of these, except peptide env35 (also referred to as E1-35), was able to detect antibodies in sera of approximately 200 HCV cases. Only 2 sera reacted slightly with the env35 peptide. However, by means of the anti-E1 ELISA as described in example 6, it was possible to discover additional epitopes as follows: The anti-E1 ELISA as described in example 6 was modified by mixing 50 ug/ml of E1 peptide with the 1/20 diluted human serum in sample diluent. Figure 13 shows the results of reactivity of human sera to the recombinant E1 (expressed from vvHCV-40) protein, in the presence of single or of a mixture of E1 peptides. While only 2% of the sera could be detected by means of E1 peptides coated on strips in a Line Immunoassay format, over half of the sera contained anti-E1 antibodies which could be competed by means of the same peptides, when tested on the recombinant E1 protein. Some of the murine monoclonal antibodies obtained from Balb/C mice after injection with purified E1 protein were subsequently competed for reactivity to E1 with the single peptides (Figure 14). Clearly, the region of env53 contained the predominant epitope, as the addition of env53 could substantially compete reactivity of several sera with E1, and antibodies to the env31 region were also detected. This finding was surprising, since the env53 and env31 peptides had not shown any reactivity when coated directly to the solid phase.

Therefore peptides were synthesized using technology described by applicant previously (in WO 93/18054). The following peptides were synthesized:

peptide env35A-biotin

15

20

25

30

NH₂-SNSSEAADMIMHTPGCV-GKbiotin (SEQ ID NO:51)

spanning amino acids 208 to 227 of the HCV polyprotein in the E1 region peptide biotin-env53 ('epitope A')

biotin-GG-ITGHRMAWDMMMNWSPTTAL-COOH (SEQ ID NO:52) spanning amino acids to 313 of 332 of the HCV polyprotein in the E1 region peptide 1bE1 ('epitope B')

H₂N-YEVRNVSGIYHVTNDCSNSSIVYEAADMIMHTPGCGK -biotin (SEQ ID NO:53)

spanning amino acids 192 to 228 of the HCV polyprotein in the E1 region and compared with the reactivities of peptides E1a-BB (biotin-GG-TPTVATRDGKLPATQLRRHIDLL, SEQ ID NO:54) and E1b-BB (biotin-GG-TPTLAARDASVPTTTIRRHVDLL, SEQ ID NO:55) which are derived from the same region of sequences of genotype 1a and 1b respectively and which have been described at the

IXth international virology meeting in Glasgow, 1993 ('epitope C'). Reactivity of a panel of HCV sera was tested on epitopes A, B and C and epitope B was also compared with env35A (of 47 HCV-positive sera, 8 were positive on epitope B and none reacted with env35A). Reactivity towards epitopes A, B, and C was tested directly to the biotinylated peptides (50) μg/ml) bound to streptavidin-coated plates as described in example 6. Clearly, epitopes A and B were most reactive while epitopes C and env35A-biotin were much less reactive. The same series of patients that had been monitored for their reactivity towards the complete E1 protein (example 7.1.) was tested for reactivity towards epitopes A, B, and C. Little reactivity was seen to epitope C, while as shown in Figures 15, 16, 17, and 18, epitopes A and B reacted with the majority of sera. However, antibodies to the most reactive epitope (epitope A) did not seem to predict remission of disease, while the anti-1bE1 antibodies (epitope B) were present almost exclusively in long term responders at the start of IFN treatment. Therefore, anti-1bE1 (epitope B) antibodies and anti-env53 (epitope A) antibodies could be shown to be useful markers for prognosis of hepatitis C disease. The env53 epitope may be advantageously used for the detection of cross-reactive antibodies (antibodies that cross-react between major genotypes) and antibodies to the env53 region may be very useful for universal E1 antigen detection in serum or liver tissue. Monoclonal antibodies that recognized the env53 region were reacted with a random epitope library. In 4 clones that reacted upon immunoscreening with the monoclonal antibody 5E1A10, the sequence -GWDwas present. Because of its analogy with the universal HCV sequence present in all HCV variants in the env53 region, the sequence AWD is thought to contain the essential sequence of the env53 cross-reactive murine epitope. The env31 clearly also contains a variable region which may contain an epitope in the amino terminal sequence -YQVRNSTGL- (SEQ ID NO:93) and may be useful for diagnosis. Env31 or E1-31 as shown in Table 3, is a part of the peptide 1bE1. Peptides E1-33 and E1-51 also reacted to some extent with the murine antibodies, and peptide E1-55 (containing the variable region 6 (V6); spanning amino acid positions 329-336) also reacted with some of the patient sera.

10

15

20

25

30

Anti-E2 antibodies clearly followed a different pattern than the anti-E1 antibodies, especially in patients with a long-term response to treatment. Therefore, it is clear that the decrease in anti-envelope antibodies could not be measured as efficiently with an assay employing a recombinant E1/E2 protein as with a single anti-E1 or anti-E2 protein. The anti-E2 response would clearly blur the anti-E1 response in an assay measuring both kinds of antibodies at the same time. Therefore, the ability to test anti-envelope antibodies to the

WO 03/051912 PCT/EP02/14480

74

single E1 and E2 proteins, was shown to be useful.

7.4. Mapping of anti-E2 antibodies

10

15

20

25

30

Of the 24 anti-E2 Mabs only three could be competed for reactivity to recombinant E2 by peptides, two of which reacted with the HVRI region (peptides E2-67 and E2-69, designated as epitope A) and one which recognized an epitope competed by peptide E2-13B (epitope C). The majority of murine antibodies recognized conformational anti-E2 epitopes (Figure 19). A human response to HVRI (epitope A), and to a lesser extent HVRII (epitope B) and a third linear epitope region (competed by peptides E2-23, E2-25 or E2-27, designated epitope E) and a fourth linear epitope region (competed by peptide E2-17B, epitope D) could also frequently be observed, but the majority of sera reacted with conformational epitopes (Figure 20). These conformational epitopes could be grouped according to their relative positions as follows: the IgG antibodies in the supernatant of hybridomas 15C8C1, 12D11F1, 9G3E6, 8G10D1H9, 10D3C4, 4H6B2, 17F2C2, 5H6A7, 15B7A2 recognizing conformational epitopes were purified by means of protein A affinity chromatography and 1 mg/ml of the resulting IgG's were biotinylated in borate buffer in the presence of biotin. Biotinylated antibodies were separated from free biotin by means of gelfiltration chromatography. Pooled biotinylated antibody fractions were diluted 100 to 10,000 times. E2 protein bound to the solid phase was detected by the biotinylated IgG in the presence of 100 times the amount of non-biotinylated competing antibody and subsequently detected by alkaline phosphatase labeled streptavidin.

Percentages of competition are given in Table 6. Based on these results, 4 conformational anti-E2 epitope regions (epitopes F, G, H and I) could be delineated (Figure 38). Alternatively, these Mabs may recognize mutant linear epitopes not represented by the peptides used in this study. Mabs 4H6B2 and 10D3C4 competed reactivity of 16A6E7, but unlike 16A6E7, they did not recognize peptide E2-13B. These Mabs may recognize variants of the same linear epitope (epitope C) or recognize a conformational epitope which is sterically hindered or changes conformation after binding of 16A6E7 to the E2-13B region (epitope H).

Example 8: E1 glycosylation mutants

8.1. Introduction

10

15

20

25

30

The E1 protein encoded by vvHCV10A, and the E2 protein encoded by vvHCV41 to 44 expressed from mammalian cells contain 6 and 11 carbohydrate moieties, respectively. This could be shown by incubating the lysate of vvHCV10A-infected or vvHCV44-infected RK13 cells with decreasing concentrations of glycosidases (PNGase F or Endoglycosidase H, (Boehringer Mannhein Biochemica) according to the manufacturer's instructions), such that the proteins in the lysate (including E1) are partially deglycosylated (Fig. 39 and 40, respectively).

Mutants devoid of some of their glycosylation sites could allow the selection of envelope proteins with improved immunological reactivity. For HIV for example, gp120 proteins lacking certain selected sugar-addition motifs, have been found to be particularly useful for diagnostic or vaccine purpose. The addition of a new oligosaccharide side chain in the hemagglutinin protein of an escape mutant of the A/Hong Kong/3/68 (H3N2) influenza virus prevents reactivity with a neutralizing monoclonal antibody (Skehel et al, 1984). When novel glycosylation sites were introduced into the influenza hemaglutinin protein by sitespecific mutagenesis, dramatic antigenic changes were observed, suggesting that the carbohydrates serve as a modulator of antigenicity (Gallagher et al., 1988). In another analysis, the 8 carbohydrate-addition motifs of the surface protein gp70 of the Friend Murine Leukemia Virus were deleted. Although seven of the mutations did not affect virus infectivity, mutation of the fourth glycosylation signal with respect to the amino terminus resulted in a non-infectious phenotype (Kayman et al., 1991). Furthermore, it is known in the art that addition of N-linked carbohydrate chains is important for stabilization of folding intermediates and thus for efficient folding, prevention of malfolding and degradation in the endoplasmic reticulum, oligomerization, biological activity, and transport of glycoproteins (see reviews by Rose et al., 1988; Doms et al., 1993; Helenius, 1994).

After alignment of the different envelope protein sequences of HCV genotypes, it may be inferred that not all 6 glycosylation sites on the HCV subtype 1b E1 protein are required for proper folding and reactivity, since some are absent in certain (sub)types. The fourth carbohydrate motif (on Asn251), present in types 1b, 6a, 7, 8, and 9, is absent in all other types known today. This sugar-addition motif may be mutated to yield a type 1b E1 protein with improved reactivity. Also the type 2b sequences show an extra glycosylation site

in the V5 region (on Asn299). The isolate S83, belonging to genotype 2c, even lacks the first carbohydrate motif in the V1 region (on Asn), while it is present on all other isolates (Stuyver et al., 1994). However, even among the completely conserved sugar-addition motifs, the presence of the carbohydrate may not be required for folding, but may have a role in evasion of immune surveillance. Therefore, identification of the carbohydrate addition motifs which are not required for proper folding (and reactivity) is not obvious, and each mutant has to be analyzed and tested for reactivity. Mutagenesis of a glycosylation motif (NXS or NXT sequences) can be achieved by either mutating the codons for N, S, or T, in such a way that these codons encode amino acids different from N in the case of N, and/or amino acids different from S or T in the case of S and in the case of T. Alternatively, the X position may be mutated into P, since it is known that NPS or NPT are not frequently modified with carbohydrates. After establishing which carbohydrate-addition motifs are required for folding and/or reactivity and which are not, combinations of such mutations may be made.

15 8.2. Mutagenesis of the E1 protein

10

20

25

30

All mutations were performed on the E1 sequence of clone HCCl10A (SEQ ID NO:5). The first round of PCR was performed using sense primer 'GPT' (see Table 7) targetting the GPT sequence located upstream of the vaccinia 11K late promoter, and an antisense primer (designated GLY#, with # representing the number of the glycosylation site, see Fig. 41) containing the desired base change to obtain the mutagenesis. The six GLY# primers (each specific for a given glycosylation site) were designed such that:

- Modification of the codon encoding for the N-glycosylated Asn (AAC or AAT) to a Gln codon (CAA or CAG). Glutamine was chosen because it is very similar to asparagine (both amino acids are neutral and contain non-polar residues, glutamine has a longer side chain (one more -CH₂- group).
- The introduction of silent mutations in one or several of the codons downstream of the glycosylation site, in order to create a new unique or rare (e.g. a second Smal site for E1Gly5) restriction enzyme site. Without modifying the amino acid sequence, this mutation will provide a way to distinguish the mutated sequences from the original E1 sequence (pvHCV-10A) or from each other (Figure 41). This additional restriction site may also be useful for the construction of new hybrid (double, triple, etc.) glycosylation mutants.
- 18 nucleotides extend 5' of the first mismatched nucleotide and 12 to 16 nucleotides extend to the 3' end. Table 7 depicts the sequences of the six GLY# primers overlapping the

15

20

25

30

sequence of N-linked glycosylation sites.

For site-directed mutagenesis, the 'mispriming' or 'overlap extension' (Horton, 1993) was used. The concept is illustrated in Figures 42 and 43. First, two separate fragments were amplified from the target gene for each mutated site. The PCR product obtained from the 5' end (product GLY#) was amplified with the 5' sense GPT primer (see Table 7) and with the respective 3' antisense GLY# primers. The second fragment (product OVR#) was amplified with the 3' antisense TK_R primer and the respective 5' sense primers (OVR# primers, see Table 7, Figure 43).

The OVR# primers target part of the GLY# primer sequence. Therefore, the two groups of PCR products share an overlap region of identical sequence. When these intermediate products are mixed (GLY-1 with OVR-1, GLY-2 with OVR-2, etc.), melted at high temperature, and reannealed, the top sense strand of product GLY# can anneal to the antisense strand of product OVR# (and vice versa) in such a way that the two strands act as primers for one another (see Fig. 42.B.). Extension of the annealed overlap by Taq polymerase during two PCR cycles created the full-length mutant molecule E1Gly#, which carries the mutation destroying the glycosylation site number #. Sufficient quantities of the E1GLY# products for cloning were generated in a third PCR by means of a common set of two internal nested primers. These two new primers are respectively overlapping the 3' end of the vaccinia 11K promoter (sense GPT-2 primer) and the 5' end of the vaccinia thymidine kinase locus (antisense TK_R-2 primer, see Table 7). All PCR conditions were performed as described in Stuyver et al. (1993).

Each of these PCR products was cloned by EcoRI/BamHI cleavage into the EcoRI/BamHI-cut vaccinia vector containing the original E1 sequence (pvHCV-10A).

The selected clones were analyzed for length of insert by EcoRI/BamH I cleavage and for the presence of each new restriction site. The sequences overlapping the mutated sites were confirmed by double-stranded sequencing.

8.3. Analysis of E1 glycosylation mutants

Starting from the 6 plasmids containing the mutant E1 sequences as described in example 8.2, recombinant vaccinia viruses were generated by recombination with wt vaccinia virus as described in example 2.5. Briefly, 175 cm²-flasks of subconfluent RK13 cells were infected with the 6 recombinant vaccinia viruses carrying the mutant E1 sequences, as well as with the vvHCV-10A (carrying the non-mutated E1 sequence) and wt

vaccinia viruses. Cells were lysed after 24 hours of infection and analyzed on western blot as described in example 4 (see Figure 44A). All mutants showed a faster mobility (corresponding to a smaller molecular weight of approximately 2 to 3 kDa) on SDS-PAGE than the original E1 protein; confirming that one carbohydrate moiety was not added. Recombinant viruses were also analyzed by PCR and restriction enzyme analysis to confirm the identity of the different mutants. Figure 44B shows that all mutants (as shown in Figure 41) contained the expected additional restriction sites. Another part of the cell lysate was used to test the reactivity of the different mutant by ELISA. The lysates were diluted 20 times and added to microwell plates coated with the lectin GNA as described in example 6. Captured (mutant) E1 glycoproteins were left to react with 20-times diluted sera of 24 HCVinfected patients as described in example 6. Signal to noise (S/N) values (OD of GLY#/OD of wt) for the six mutants and E1 are shown in Table 8. The table also shows the ratios between S/N values of GLY# and E1 proteins. It should be understood that the approach to use cell lysates of the different mutants for comparison of reactivity with patient sera may result in observations that are the consequence of different expression levels rather then reactivity levels. Such difficulties can be overcome by purification of the different mutants as described in example 5, and by testing identical quantities of all the different E1 proteins. However, the results shown in table 5 already indicate that removal of the 1st (GLY1), 3rd (GLY3), and 6th (GLY6) glycosylation motifs reduces reactivity of some sera, while removal of the 2nd and 5th site does not. Removal of GLY4 seems to improve the reactivity of certain sera. These data indicate that different patients react differently to the glycosylation mutants of the present invention. Thus, such mutant E1 proteins may be useful for the diagnosis (screening, confirmation, prognosis, etc.) and prevention of HCV disease.

10

15

20

25

30

Example 9: Expression of HCV E2 protein in glycosylation-deficient yeasts

The E2 sequence corresponding to clone HCCl41 was provided with the α -mating factor pre/pro signal sequence, inserted in a yeast expression vector and $\underline{S.\ cerevisiae}$ cells transformed with this construct secreted E2 protein into the growth medium. It was observed that most glycosylation sites were modified with high-mannose type glycosylations upon expression of such a construct in $\underline{S.\ cerevisiae}$ strains (Figure 45). This resulted in a too high level of heterogeneity and in shielding of reactivity, which is not desirable for either vaccine or diagnostic purposes. To overcome this problem, $\underline{S.\ cerevisiae}$ mutants with modified glycosylation pathways were generated by means of selection of vanadate-resistant clones.

20

25

30

Such clones were analyzed for modified glycosylation pathways by analysis of the molecular weight and heterogeneity of the glycoprotein invertase. This allowed us to identify different glycosylation deficient <u>S. cerevisiae</u> mutants. The E2 protein was subsequently expressed in some of the selected mutants and left to react with a monoclonal antibody as described in example 7, on western blot as described in example 4 (Figure 46).

Example 10. General utility

The present results show that not only a good expression system but also a good purification protocol are required to reach a high reactivity of the HCV envelope proteins with human patient sera. This can be obtained using the proper HCV envelope protein expression system and/or purification protocols of the present invention which guarantee the conservation of the natural folding of the protein and the purification protocols of the present invention which guarantee the elimination of contaminating proteins and which preserve the conformation, and thus the reactivity of the HCV envelope proteins. The amounts of purified HCV envelope protein needed for diagnostic screening assays are in the range of grams per year. For vaccine purposes, even higher amounts of envelope protein would be needed. Therefore, the vaccinia virus system may be used for selecting the best expression constructs and for limited upscaling, and large-scale expression and purification of single or specific oligomeric envelope proteins containing high-mannose carbohydrates may be achieved when expressed from several yeast strains. In the case of hepatitis B for example, manufacturing of HBsAg from mammalian cells was much more costly compared with yeast-derived hepatitis B vaccines.

The purification method dislcosed in the present invention may also be used for 'viral envelope proteins' in general. Examples are those derived from Flaviviruses, the newly discovered GB-A, GB-B and GB-C Hepatitis viruses, Pestiviruses (such as Bovine viral Diarrhoea Virus (BVDV), Hog Cholera Virus (HCV), Border Disease Virus (BDV)), but also less related virusses such as Hepatitis B Virus (mainly for the purification of HBsAg).

The envelope protein purification method of the present invention may be used for intra- as well as extracellularly expressed proteins in lower or higher eukaryotic cells or in prokaryotes as set out in the detailed description section.

Example 11. Demonstration of Prophylactic and Therapeutic Utility

Liver disease in chimpanzees chronically infected with HCV can be reduced by

15

20

25

30

immunization with E1. Multiple immunizations, however, were required in order to reach a significant immune response. One of ordinary skill will appreciate that viral persistence is produced with immune modulation which is either orchestrated by the virus itself or by the host. In order to analyze if such an immune modulation does exist in HCV, the immune responses against E1 and NS3 in naive and chronically infected chimpanzees were compared. Since a lower response in the chronically infected animals was anticipated, this group of animals was selected for a more rigorous immunization schedule including the following: use of an adjuvant proven in mice to be more potent for inducing cellular responses (Table 9) compared to alum, which was the adjuvant used for naive animals; and the immunization schedule for chronically infected animals consisted of 12 immunizations compared to 6 for naive animals (Fig. 47).

Although the number of immunized animals does not allow statistical analysis, the following clear tendency can be detected in the humoral responses (Table 10): the number of immunizations for seroconversion is lower in naive animals; and the magnitude of the immune response is substantially greater in the naive animals, 2/3 infected animals do not reach the level of 10 internal units, even after 12 immunizations.

The analysis of the cellular responses, after three immunizations, reveals an even larger difference (Fig. 48a-d), including the following: E1-specific T-cell proliferation is almost absent in the chronically infected animals, while a clear stimulation can be seen in the naive setting; IL-2 measurements confirmed that the low stimulation of the T-cell compartment in chronic carriers; and, a clear Th2 (IL-4) response in naive animals is induced, as expected for an alum-adjuvant containing vaccine.

This confirms that at least E1 immunization provides a prophylactic effect in naïve animals and suggest that E2 and/or combinations of E1 and E2 proteins and/or peptides may provide useful therapeutic and/or prophylactic benefits in naïve animals.

The 'impairment' to induce both cellular and humoral responses against an HCV E1 antigen can be only partially overcome by multiple immunizations, as demonstrated by the following results: an increase in antibody titer after each injection was noted but the levels as in naive animals were not reached in 2/3 animals; and the T-cell proliferative responses remain very low (Fig. 49). The ELISPOT results show, however, a minor increase in IL-2 (not shown), no change in IFN-g (not shown) and an increase in IL-4 (Fig. 49) which indicates that Th2 type responses are more readily induced. IL-4 was noted to remain at a low level compared to the level reached after three immunizations in naive animals.

WO 03/051912 PCT/EP02/14486

A quite similar observation was made for NS3 immunizations where an even stronger adjuvant (RIBI) was used in the chronic chimpanzee. As compared with an alum formulation in naive animals the following has been noted: the induced antibody titers are comparable in both groups (not shown); and both cytokine secretion and T-cell proliferation are almost absent in the chronic animals compared to the responses in naive animals (Fig. 49a-b).

Currently there have been some indications that immune responses against HCV in chronic carriers are low or at least insufficient to allow clearance of infection. The above results support the hypothesis that the immune system of HCV chronic carriers may be impaired and that they do not respond to HCV antigens as efficiently as in a naive situation.

10

15

20

In a study by Wiedmann et al., (Hepatology 2000; 31: 230-234), vaccination for HBV was less effective in HCV chronic carriers, which indicates that such an immune impairment is not limited to HCV antigens. De Maria et al. (Hepatology 2000; 32: 444-445) confirmed these data and have proposed adapted vaccine dosing regimens for HCV patients. The data presented herein indicates that increasing the number of immunizations may indeed augment humoral responses but that cellular (especially Th1) responses are difficult to induce, even when powerful adjuvants are used. It may be advantageous to begin immunization at the time of antiviral therapy, when the immune system is more prone to respond.

82

Table 1: Recombinant vaccinia plasmids and viruses

Plasmid		HCV cDNA sublcone		Vector
Name	Name	Construction	Length (nt/aa)	used for insertion
pvHCV-13A	E1s	EcoR I - Hind III	472/157	pgptATA-18
pvHCV-12A	Els	EcoR I - Hind III	472/158	pgptATA-18
pvHCV-9A	E1	EcoR I - Hind III	631/211	pgptATA-18
pvHCV-11A	Ėls	EcoR I - Hind III	625/207	pgptATA-18
pvHCV-17A	Els	EcoR I - Hind III	625/208	pgptATA-18
pvHCV-10A	E1	EcoR I - Hind III	783/262	pgptATA-18
pvHCV-18A	COREs	Acc I (Kl) – EcoR I (Kl)	403/130	pgptATA-18
pvHCV-34	CORE	Acc I (Kl) - Fsp I	595/197	pgptATA-18
pvHCV-33	CORE-E1	Acc I (Kl)	1150/380	pgptATA-18
pvHCV-35	CORE-E1b.his	EcoR I - BamH I (K1)	1032/352	pMS-66
pvHCV-36	CORE-E1n.his	EcoR I - Nco I (K1)	1106/376	pMS-66
pvHCV-37	ElΔ	Xma I - BamH I	711/239	pvHCV-10A
pvHCV-38	E1∆s	EcoR I - BstE II	553/183	pvHCV-11A
pvHCV-39	ElΔb	EcoR I - BamH I	960/313	pgsATA-18
pvHCV-40	E1∆b.his	EcoR I - BamH I (KI)	960/323	pMS-66
pvHCV-41	E2bs	BamH I (Kl)-AlwN I (T4)	1005/331	pgsATA-18
pvHCV-42	E2bs.his	BamH I (KI)-AlwN I (T4)	1005/341	pMS-66
pvHCV-43	E2ns	Nco I (Kl) – AlwN I (T4)	932/314	pgsATA-18
pvHCV-44	E2ns.his	Nco I (Kl) – AlwN I (T4)	932/321	pMS-66
pvHCV-62	Els (type 3a)	EcoR I - Hind III	625/207	pgsATA-18
pvHCV-63	Els (type 5)	EcoR I - Hind III	625/207	pgsATA-18
pvHCV-64	E2	BamH I - Hind III	1410/463	pgsATA-18
pvHCV-65	E1-E2	BamH I - Hind III	2072/691	pvHCV-10A
pvHCV-66	CORE-E1-E2	BamH I - Hind III	2427/809	pvHCV-33

nt: nucleotide; aa: amino acid; Kl: Klenow DNA Pol filling; T4: T4 DNA Pol filling Position: amino acid position in the HCV polyprotein sequence

Table 1 - continued: Recombinant vaccinia plasmids and viruses

Plasmid		HCV cDNA subclone		Vector
Name	Name	Construction	Length (nt/aa)	used for insertion
pvHCV-81	E1*-GLY 1	EcoRI – BamH I	783/262	pvHCV-10A
pvHCV-82	E1*-GLY 2	EcoRI – BamH I	783/262	pvHCV-10A
pvHCV-83	E1*-GLY 3	EcoRI – BamH I	783/262	pvHCV-10A
pvHCV-84	E1*-GLY 4	EcoRI – BamH I	783/262	pvHCV-10A
pvHCV-85	E1*-GLY 5	EcoRI – BamH I	783/262	pvHCV-10A
pvHCV-86	E1*-GLY 6	EcoRI – BamH I	783/262	pvHCV-10A

nt: nucleotide; aa: amino acid; Kl: Klenow DNA Pol filling; T4: T4 DNA Pol filling Position: amino acid position in the HCV polyprotein sequence

TO ARTICLE A SUBSTRICT OF A STATE AND CONTRACT AND AREA OF A TRACT AND A MADERIAL CONTRACT OF A CONTRACT OF A

WO 03/051912 PCT/EP02/14480

84
Table 2 : Summary of anti-E1 tests

 $S/N \pm SD$ (mean anti-E1 titer)

	Start of treatment	End of treatment	Follow-up
LTR	6.94 ± 2.29 (1:3946)	4.48 ± 2.69 (1:568)	2.99 ± 2.69 (1:175)
NR	5.77 <u>+</u> 3.77 (1:1607)	5.29 + 3.99 (1:1060)	6.08 <u>+</u> 3.73 (1:1978)

LTR: Long-term, sustained response for more than 1 year

NR : No response, response with relapse, or partial response

85 **Table 3: Synthetic peptides for competition studies**

PROTEIN	PEPTIDE	AMINO ACID SEQUENCE	POSITION	SEQ ID NO
E1	E1-31	LLSCLTVPASAYQVRNSTGL	181-200	56
•.	E1-33	QVRNSTGLYHVTNDCPNSSI	193-212	57
	E1-35	NDCPNSSIVYEAHDAILHTP	205-224	58
	E1-35A	SNSSIVYEAADMIMHTPGCV	208-227	59
•	E1-37	HDAILHTPGCVPCVREGNVS	217-236	60
	E1-39	CVREGNVSRCWVAMTPTVAT	229-248	61
•	E1-41	AMTPTVATRDGKLPATQLRR	241-260	62
	E1-43	LPATQLRRHIDLLVGSATLC	253-272	63
	E1-45	LVGSATLCSALYVGDLCGSV	265-284	64
	E1-49	QLFTFSPRRHWTTQGCNCSI	289-308	65
	E1-51	TQGCNCSIYPGHITGHRMAW	301-320	66
	E1-53	ITGHRMAWDMMMNWSPTAAL	313-332	67
	E1-55	NWSPTAALVMAQLLRIPQAI	325-344	68
	E1-57	LLRIPQAILDMIAGAHWGVL	337-356	69
	E1-59	AGAHWGVLAGIAYFSMVGNM	349-368	70
	E1-63	VVLLLFAGVDAETIVSGGQA	373-392	71
E2	E2-67	SGLVSLFTPGAKQNIQLINT	397-416	72
	E2-69	QNIQLINTNGSWHINSTALN	409-428	73
	E2-\$3B	LNCNESLNTGWWLAGLIYQHK	427-446	74
	E2-\$1B	AGLIYQHKFNSSGCPERLAS	439-458	75
	E2-1B	GCPERLASCRPLTDFDQGWG	451-470	76
	E2-3B	TDFDQGWGPISYANGSGPDQ	463-482	77

Table 3 - continued : Synthetic peptides for competition studies

E2-5B	ANGSGPDQRPYCWHYPPKPC	475-494	78
E2-7B	WHYPPKPCGIVPAKSVCGPV	487-506	79
E2-9B	AKSVCGPVYCFTPSPVVVGT	499-518	80
E2-11B	PSPVVVGTTDRSGAPTYSWG	511-530	81
E2-13B	GAPTYSWGENDTDVFVLNNT	523-542	82
E2-17B	GNWFGCTWMNSTGFTKVCGA	547-566	83
E2-19B	GFTKVCGAPPVCIGGAGNNT	559-578	84
E2-21	IGGAGNNTLHCPTDCFRKHP	571-590	85
E2-23	TDCFRKHPDATYSRCGSGPW	583-602	86
E2-25	SRCGSGPWITPRCLVDYPYR	595-614	87
E2-27	CLVDYPYRLWHYPCTINYTI	607-626	88
E2-29	PCTINYTIFKIRMYVGGVEH	619-638	89
E2-31	MYVGGVEHRLEAACNWTPGE	631-650	90
E2-33	ACNWTPGERCDLEDRDRSEL	643-662	91
E2-35	EDRDRSELSPLLLTTTQWQV	655-674	92

Table 4. Change of Envelope Antibody levels over time (complete study, 28 patients)

Wilcoxon Signed	E1Ab NR E1Ab		E1Ab NR	E1Ab LTR	NR EIAB NR EIAB LTR EIAB LTR EIAB LTR E2AB NR	E1Ab LTR	E2Ab NR	E1A	E1Ab LTR	
Rank test (P values)		All	i i kin il	type 1b	type 3a	All	,	type 1b	type 1b type 3a All	All
			. 45				· .			
End of therapy*	0.1167	0.2604	0.285		0.0058**	0.043**	0.0499** 0.0186** 0.0640	0.0186**	0.0640	
6 months follow up* 0.86	98.0		0.7213	0.5930	0.0047**	0.043**	0.063		0.04326	0.04326 0.0464**
12 months follow up* 0.7989		0.3105			0.0051**	0.0679	0.0277** 0.0869		0.0058**	

*Data were compared with values obtained at initiation of therapy

*P values < 0.0

Table 5. Difference between LTR and NR (complete study)

Mann-Withney	E1Ab S/N	E1Ab titers	E1Ab S/N	E1Ab S/N	E2Ab S/N
U test (P values)	VIII	All	type 1b type 3aAll	3aAll	
Initiation of therapy	0.0257*	0.05	89.0	0.1078	
End of therapy	0.1742	·.		0.1295	
6 months follow up	V Sylveni Chushaquasi	0.6099	0.425	0.3081	
12 months follow up	29.0	0.23	0.4386	0.6629	
	* 12 () () () () () () () () () (- ·

P values < 0.05

Table 6. Competition experiments between murine E2 monoclonal antibodies

	-	Decrease (%) o	of anti-E2 reactivity of biotinylated anti-E2 mabs	ctivity of	biotinylate	d anti-E2	mabs				
2	competitor	competitor 17H10F4D10	2F10H10	16A6E7	10D3C4	4H6B2	17C2F2	9G3E6	12D11F1	15C8C1	8G10D1H9
	17H10F4D10 -	- 0	62	10	ND	11	ND	S	. 9	30	N QN
	2F10H10	06		. —	N QN	30	ND	0	4	12	ND
	16A6E7	ND	QX		ND	S	ND	S S	N Q	<u>Q</u>	ND
	10D3C4	11	20	92		8	26	28	43	53	30
10	4H6B2	ND	QN	82	ND		ND	NO	QN	ND QN	ND
	17C2F2	2	QN	75	QN QN	56	·	11	10	. 0	0
	9G3E6	ND	S Q	. 89	ND	11	ND	•	09	92	NO ON
	12D11F1	ND	NO	26	NO	13	ND CN	Z	ł	88	ND
	15C8C1	ND	ON ON	. 2	N Q N	10	S S	ND	ND	•	ND
15	8G10D1H9	2	2		ND	15		<u>79</u>	082	81	
	competitor controls	ontrols									
	15B7A2	0	0	^6	15	10	6	0	0	0	, 5
	5H6A7	0	. 2	0	12	∞	0	0	4	0	0
	23C12H9	ND	N	2	12	ND	41	ND	ND	ND ND	2
20	ND, not done	a)		List y							

ers	
ri m	
7. P	
, <u>a</u>	
ab	
	ı

5 -GTTTAACCACTGCATGATG-3'	5'-GTCCCATCGAGTGCGGCTAC-3'	5'-CGTGACATGGTACAT <u>TCCGGA</u> CACTTGGCGCACTTCATAAGCGGA-3'	5'-TGCCTCATACACAATGGAGCTCTGGGACGAGTCGTTCGTGAC-3'	5'-TACCCAGCAGCGGAGCTCTGGTTGCTCCCGAACGCAGGGCAC-3'	5'-TGTCGTGGTGGGGACGGAGGCCTGCCTAGCTGCGAGCGTGGG-3'	5'-CGTTATGTGGCCCGGGTAGATTGAGCACTGGCAGTCCTGCACCGTCTC-3'	5'-cagggccgttgt <u>aggcct</u> cca c tgcatcatctatcccaagc-3'	5'-ccggaatgtaccatgtcacgaacgac-3'	5'- <u>GCTC</u> CATTGTGTATGAGGCAGCGG-3'	5'- <u>GAGCTC</u> CCGCTGCTGGGTAGCGC-3'	5'-CCTCCCCCCCCCCCACGACAATACG-3'	5'-CTA <i>CCCGGG</i> CCACATAACGGGTCACCG-3'	5'-GGAGCCTACAACGGCCCTGGTGG-3'	5'-TTCTATCGATTAAATAGAATTC -3'	5'-GCCATACGCTCACAGCCGATCCC-3'	
EL C	r,	GLY1	,¥2	GLY3	GLY4	GLY5	GLY6	OVR1	OVR2	OVR3	OVR4	OVR5	OVR6	GPT-2	TK_R-2	,
NO:96 GPT	NO:97 TKR	NO:98 GI	NO:99 GLY2	NO:100	NO:101	NO:102	NO:103	NO:104	NO:105	NO:106	NO:107	NO:108	NO:109	NO:110	NO:111	;
ID	ID	ΩĦ	ΠD	ID	ID	ID	ID	ID	QI-	ID	ID	ID	ID	ID	Q.	•
SEQ	SEQ	SEQ	SEQ	SEQ	SEO	SEQ	SEO	SEQ	SEQ	SEQ	SEO	SEQ	SEQ	SEQ	SEO	•
	2					10					15					,

nucleotides in bold represent mutations with respect to the original HCC110A sequence nucleotides underlined represent additional restriction site 20

Table 8. Analysis of E1 glycosylation mutants by ELISA

-									,	
	1	2	3	4	5	9	7	8	6	
SN GLY1	SN GLY1 1.802462	2.120971	1,403871	1.205597	2.120191	2.866913	1.950345	1.866183	1.730193	
SN GLY2	SN GLY2 2.400795	1.76818	2.325495	2.325495 2.639308	2.459019	5.043993	2.146302	1.595477	1.688973	
SN GLY3	SN GLY3 1.642718	1.715477	2.261646	2.261646 2.354748	1.591818	4.833742	1.96692	1.482099	1.602222	
SN GLY4	SN GLY4 2.578154	3.824038	3.874605	1.499387	3.15	4.71302	4.198751	3.959542	3.710507	
SN GLY5	SN GLY5 2.482051	1.793761	793761 2.409344	2.627358	1.715311	4.964765	2.13912	1.576336	1.708937	
SN GLY6	SN GLY6 2.031487	1 495737	2.131613	2.527925	2.494833	4.784027	2.02069	1.496489	1.704976	
SN E1	2.828205	2.227036	2.227036 2.512792	2.790881	3.131579	4.869128	2.287753	1.954198	1.805556	
-		,								
	10	11	12	13	14	15	16	17	- 18	
SN GLY1	SN GLY1 2.468162	1.220654	1.629403 5.685561	5.685561	3.233604	3.763498	1.985105	2.317721	6.675179	
SN GLY2	SN GLY2 2.482212	1.467582	2.070524	7.556682	2.567613	3.621928	3.055649	2.933792	7.65433	

		-							
	10	11	12	13	14	15	16	17	- 18
SN GLY1	3N GLY1 2.468162	1.220654	1.629403	5.685561	.220654 1.629403 5.685561 3.233604 3.763498 1.985105 2.317721	3.763498	1.985105	2.317721	6.675179
SN GLY2	SN GLY2 2.482212	1.467582	467582 2.070524 7.556682	7.556682	2.567613	2.567613 3.621928 3.055649	3.055649	2.933792	7.65433
SN GLY3	SN GLY3 2.191558	1.464216	.464216 1.721164	7.930538	7.930538 2.763055	3.016099 2.945628	2.945628	2.515305	5.775357
SN GLY4 5.170841	5.170841	4.250784	.250784 3.955153 8.176816 6.561122	8.176816	6.561122	_	5.707668 5.684498	5.604813 6.4125	6.4125
SN GLYS	SN GLY5 3.021807	1.562092	2.07278	8.883408	2.940334	2.940334 3.125561 3.338912	3.338912	2.654224	5.424107
SN GLY6	SN GLY6 2.677757	1.529608	529608 1.744221	8.005561	2.499952	2.621704 2.572385	2.572385	2.363301	5.194107
SN E1	2.616822	1.55719	2.593886	8.825112	2.593886 8.825112 3.183771 3.067265 3.280335 2.980354 7.191964	3.067265	3.280335	2.980354	7.191964

						The second secon	The second secon	
	19	20	21	22	23	24	S/N	S/N
SN GLY1	1.93476	2.47171	4.378633	1.188748	2.158889	1.706992	59.88534	2.495223
SN GLY2	2.127712	2.921288	4.680101	1.150781	1.661914	1.661914 1.632785	69.65243	2.902185
SN GLY3	1.980185	2.557384	4.268633	0.97767	1.336775	1.20376	62.09872	2.587447
SN GLY4	3.813321	3.002535	.002535 4.293038	2.393011	3.68213	2.481585	102.6978	4.279076
SN GLY5	2.442804	3.126761	4.64557	1.153656	1.817901	1.638211	69.26511	2.886046
SN GLY6	1.506716	2.665433	2.781063	1.280743	1.475062	1.716423	61.32181	2.555075
SN E1	2.771218	3.678068	5.35443	1.167286	2.083333	1.78252	76.54068	3.189195

Table 8 (continued). Analysis of E1 glycosylation mutants by ELISA

_	ı	1	_	1)	_	1	_	<u> </u>	1	· ·		1								
6	0.958261	0.935431	0.887385	2.05505	0.946488	0.944294		18	0.928144	1.064289	0.803029	0.89162	0.75419	0.72221									•
∞	0.954961	0.816436	0.758418	2.026172	0.806641	0.765781		17	0.777666	0.984377	0.843962	1.880587	0.890574	0.79296		AVERAGE	E1/GLY#	0.806885	0.903077	0.799967	1.51608	0.907783	0.816538
7	0.852516	0.93817	0.859761	1.835317	0.935031	0.883264		16	0.605153	0.931505	0.897966	1.732902	1.017857	0.784184		SUM	E1/GLY#	19.36524	21.67384	19.19921	36.38592	21.78679	19.59691
9	0.588794	1.035913	0.992733	0.967939	1.019642	0.982522		15	1.226988	1.180833	0.983319	1.860833	1.019006	0.854737			24	0.957628	0.915998	0.675314	1.392178	0.919042	0.962919
5	0.677036	0.785233	0.508312	1.005882	0.547746	0.796669		14	1.015652	0.806469	0.867856	2.060802	0.923538	0.785217			23	1.036267	0.797719	0.641652	1.767422	0.872593	0.70803
4	0.431977	0.94569	0.84373	0.537245	0.941408	0.90578		13	0.644248	0.85627	0.898633	0.92654	1.006606	0.907134	i		22	1.018386	0.98586	0.837558	2.050064	0.988323	1.097197
3	0.55869	0.925463	0.900053	1.541952	0.958831	0.848305		12	0.628171	0.798232	0.663547	1.524798	0.799102	0.672435			21	0.817759	0.874061	0.797215	0.801773	0.867612	0.519395
2	0.952374	0.793961	0.770296	1.717097	0.805447	0.671626		11	0.783882	0.942455	0.940294	2.72978	1.003148	0.982288			20	0.672013	0.794245	0.695306	0.816335	0.850109	0.724683
1	0.637316	0.848876	0.580834	0.911587	0.877607	0.718296		10	0.94319	0.94856	0.837488	1.976	1.154762	1.023286			19	0.698162	0.76779	0.714554	1.376045	0.881491	0.543702
	GLY1/E1	GLY2/E1	GLY3/E1	GLY4/E1	GLY5/E1	GLY6/E1			GLY1/E1	GLY2/E1	GLY3/E1	GLY4/E1	GLY5/E1	GLY6/E1				GLY1/E1	GLY2/E1	GLY3/E1	GLY4/E1	GLY5/E1	GLY6/E1

Table 9. Profile of adjuvated E1 in Balb/c mice

·	alum	T-cell adjuvant	RBI
antibody titre (mean ± . SD, n=6)	96000 ± 101000	62000 ± 60000	176000 ± 149000
antibody isotypes	IgG1	IgG1/2b	IgG1/2a
T-cell preliferation in spleen ¹ (n=3)	11750 (2/3)	48300 (3/3)	26000 (3/3)
T-cell proliferation in lymph node ²	no specific stimulation	4000	8000
cytokine profile (spleen)	Il-4	IFN-g/Il-4	IFN-g/Il-4

- ¹ after three s.c./i.m. immunizations, 3 randomly selected mice were analyzed individually, the result is expressed as the mean specific cpm obtained after 4 days of E1 stimulation (1 μg/ml), the number in brackets refers to the number of mice with specific stimulation above background
- ² after one single intra footpath immunization (n=2), the result is expressed as the mean specific cpm obtained after 5 days of E1 stimulation (1 μg/ml)

<u>Table 10. Humoral Responses: No. of immunizations required for different E-1</u> antibodies levels

Animal	status	seroconversion	> 1 U/ml ²	> 10 U/ml
Marcel	chronic	3	4	5
Peggy	chronic	3	5	>12
Femma	chronic	4	5	>12
Yoran	naive	3	4	5
Marti	naive	2	3	5

the unit is defined as follows: the level of E1 antibodies in human chronic carriers prior to interferon therapy and infected with genotype 1b is < 0.1 U/ml for 50% of the patients, between 0.1 to 1 U/ml for 25% of the patients and > 1 U/ml in the remaining 25% of patients, n=58

¹ defined as ELISA signal higher than cut-off level if no E1-antibodies were present prior to immunization, in the other cases the observation of a titer higher than the 3 individual time points of pre-immunization titers was considered as the point of seroconversion.

WO 03/051912

5

10

15

20

25

30

Example 12: Immunization of a chimpanzee chronically infected with HCV subtype 1b

A chimpanzee (Phil) already infected for over 13 years (5015 days before immunization) with an HCV subtype Ib strain was vaccinated with El (aa 192-326) which was derived from a different strain of genotype 1 b, with a 95.1% identity on the amino acid level (see also Table 2 of WO 99/67285 the whole of which is incorporated herein by reference), and which was prepared as described in examples 1-3 of WO 99/97285. The chimpanzee received in total 6 intramuscular immunizations of each 50 µg E1 in PBS/0.05% CHAPS mixed with RIBI R-730 (MPLA+TDM+CWS) according to the manufacturer's protocol (Ribi Inc. Hamilton, MT). The 6 immunizations were given in two series of three shots with a three week interval and with a lag period of 6 weeks between the two series. Starting 150 days prior to immunization, during the immunization period and until 1 year post immunization (but see below and WO 99/67285) the chimpanzee was continuously monitored for various parameters indicative for the activity of the HCV induced disease. These parameters included blood chemistry, ALT, AST, gammaGT, blood chemistry, viral load in the serum, viral load in the liver and liver histology. In addition, the immune answer to the immunization was monitored both on the humoral and cellular level. During this period the animal was also monitored for any adverse effects of the immunization, such as change in behaviour, clinical symptoms, body weight, temperature and local reactions (redness, swelling, indurations). Such effects were not detected.

Clearly, ALT (and especially gammaGT, data not shown) levels decreased as soon as the antibody level against El reached its maximum (see, Figure 8 of WO 99/67285). ALT rebounded rather rapidly as soon as the antibody levels started to decline, but gammaGT remained at a lower level as long as anti-El remained detectable.

E2 antigen in the liver decreased to almost undetectable levels during the period in which anti-El was detectable and the E2 antigen rebounded shortly after the disappearance of these antibodies. Together with the Core and E2 antigen becoming undetectable in the liver, the inflammation of the liver markedly decreased (see also Table 3 of WO 99/67285). This is a major proof that the vaccine induces a reduction of the liver damage, probably by clearing, at least partially, the viral antigens from its major target organ, the liver.

The viraemia level, as measured by Amplicor HCV Monitor (Roche, Basel, Switzerland),

remained approximately unchanged in the serum during the whole study period.

5

10

15

20

25

30

More detailed analyses of the humoral response revealed that the maximum end-point titer reached 14.5 x 10³ (after the sixth immunization) and that this titer dropped to undetectable 1 year post immunization (Figure 8 of WO 99/67285). Figure 9 of WO 99/67285 shows that the main epitopes, which can be mimicked by peptides, recognized by the B-cells are located at the N-terminal region of E2 (peptides V1V2 and V2V3, for details on the peptides used see Table 4 of WO 99/67285). Since the reactivity against the recombinant El is higher and longer lasting, it can also be deduced from this figure, that the antibodies recognizing these peptides represent only part of the total antibody population against El. The remaining part is directed against epitopes which cannot be mimicked by peptides, i.e discontinuous epitopes. Such epitopes are only present on the complete E1 molecule or even only on the particle-like structure. Such an immune response against El is unique, at least compared to what is normally observed in human chronic HCV carriers (WO 96/13590 to Maertens et al.) and in chimpanzees (van Doorn et al., 1996), who raise anti-E1 antibodies in their natural course of infection. In those patients, anti-E1 is in part also directed to discontinuous epitopes but a large proportion is directed against the C4 epitope (±50% of the patient sera), a minor proportion against V1V2 (ranging from 2-70% depending on the genotype), and reactivity against V2V3 was only exceptionally recorded (Maertens et al., 1997).

Analysis of the T-cell reactivity indicated that also this compartment of the immune system is stimulated by the vaccine in a specific way, as the stimulation index of these T-cells rises from 1 to 2.5, and remains somewhat elevated during the follow up period (Figure 10 of WO 99/67285). It is this T cell reactivity that is only seen in Long term responders to interferon therapy (see: PCT/EP 94/03555 to Leroux-Roels et al.;Leroux-Roels et al., 1996).

Example 13: Immunization of a chronic HCV carrier with different subtype

A chimpanzee (Ton) already infected for over 10 years (3809 days before immunization) with HCV from genotype la was vaccinated with El from genotype lb, with only a 79.3 % identity on the amino acid level (see also Table 2 of WO 99/67285), and prepared as described in the previous examples. The chimpanzee received a total of 6 intramuscular immunizations of 50 µg El in PBS/0.05% CHAPS each mixed with RIBI R-730 according

to the manufacturer's protocol (Ribi Inc. Hamilton, MT). The 6 immunizations were given in two series of three shots with a three week interval and with a lag period of 4 weeks between the two series. Starting 250 days prior to immunization, during the immunization period and until 9 months (but see below and WO 99/67285) post immunization the chimpanzee was continuously monitored for various parameters indicative for the activity of the HCV induced disease. These parameters included blood chemistry, ALT, AST, gammaGT, viral load in the serum, viral load in the liver and liver histology. In addition, the immune answer to the immunization was monitored both on the humoral and cellular level. During this period the animal was also monitored for any adverse effects of the immunization, such as change in behaviour, clinical symptoms, body weight, temperature and local reactions (redness, swelling, indurations). Such effects were not detected. Clearly, ALT levels (and gammaGT levels, data not shown) decreased as soon as the antibody level against El reached its maximum (Figure 11 of WO 99/67285). ALT and

15

10

5

antibody level against El reached its maximum (Figure 11 of WO 99/67285). ALT and gammaGT rebounded as soon as the antibody levels started to decline, but ALT and gammaGT remained at a lower level during the complete follow up period. ALT levels were even significantly reduced after vaccination (62 ± 6 U/1) as compared to the period before vaccination (85 ± 11 U/1). Since less markers of tissue damage were recovered in the serum, these findings were a first indication that the vaccination induced an improvement of the liver disease.

20

E2 antigen levels became undetectable in the period in which anti-E1 remained above a titer of 1.0×10^3 , but became detectable again at the time of lower El antibody levels. Together with the disappearance of HCV antigens, the inflammation of the liver markedly decreased from moderate chronic active hepatitis to minimal forms of chronic persistent hepatitis (Table 3 of WO 99/67285). This is another major proof that the vaccine induces a reduction of the liver damage, probably by clearing, at least partially, the virus from its major target organ, the liver .

30

25

The viraemia level, as measured by Amplicor HCV Monitor (Roche, Basel, Switzerland), in the serum remained at approximately similar levels during the whole study period. More detailed analysis of the humoral response revealed that the maximum end-point titer reached was 30×10^3 (after the sixth immunization) and that this titer dropped to 0.5×10^3 nine months after immunization (Figure 11 of WO 99/67285). Figure 12 of WO 99/67285

shows that the main epitopes, which can be mimicked by peptides and are recognized by the B-cells, are located at the N-terminal region (peptides V1V2 and V2V3, for details on. the peptides used see Table 4 of WO 99/67285). Since the reactivity against the recombinant El is higher and longer lasting, it can also be deduced from this figure, that the antibodies recognizing these peptides represent only part of the total antibody population against El. The remaining part is most likely directed against epitopes which cannot be mimicked by peptides, i.e. discontinuous epitopes. Such epitopes are probably only present on the complete E1 molecule or even only on the particle-like structure. Such an immune response against E1 is unique, at least compared to what is normally observed in human chronic HCV carriers, which have detectable anti-El. In those patients, anti-El is in part also discontinuous, but a large proportion is directed against he C4 epitope (50% of the patient sera), a minor proportion against V1V2 (ranging from 2-70% depending on the genotype) and exceptionally reactivity against V2V3 was recorded (Maertens et al., 1997). As this chimpanzee is infected with an la isolate the antibody response was also evaluated for cross-reactivity towards a El-la antigen. As can be seen in Figure 13 of WO 99/67285, such cross-reactive antibodies are indeed generated, although, they form only part of the total antibody population. Remarkable is the correlation between the reappearance of viral antigen in the liver and the disappearance of detectable anti-la El antibodies in the serum.

20

15

5

10

Analysis of the T-cell reactivity indicated that also this compartment of the immune system is stimulated by the vaccine in a specific way, as the stimulation index of these T-cells rises from 0.5 to 5, and remains elevated during the follow up period (Figure 14 of WO 99/67285).

25

30

Example 14: Reboosting of HCV chronic carriers with El

As the El antibody titers as observed in examples 12 and 13 were not stable and declined over time, even to undetectable levels for the 1b infected chimp, it was investigated if this antibody response could be increased again by additional boosting. Both chimpanzees were immunized again with three consecutive intramuscular immunization with a three week interval (50 µg El mixed with RIBI adjuvant). As can be judged from Figures 8 and 11 of WO 99/67285, the anti-El response could indeed be boosted, once again the viral antigen in the liver decreased below detection limit. The viral load in the serum remained constant

although in Ton (Figure 11 of WO 99/67285). A viremia level of < 10⁵ genome equivalents per ml was measured for the first time during the follow up period.

5

10

15

20

25

30

Notable is the finding that, as was already the case for the first series of immunizations, the chimpanzee infected with the subtype 1b HCV strain (Phil) responds with lower anti-El titers, than the chimpanzee infected with subtype la HCV strain (maximum titer in the first round 14.5 x 10³ versus 30 x 10³ for Ton and after additional boosting only 1.2 x 10³ for Phil versus 40 x 10³ for Ton). Although for both animals the beneficial effect seems to be similar, it could be concluded from this experiment that immunization of a chronic carrier with an El protein derived from another subtype or genotype may be especially beneficial to reach higher titers, maybe circumventing a preexisting and specific immune suppression existing in the host and induced by the infecting subtype or genotype. Alternatively, the lower titers observed in the homologous setting (1b vaccine +1b infection) may indicate binding of the bulk of the antibodies to virus. Therefore, the induced antibodies may possess neutralizing capacity.

Example 15: Demonstration of prophylactic utility of E1-vaccination in chimpanzee

The HCV Els protein (amino acids 192-326) was expressed in Vero cells using recombinant vaccinia virus HCV11B. This vaccinia virus is essentially identical to vvHCV11A (as described in U.S. Patent No. 6,150,134, the entire contents of which is hereby incorporated by reference) but has been passaged from RK13 to Vero cells. The protein was purified (by means of lentil chromatography, reduction-alkylation and size exclusion chromatography) essentially as described in example 9 of PCT/E99/04342 (WO 99/67285), making use of iodoacetamide as alkylating agent for the cysteines. After purification the 3% empigen-BB was exchanged to 3% betain by size exclusion chromatography as described in example 1 of PCT/E99/04342 this process allows to recover E1s as a particle. Finally the material was desalted to PBS containing 0.5% betain and an E1s concentration of 500 μg/ml. This El was mixed with an equal volume of Alhydrogel 1.3% (Superfos, Denmark) and finally further diluted with 8 volumes of 0.9% NaCl to yield alum-adjuvanted E1 at a concentration of 50 μg El/ml and 0.13% of Alhydrogel.

The HCV E2deltaHVRI (amino acids 412-715) was expressed in and purified from Vero essentially as described for El using recombinant vaccinia virus HCV101 which has been recombined from pvHCV-101 described in Example 8 of PCT/E99/04342 and wild type vaccinia virus. Also E2deltaHVRI behaves as a particle (measured by dynamic light scattering) after exchange of empigen to betain.

Five chimpanzees were selected which tested negative for HCV-RNA and HCV-antibodies. One of the animals (Huub) was not immunized, 2 animals received 6 immunizations with 50 µg El adjuvanted with alum (Marti and Yoran) while the remaining 2 animals received 6 immunizations with 50 µg E2deltaHVRI adjuvanted with alum (Joost and Karlien). All immunizations were administered intra-muscularly with a 3 week interval. Humoral and cellular immune responses were assessed in each animal against the antigen with which they where immunized and in each animal both type of responses was detected as shown in Table 11.

15

20

25

30

10

5

All chimpanzees became HCV-RNA positive (determined with Monitor HCV, Roche, Basel, Switzerland) on day 7 post challenge and a first ALT and gammaGT peak was measured between days 35 and 63. This evidences that all chimps developed acute hepatitis. Remarkably, both El immunized animals resolved their infection while the E2deltaHVRI and the control animal did not. This is evidenced by the fact that the El immunized animals lost HCV-RNA (determined with Monitor HCV, Roche, Basel, Switzerland) at day 98 (Yoran) and 133 (Marti) and remained negative so far until day 273 with monthly testing. All the other animals stayed RNA-positive during the entire follow up period of 273 days so far with ALT and gammaGT values not returning to normal as for the El immunized chimpanzees but gradually increasing.

Table 11: antibody titers were determined by ELISA two weeks after the 6th immunization. A serial dilution of the sample was compared to an in house standard (this in house standard defined as having 1000 mU/ml of El or anti-E2deltaHVR I antibody is a mixture of three sera from HCV chronic carriers selected based on a high anti-envelope titer). The stimulation index, which reflects the cellular immune response, was obtained by culturing PBMC, drawn from the animals two weeks after the third immunization, in the presence or

absence of envelope antigen and determining the amount of tritiated thymidine

incorporated in these cells during a pulse of 18 hours after 5 days of culture. The stimulation index is the ratio of thymidine incorporated in the cells cultured with envelope antigen versus the ones cultured without antigen. A stimulation index of >3 is considered a positive signal.

5

10

20

Chimpanzee	Anti-E1 respons	se	Anti-E2deltaHV	'RI response
	Antibody titer	Stimulation	Antibody titer	Stimulation
		index		Index
Yoran	14110	10.9		
Marti	5630	14.2		
Joost			3210	8.5
Karlien			1770	11.2

Three weeks after the last of 6 immunizations all animals including the control were challenged with 100 CID (chimpanzee infectious doses) of a genotype 1b inoculum (J4.91, kindly provided by Dr. J. Bukh, NIH, Bethesda, Maryland). The amino acid sequence divergence between the vaccine proteins and the J4.91 isolate (of which the sequence information is available under accession number BAA01583) is 7% (9 out of 135 amino acids) for Els and 11% (32 out of 304 amino acids) for E2delta HVRI; Consequently this challenge is considered heterologous and reflects a real life challenge.

In conclusion we have shown that El-immunization changes the natural history of HCV infection by preventing evolution to a chronic infection, which is the major health problem related with HCV.

Example 16: Similar El responses which allowed clearing of infection in chimpanzee can be induced in man

In order to obtain a prophylactic effect of El immunization in man it is required that similar immune responses can be induced in man compared to chimpanzee. Therefore we vaccinated 20 male human volunteers, in which no anti-El responses (humoral or cellular) could be detected, with 3 doses of 20 µg Els formulated on 0.13% Alhydrogel in 0.5 ml.

All immunizations were given intramuscularly with a 3 week interval. As evidenced in

Table 12, 17 out of 20 volunteers indeed mounted a significant humoral and cellular immune response against El and this without serious adverse events. Only 1 volunteer (subject 021) should be considered as a non-responder since neither humoral nor cellular responses were above the cut-off level after 3 El immunizations. The observation that the humoral response is lower compared to chimpanzee relates to the fact that only

3 immunizations with 20 μg were given and not 6 with 50 μg .

10

Table 12: antibody titers were determined by ELISA two weeks after the third immunization. A serial dilution of the sample was compared to an in house standards (this in house standard defined as having 1000 mU/ml of El or anti-E2deltaHVR I antibody is a mixture of three sera from HCV chronic carriers selected based on a high anti-envelope titer). The stimulation index (cellular immune response) was obtained by culturing PBMC, drawn from the individuals two weeks after the third immunization, in the presence or absence of 1 μg of Els and determining the amount of tritiated thymidine incorporated in these cells during a pulse of 18 hours after 5 days of culture. The stimulation index is the ratio of thymidine incorporated in the cells cultured with envelope antigen versus the ones cultured without antigen. A stimulation index of >3 is considered a positive signal.

Subject	Antibody	Stimulation	Subject	Antibody	Stimulation
no	titer	index	no	titer	index
002	1370	30.9	014	49	4.6
003	717	13.2	015	228	3.8
004	800	9.1	016	324	4.1
007	680	3.8	017	<20*	6.2
008	1026	3.9	018	<20	6.7
009	325	4.6	019	624	3.1
010	898	7.7	020	84	5.5
011	284	4.1	021	<20	2.1
012	181	3.6	022	226	2.7
013	<20	3.5	023	163	7.6

*this individual is considered anti-E1 positive after immunization since a significant increase in ELISA signal was seen between the preimmune sample and the sample after three immunization, the titer however is very low and does not allow accurate determination.

Example 17: Boosting of E1 responses in vaccinated healthy volunteers

19 out of the 20 human volunteers of example 16 were boosted once more with 20 µg E1s formulated on 0.13% Alhydrogel in 0.5 ml at week 26 (i.e. 20 weeks after the third immunization). Again antibody titers and cellular immune responses were determined 2 weeks after this additional immunization. In all individuals the antibody titer had decreased during the 20 week interval but could easily be boosted by this additional immunization to a level equal or higher of that observed at week 8. On average the antibody titer was double as high after this boost compared to the week 8 titer, and 7 times as high compared to the week 26 titer (Table 13).

Remarkably the T-cell responses were for the majority of individuals still high after the 20 week interval. Taking in account a normalization to the tetanos response, which is present in most individuals as a consequence of previous vaccinations, there is no change in the geomeatric mean of the stimulation index. After the additional boost, taking in account a normalization to the tetanos response, no change is noted (figure 51). This confirms that a strong T-help response was induced after 3 E1 immunizations and indicates that these immunizations induced already a very good T-help memory which requires, at leeast for a period of 6 months, no further boosting.

20

5

10

15

25

<u>Table 13:</u> antibody titers were determined by ELISA two weeks (= week 8) and 20 weeks (= week 26) after the third immunization and finally also 2 weeks after the boost (= Week 28). A serial dilution of the sample was compared to an in house standards (this in house standard defined as having 1000 mU/ml of E1 antibody, is a mixture of three sera from HCV chronic carriers selected based on a high anti-envelope titer). For accurate comparison the determination of the titer at week 8 was repeated within the same assay as for the week 26 and 28 samples, which explains the differences with table 12 of example 16.

10

5

Subject no	Antibody titer							
	Week 8	Week 26	Week 28					
002	1471	443	3119					
003	963	95	2355					
004	1006	409	2043					
007	630	65	541					
008	926	81	819					
009	704	77	269					
010	1296	657	3773					
011	253	65	368					
012 ,	254	148	760					
013	36	<20	166					
014	53	40	123					
016	159	45	231					
017	109	39	568					
018	43	23	50					
019	425	157	1894					
020	.73	33	113					
021	25	<20	26					
022	280	150	357					
024	177	81	184					
average	467	138	936					

Legend to figure 51: The stimulation index (cellular immune response) was obtained by culturing PBMC (10⁵ cells), drawn from the individuals before immunization (week 0), two weeks after the third immunization (week 8), before the booster immunization (week 26) and two weeks after the booster immunization (week 28), in the presence or absence of 3 µg of recombinant E1s or 2 µg tetanos toxoid and determining the amount of tritiated thymidine incorporated in these cells during a pulse of 18 hours after 5 days of culture. The stimulation index is the ratio of thymidine incorporated in the cells cultured with envelope antigen versus the ones cultured without antigen. Samples of week 0 and 8 were determined in a first assay (A), while the samples of week 26 and 28 were determined in a second assay (B) in which the samples of week 0 were reanalyzed. Results are expressed as the geometric mean stimulation index of all 20 (A, experiment) or 19 (B, experiment) volunteers.

5

10

15

20

25

30

In addition the Th1 cytokine interferon-gamma and Th2 cytokine interleukin-5 were measured in the supernatants of the PBMC cultures of samples taken at week 26 and 28 and restimulated with E1. As can be judged from figure 52 the predominant cytokine secreted by the E1 stimulated PBMC is interferon-gamma. It is highly surprising to see that a strong Th1 biased response is observed with an alum adjuvanted E1, since alum is known to be a Th2 inducer. Once more the results confirm that a good T-cell memory response is induced, as prior to the final boost (week 26) already a very strong response is observed. The interferon-gamma secretion was found to be specific as in an additional experiment we saw no difference in interferon-gamma secretion between E1 stimulated cell cultures and non-stimulated cell cultures of these volunteers using samples drawn at week 0.

Legend to figure 52: PBMC (10⁵ cells), drawn from the individuals before the booster immunization (week 26) and two weeks after the booster immunization (week 28), were cultured in the presence of 3 μg of recombinant E1s (E1) or 2 μg of tetanos toxoid (TT) or no antigen (Bl). Cytokines were measured in the supernatant taken after 24 hours (interleukin-5) or after 120 hours (interferon-gamma) by means of ELISA. The stimulation index is the ratio of cytokine measured in the supernatants of cells cultured with envelope antigen versus the ones cultured without antigen. Results are expressed as the geometric mean of pg cytokine/ml secreted of all 19 volunteers. Samples with a cytokine amount below detection limit were assigned the value of the detection limit. Similarly samples with

extremely high concentrations of cytokine out of the linear range of the assay were assigned the value of the limit of the linear range of the assay.

Example 18: Fine mapping of cellular response against E1 in vaccinated healthy volunteers.

In order to map the E1 specific responses a series of 20-mer peptides was synthesized, using standard Fmoc chemistry, with 8 amino acids overlap and covering the entire sequence of E1s. All peptides were C-terminally amidated and N-terminally acetylated, with the exception of IGP 1626 which has a free amino-terminus.

10

25

30

5

IGP1626: YEVRNVSGIYHVTNDCSNSS (amino acid 192-211)(SEQ ID NO:112)

IGP1627: TNDCSNSSIVYEAADMIMHT (amino acid 204-223)(SEQ ID NO:113)

IGP1628: AADMIMHTPGCVPCVRENNS (amino acid 216-235)(SEQ ID NO:114)

IGP1629: PCVRENNSSRCWVALTPTLA (amino acid 228-247)(SEQ ID NO:115)

15 IGP1630: VALTPTLAARNASVPTTTIR (amino acid 240-259)(SEQ ID NO:116)

IGP1631: SVPTTTIRRHVDLLVGAAAF (amino acid 252-271)(SEQ ID NO:117)

IGP1632: LLVGAAAFCSAMYVGDLCGS (amino acid 264-283)(SEQ ID NO:118)

IGP1633: YVGDLCGSVFLVSQLFTISP (amino acid 276-295)(SEQ ID NO:119)

IGP1634: SQLFTISPRRHETVQDCNCS (amino acid 288-307)(SEQ ID NO:120)

20 IGP1635: TVQDCNCSIYPGHITGHRMA (amino acid 300-319)(SEQ ID NO:121)

IGP1636: HITGHRMAWDMMMNWSPTTA (amino acid 312-331)(SEO ID NO:122)

PBMC from 14 different healthy donors not vaccinated with E1s or 10 donors vaccinated with E1s were cultured in the presence of 25 μg/ml (non vaccinated persons) or 10 μg/ml (vaccinated persons, samples taken after the third or booster injection) of each peptide separately. As can be judged from figure 53 the peptides IGP 1627, 1629, 1630, 1631, 1633, 1635 and 1635 all induced significantly higher responses in vaccinated persons compared to non-vaccinated persons. Using a stimulation index of 3 as cut-off the peptides IGP 1627, 1629, 1631 and 1635 were the most frequently recognized (i.e. recognized by at least half of the vaccinated persons tested).

This experiment proofs that the T-cell responses induced by E1s derived from mammalian cell culture are specific against E1 since these responses can not only be recalled by the same E1s derived from mammalian cell culture but also by synthetic peptides. In addition

this experiment delineates the most immunogenic T-cell domains in E1 are located between amino acids 204-223, 228-271, 276-295, 300-331 and more particularly even between amino acids 204-223, 228-247, 252-271 and 300-319.

Legend to figure 53: The stimulation index (cellular immune response) was obtained by culturing PBMC (3 x10⁵ cells), in the presence or absence of peptides and determining the amount of tritiated thymidine incorporated in these cells during a pulse after 5-6 days of culture. The stimulation index is the ratio of thymidine incorporated in the cells cultured with peptide versus the ones cultured without peptide. Results are expressed as individual values for vaccinated persons (top panel) or non vaccinated or controls (lower panel).

The present invention also provides therefor, the following E1 peptides, proteins, compisitions and kits containing the same, nucleic acid sequences coding for these peptides and proteins containing the same, and methods of their manufacture and use, as are generally described herein for other E1 and related peptides of the present invention.

	IGP 1626	spanning positions 192-211 of the E1 region (SEQ ID NO:112),
	IGP 1627	spanning positions 204-223 of the E1 region (SEQ ID NO:113),
	IGP 1628	spanning positions 216-235 of the E1 region (SEQ ID NO:114),
	IGP 1629	spanning positions 228-247 of the E1 region (SEQ ID NO:115),
20	IGP 1630	spanning positions 240-259 of the E1 region (SEQ ID NO:116),
	IGP 1631	spanning positions 252-271of the E1 region (SEQ ID NO:117),
	IGP 1632	spanning positions 264-283 of the E1 region (SEQ ID NO:118),
	IGP 1633	spanning positions 276-295 of the E1 region (SEQ ID NO:119),
	IGP 1634	spanning positions 288-307 of the E1 region (SEQ ID NO:120),
25	IGP 1635	spanning positions 300-319 of the E1 region (SEQ ID NO:121),
	IGP 1636	spanning positions 312-331 of the E1 region (SEQ ID NO:122).

15

30

Example 19: Exemplification of therapeutic utility of E1-vaccination in man

The HCV E1s protein (amino acids 192-326 (SEQ 10 NO: 123:
YEVRNVSGMYHVTNDCSNSSIVYEAADMIMHTPGCVPCVRENNSSRCWVALTPT
LAARNASVPTTTIRRHVDLLVGAAAFCSAMYVGDLCGSVFLVSQLFTISPRRHETV
QDCNCSIYPGHITGHRMAWDMMMNW)) was expressed in Vero cells using recombinant vaccinia virus HCV11B. This vaccinia virus is essentially identical to

vvHCV11 A (described in, for example, PCT/EP95/03031 and U.S. Patent No. 6,510,134, the entire contents of each of which are incorporated herein by reference) but has been passaged from RK13 to Vero cells. The protein was purified (by means of lentil chromatography, reduction-alkylation and size exclusion chromatography) essentially as described in Example 9 of PCT/E99/04342 (the entire contents of each of which are incorporated herein by reference), making use of iodoacetamide as alkylating agent for the cysteines. After purification the 3% Empigen-BB (N-Dodecyl-N,N-dimethylglycine) was exchanged to 3% betain by size exclusion chromatography as described in Example 1 of PCT/E99/04342 this process allows to recover E1s as a particle. Finally the material was desalted to PBS containing 0.5% betain and an E1s concentration of 400 μg/mL. This E1 was mixed with an equal volume of Alhydrogel 1.3% (Superfos, Denmark) and finally further diluted with 8 volumes of 0.9% NaCl to yield alum-adjuvanted E1 at a concentration of 40 μg E1/mL and 0.13% of Alhydrogel.

5

10

15

20

25

30

In order to demonstrate a therapeutic effect of E1 immunization in man, an immune response was induced in chronically infected patients. This immune response was both quantitatively and qualitatively different from the base line response against E1 which is present in such patients.

Twenty-six chronically genotype 1 infected HCV patients were vaccinated with 5 doses ot 20 µg E1s formulated on 0.13% Alhydrogel in 0.5 mL. All immunizations were given intramuscularly. Immunizations were performed at week 0, 4, 8, 12 and 24. In addition, 9 patients received an identical number of placebo injections consisting of alum only.

As evidenced in the following Table 14, a T -cell response is normally absent in chronic HCV carriers (only 4%, 1 out ot 26, have a detectable T -cell reactivity). Upon immunization this increases to about 70% (18 out of 26) already after 4 immunizations.

This observation demonstrates that the immune response has been qualitatively changed from a T -cell non-responsiveness to a clear response. Furthermore this immune response can be sustained, by boosting with larger intervals since after the fifth immunization 3 monhts later, the cellular immune response is still of the same level or slightly increased. No significant changes were observed in the placebo group.

Table 14: The stimulation index (SI; cellular immune response) was obtained by culturing PBMC, drawn from the individuals four weeks (W16) after the fourth immunization and two weeks (W26) after the fifth immunization in the presence or absence of 3 µg of E1s and determining the amount of tritiated thymidine incorporated in these cells during a pulse

10

15

20

25

of 18 hours after 5 days of culture. The stimulation index is the ratio of thymidine incorporated in the cells cultured with envelope antigen versus the ones cultured without

antigen. A stimulation index of >3 is considered a positive signal.

	T-cell response			
· · · · · · · · · · · · · · · · · · ·	W0	W16	W26	
SI>3	1/26	18/26	17/25	
Mean SI	1.5	13.7	19.3	

In addition the antibody titers were determined by ELISA prior to the first immunization (this was done for each patient on three samples taken at different time points before immunization) and after the fifth immunization (this was done for each patient on two samples: W26 and W28). A serial dilution of the sample was compared to an in-house standard (this in-house standard is, as previously described, defined as having 1000 mU/mL of E1 antibody is a mixture of three sera from HCV chronic carriers selected based on a high anti-envelope titer). From this analysis it was concluded that, on average, the titer doubled from 331 to 715 mU/mL. This result demonstrates that the humoral arm of the immune response has at least been quantitatively altered.

An El vaccine formulated on alum significantly changes both the qualitative and quantitative immune response against El. Such an El based vaccine and/or any of the vaccines described herein may be additionally useful if administered in conjunction with antiviral therapy such but not limited to interferon and alternatively with its combination with ribavirin (i.e., prior to, after or with a composition of the present invention).

The following as well as all previously and subsequently identified text, references, patents, publication, etc., are hereby incorporated herein in their entirety by reference.

Example 20: Effects of therapeutic E1-vaccination in chronically infected patients.

In a first course of this study, 26 patients received 5 doses of 20 µg E1s as described in Example 19. In a second course, 25 of said 26 patients received a further 6 intramuscular doses of 20 µg E1s formulated on 0.13% Alhydrogel in 0.5 mL (as in Example 19). The immunizations of this second series were administered with 3-week intervals and the first injection was given at week 50. Four weeks after the last injection of the second course, a liver biopsy was performed in 24 out of the 25 patients who completed the two courses of therapeutic E1s vaccination. A liver biopsy was also performed in all patients prior to the

onset of the therapeutic vaccine treatment (i.e. prior to course 1 vaccination scheme). The mean time elapsed between pre-treatment and post-treatment biopsies was 17 months. Liver histology slides thus obtained before and after therapeutic vaccination were scored centrally in a blind way by two expert pathologists for fibrosis and inflammation, this according to the Ishak and Metavir scoring systems (Ishak et al. 1995 which is a modification of the scoring system of Knodell et al. 1981; Bedossa and Poynard 1996), as well as for anti-E2 immunostain using the IGH222 murine anti-E2 HVRI monoclonal antibody as described in International Patent Application WO99/50301. Perisinusoidal fibrosis was assessed based on staining of collagen with Sirius Red (on liver histology slides).

5

10

15

30

The Ishak scores range from 0 to 18 for grading of inflammation and from 0 to 6 for staging of fibrosis/cirrhosis. The sum of the Ishak inflammation and fibrosis scores comes closest to the Histological Activity Index (HAI; Knodell et al. 1981) which has been widely used. The change in Ishak fibrosis score in the 24 patients who followed the two courses of therapeutic E1s vaccination is -0.04 (with a 95% confidence interval of -0.60 to +0.68) and with a change from baseline- to end-value from 2.54 (baseline) to 2.50 (end). An overview of the different assessed necro-inflammatory intensities (Ishak scoring) is given in Table 15.

The Ishak equivalent of the HAI scores for the treated patients showed a mean absolute change from baseline of -0.17 (with a 95% confidence interval of -1.36 to 1.03) and with a change from baseline- to end-value from 8.88 (baseline) to 8.71 (end). Furthermore, nine (9) out of the 24 patients (38%) improved 2 points or more on the sum of Ishak inflammation- and Ishak fibrosis- scores whereas ten (10) out of the 24 patients remained stable (no change or a change of +1 or -1) and five (5) patients evolved to a worse condition (worsening of 2 points or more).

The Metavir scores range from 0 to 3 for grading of inflammation and from 0 to 4 for staging of fibrosis/cirrhosis. The overall progression rate of the Metavir score in an untreated patient is estimated to be 0.133 per year (Poynard et al. 1997).

For the patients of the current study, the average progression over the 17-month period based on the linear extension of the baseline score and the estimated duration of the infection (which is reported for 19 out of the 24 patients who followed the two courses of

therapeutic E1s vaccination) would be 0.20. This correlates well with the published overall rate of progression which would be 0.19 for the 17 month period.

The change in Metavir score observed for the treated patients is, however, 0.00 (with a 95% confidence interval of -0.43 to +0.43) and with a mean baseline- an end-score of 1.67.

An overview of Metavir scores at baseline and at the end of the second course treatment is given in Table 16. Unblinded comparison of pre- and post treatment slides revealed that 10 patients had diminished perisinusoidal fibrosis based on Sirius Red staining.

The anti-E2 immunostain scores range from 0 to 4, with 0 = no E2 anitgen detectable, 1 = occasional cell with detectable E2 antigen, 2= clusters of E2 antigen positive cells but less than 25% of cells positive, 3 = clusters of E2 antigen positive cells and 25-50% of cells positive, 4 = clusters of E2 antigen positive cells and more than 50% of cells positive. The anti-E2 immunostain scores for the treated patients showed a mean absolute change from baseline of -0.75 (with a 95% confidence interval of -1.64 to 0.14) and with a change from baseline- to end-value from 2.54 (baseline) to 1.79 (end). The reduction seen for anti-E2 immoreactivity in the liver using blind scoring was confimed by unblinded comparison of paired slides per patient. Eleven patients showed negativation or a marked reduction in HCV E2 immunostaining, while only three patients had a stronger immunostain after treatment. Of these 11 patients, 3 also showed a reduction in steatosis.

20

25

30

10

15

Serum HCV RNA levels were determined using the Amplicor HCV Monitor kit (Roche, Basel, Switzerland). The serum HCV RNA levels remained unchanged or did not change more than one log from baseline except in 1 patient. This concerned a 37-year old treatment-naïve female patient, infected with a genotype 1a virus and with flu-like symptoms at baseline. HCV-RNA dropped 3 logs from week 8 (after two injections with E1) to reach levels below 3000 IU/ml at weeks 16 and 20, in parallel ALT dropped from a single peak value of 400 U/ml at week 8 to normal ALT values at weeks 16, 20 and 24. This was accompanied by disappearance of the flu-like symptoms. After this period both ALT and HCV-RNA increased again, and symptoms re-appeared. The sequence of the virus present during the emerging viral load increase was compared with the baseline sequence. No evidence for the presence of escape mutant virus was found.

Serum ALT (alanine aminotransferase activity) levels in the treated patients decreased on average 22% (with a 95% confidence interval of -15% to -30%) as compared to the baseline levels. A positive correlation between % change from baseline in ALT levels and absolute change from baseline in fibrosis scores was noticed: a Spearman rank of p=0.0007 for Ishak fibrosis score and of p=0.002 for Metavir fibrosis score were obtained as correlations between the change from baseline in serum ALT and the absolute change from baseline Ishak and Metavir fibrosis scores, respectively.

A further outcome of the current study is the predictive character of the immune response (in terms of increase in serum anti-E1s antibody levels) to treatment for improvement in histological scores (fibrosis and overall) as well as serum ALT levels.

Antibody titers were determined by ELISA. A serial dilution of a serum sample was compared to an in house standard (this in house standard defined as having 1000 mU/mL of E1s antibody is a mixture of three sera from HCV chronic carriers selected based on a high anti-envelope titer). The detection limit for this assay is 5 mU/mL.

15

20

30

A Spearman rank of p=0.007 was obtained as correlation between the change from baseline in serum anti-E1 antibody level and the absolute change from baseline in total Ishak (inflammation plus fibrosis) score. Pearson p-values of p=0.06 and of p=0.009 were obtained as correlation between the change from baseline in serum anti-E1 antibody level and the absolute (p= 0.06) and relative (p=0.009) change from baseline in Ishak fibrosis score, respectively. A Pearson p-value of p=0.01 was obtained as correlation between the change from baseline in serum anti-E1 antibody level and the relative change from baseline in ALT value.

These associations remain after correction for baseline liver histology scores, ALT, serum

HCV-RNA viral load, age and sex, and IFN exposure and thus as add to the likelihood of a real positive effect induced by the therapeutic E1s vaccination treatment.

The seven patients with the highest increase in serum antibody levels in response to the therapeutic vaccine candidate (i.e., patients with an increase in anti-E1 antibody level of at least 700 mU/mL) had on average a significant decrease of -0.9 points (with a 95% confidence interval of -0.2 to -1.5) on Metavir liver fibrosis score. In this subgroup, serum ALT on average decreased 37% (with a 95% confidence interval of -25 to -49%). Table 17 provides an overview of the correlation between immune response (in terms of anti-E1s

antibody levels induced by treatment) and overall change (relative to baseline) in Ishak scores. Figure 54 illustrates the correlation between changes in Ishak fibrosis score, changes in ALT-levels and changes in anti-E1s antibody levels. Figure 55 illustrates the correlation between changes in Metavir fibrosis score, changes in ALT-levels and changes in anti-E1s antibody levels. Figure 56 illustrates Ishak fibrosis score versus ALT levels both at the start of the first treatment course (panel A) and at the end of the second treatment course (panel B). Figure 57 illustrates patient's age versus Ishak fibrosis score both at the start of the first treatment course (panel A) and at the end of the second treatment course (panel B). Both Figures 56 and 57 further indicate the seven patients with the highest increase in anti-E1s antibody levels induced by the therapeutic vaccination treatment.

A positive correlation between serum anti-E1s antibody levels and T cell proliferation index values at the end of the second treatment course was observed, with a Pearson p-value of p=0.009.

10

15

20

25

Concludingly, the increase in antibody levels to the E1s vaccination significantly predicted improvement in liver fibrosis (Metavir and Ishak scores), sum of inflammation and fibrosis scores (Ishak), and in ALT levels, even after correcting for any other baseline prognostic variables. The increase in anti-E1 antibodies after vaccination was also significantly correlated with an increase in T cell proliferation index to E1.

This study is clearly supportive for a E1-based therapeutic vaccination strategy to have the potential to halt disease progression towards liver cirrhosis.

Table 15. Ishak grading of necro-inflammatory intensities for periportal hepatitis, confluent necrosis, focal inflammation, portal inflammation and the overall total inflammation grading. Scores are indicated as the change from baseline (mean and 95 % confidence interval) and the mean baseline-to end-values.

Score for	Change of score from baseline mean (95% confidence interval)	Change of score from baseline to end (mean)
periportal hepatitis	-0.21 (-0.62 to 0.20)	1.42 to 1.21
confluent necrosis	0.38 (-0.17 to 0.92)	0.00 to 0.38
focal inflammation	-0.17 (-0.59 to 0.26)	2.63 to 2.46
portal inflammation	-0.13 (-0.51 to 0.26)	2.29 to 2.17
total inflammation grading	-0.13 (-1.18 to 0.93)	6.33 to 6.21

Table 16. Overview of frequencies (given as number of patients) of changes of a given baseline Metavir score (given in top row; Baseline 0 to 4) to a given Metavir score at the end of the second course of therapeutic E1s vaccination (given in left row; EOT 0 to 4). For instance, the "5" marked with a "*" (i.e., "5*") means that 5 patients had a baseline Metavir score of 1 and a Metavir score of 0 at the end of the second course treatment (EOT = end of treatment).

	Baseline 0	Baseline 1	Baseline 2	Baseline 3	Baseline 4	Total
ЕОТ 0	0	5*	11_	0	0	6
EOT 1	1	:3	2		0	6
EOT 2	0	5	1	0	0	6
ЕОТ 3	0	0	0	1	1	2
ЕОТ4	0	0	1	2	1	4
Totai	1	13	5	3	2	24

10

15

20

25

30

Table 17. Correlation between serum anti-E1 antibody levels induced by therapeutic E1s vaccination and change in overall Ishak scores. Given are the number of patients corresponding to the possible criteria as outlined in the Table.

Overall change of Ishak score	<-1	-1, 0, or +1	>+1
(change from baseline)	·		
High anti-E1s antibody response	5	2	0
Low anti-E1s antibody response	4	8	5

Example 21: Effects of therapeutic E1-vaccination regimen.

In a first course of this study, 26 patients received 5 doses of 20 µg E1s ("E1s patients") and 9 patients received an identical number of placebo injections ("placebo patients") consisting of alum only, as described in Example 19. In a second course, 25 of said 26 patients that received E1s during the first course and 9 of said 9 patients that received a placebo were all immunized with a further 6 intramuscular doses of 20 µg E1s formulated on 0.13% Alhydrogel in 0.5 mL (as in Example 19), thus giving rise to two groups of patiens: the "E1s/E1s patients" and "placebo/E1s patients". The immunizations of this second series, i.e. course 2, were administered with 3-week intervals (compared to 4-week intervals during the first series, i.e. course 1) and the first injection was given at week 50.

The median values for anti-E1 antibodies after 4 E1s injections were 195 mU/mL for 4-week intervals (as deduced from the E1s patients) and 274 mU/mL for 3-week intervals (as deduced from the placebo/E1s patients), thus indicating that a 3-week interval regimen induces a stronger humoral immune response in a shorter period of time.

In placebo/E1s patients E1s-specific T cell proliferation increased from 0/9 patients at baseline to 9/9 patients after 6 injections with 3-week intervals at week 69.

Examples 16 and 17) are compared with those in the patient group, a somewhat slower increase in anti-E1 antibody levels and T cell response is observed. The booster effect seen in healthy volunteers was almost absent in patients (median titer of 165 mU/mL after the fifth immunization administered to the E1s/E1s patients as a booster 12 weeks after the 4th immunization), thus suggesting a somewhat impaired build up of immunological memory to E1s in patients. Repeated intramuscular injections at 3-week intervals seem to overcome this impairment (median titer of 530 mU/mL after 6 consecutive immunizations with a 3-week

WO 03/051912 PCT/EP02/14480 117

interval in the placebo/E1s patients), thus indicating another advantage of an E1s vaccination regimen with 3-week intervals and/or administering more than 4 doses in the first series of immunizations.

REFERENCES

Alric L, Duffaut M, Selves J, Sandre K, Mularczyck M, Izopet J, Desmorat H, Bureau C, Chaouche N, Dalbergue B, Vinel JP (2001) J Hepatol 35(2):272-278.

Asseline U, Delarue M, Lancelot G, Toulme F, Thuong N (1984) Proc. Natl. Acad. Sci. USA 81:3297-301.

Bailey, J. and Cole, R. (1959) J. Biol. Chem. 234, 1733-1739.

Ballou, L., Hitzeman, R., Lewis, M. & Ballou, C. (1991) PNAS 88, 3209-3212.

Bedossa P, Poynard T. (1996) Hepatology 24(2):289-293.

10 Benesch, R., Benesch, R.E., Gutcho, M. & Lanfer, L. (1956) Science 123, 981.

Cavins, J. & Friedman. (1970) Anal. Biochem. 35, 489.

Cleland, W. (1964) Biochemistry 3, 480

Creighton, E. (1988) BioEssays 8, 57

Darbre, A., John Wiley & Sons Ltd. (1987) Practical Protein Chemistry - A Handbook.

Darbre, A., John Wiley & Sons Ltd. (1987) Practical Proteinchemistry p.69-79.

Doms et al, (1993), Virology 193, 545-562.

Ellman, G. (1959) Arch. Biochem. Biohys. 82, 70.

Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ (2002) Ann Intern Med 136(4):288-292.

20 Falkner, F. & Moss, B. (1988) J. Virol. 62, 1849-1854.

Friedman, M. & Krull. (1969) Biochem. Biophys. Res. Commun. 37, 630.

Gallagher J. (1988) J. Cell Biol. 107, 2059-2073.

Glazer, A., Delange, R., Sigman, D. (1975) North Holland publishing company, Elsevier, Biomedical. Part: Modification of protein (p. 116).

25 Graham, F. & van der Eb, A. (1973) Virology 52, 456-467.

Grakoui et al. (1993) Journal of Virology 67:1385-1395.

Grassetti, D. & Murray, J. (1969) Analyt. Chim. Acta. 46, 139.

Grassetti, D. & Murray, J. (1967) Arch. Biochem Biophys. 119, 41.

Helenius, Mol. Biol. Cell (1994), 5: 253-265.

Hijikata, M., Kato, N., Ootsuyama, Y., Nakagawa, M. & Shimotohno, K. (1991) Proc. Natl. Acad. Sci. U.S.A. 88(13):5547-51.

Hochuli, E., Bannwarth, W., Döbeli, H., Gentz, R., Stüber, D. (1988) Biochemistry 88, 8976.

Hsu, H., Donets, M., Greenberg, H. & Feinstone, S. (1993) Hepatology 17:763-771. Inoue, Y., Suzuki, R., Matsuura, Y., Harada, S., Chiba, J., Watanabe, Y., Saito, I. & Miyamura, T. (1992) J. Gen. Virol. 73:2151-2154.

Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb

- 5 G, MacSween RN, et al. (1995) J Hepatol 22(6):696-699.
 - Janknecht, R., de Martynoff, G. et al., (1991) Proc. Natl. Acad. Sci. USA 88, 8972-8976. Kayman (1991) J. Virology 65, 5323-5332.
 - Kato, N., Oostuyama, Y., Tanaka, T., Nakagawa, M., Muraiso, K., Ohkoshi, S., Hijikata, M., Shimitohno, K. (1992) Virus Res. 22:107-123.
- Kniskern, P., Hagopian, A., Burke, P., Schultz, L., Montgomery, D., Hurni, W., Yu Ip, C., Schulman, C., Maigetter, R., Wampler, D., Kubek, D., Sitrin, R., West, D., Ellis, R., Miller, W. (1994) Vaccine 12:1021-1025.
 - Kohara, M., Tsukiyama-Kohara, K., Maki, N., Asano, K., Yoshizawa, K., Miki, K., Tanaka, S., Hattori, N., Matsuura, Y., Saito, I., Miyamura, T. & Nomoto, A. (1992) J. Gen.
- 15 Virol. **73**:2313-2318.
 - Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. (1981) Hepatology 1(5):431-435.
 - Lauer GM, Walker BD (2001) N Engl J Med 345(1):41-52.
 - Lefkowitch JH (1997) Viral Hepatitis Reviews 3(3):155-166.
- Mackett, M., Smith, G. & Moss, B. (1985) In: 'DNA cloning: a practical approach' (Ed. Glover, D.) IRL Press, Oxford.
 - Mackett, M., & Smith, G. (1986) J. Gen. Virol. 67, 2067-2082.
 - Mackett, M., Smith, G. & Moss, B. (1984) J. Virol. 49, 857-864.
 - Mackett, M., Smith, G. & Moss, B. (1984) Proc. Natl. Acad. Sci. USA 79, 7415-7419.
- 25 Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen J, Broder S (1987) Proc. Natl. Acad. Sci. USA 84:7706-10.
 - Means, G. (1971) Holden Day, Inc.
 - Means, G. & Feeney, R. (1971) Holden Day p.105 & p. 217.
 - Miller P, Yano J, Yano E, Carroll C, Jayaram K, Ts'o P (1979) Biochemistry 18:5134-43.
- Mita, E., Hayashi, N., Ueda, K., Kasahara, A., Fusamoto, H., Takamizawa, A., Matsubara, K., Okayama, H. & Kamada T. (1992) Biochem. Biophys. Res. Comm. 183:925-930.
 Moore, S. (1963) J. Biol. Chem. 238, 235-237.
 - Nielsen P, Egholm M, Berg R, Buchardt O (1991) Science 254:1497-500.

Nielsen P, Egholm M, Berg R, Buchardt O (1993) Nucleic-Acids-Res. 21:197-200.

Okamoto, H., Okada, S., Sugiyama, Y., Yotsumoto, S., Tanaka, T., Yoshizawa, H., Tsuda, F., Miyakawa, Y. & Mayumi, M. (1990) Jpn. J. Exp. Med. 60:167-177.

Panicali & Paoletti (1982) Proc. Natl. Acad. Sci. USA 79, 4927-4931.

5 Piccini, A., Perkus, M. & Paoletti, E. (1987) Meth. Enzymol. 153, 545-563.

Poynard T, Bedossa P, Opolon P. (1997) Lancet 349(9055):825-832.

Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J (2002) Gastroenterology 122(5):1303-1313.

Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O (1999) J Hepatol 30(5):783-787.

Rose (1988) Annu. Rev. Cell Biol. 1988, 4: 257-288;

Ruegg, V. and Rudinger, J. (1977) Methods Enzymol. 47, 111-116.

Schvarcz R, Glaumann H, Reichard O, Weiland O (1999) J Viral Hepat 6(3):237-242.

Shan, S. & Wong (1993) CRC-press p. 30-33.

15 Shiffman ML (1999) Viral Hepatitis Reviews 5(1):27-43.

Spaete, R., Alexander, D., Rugroden, M., Choo, Q., Berger, K., Crawford, K., Kuo, C., Leng, S., Lee, C., Ralston, R., et al. (1992) Virology 188(2):819-30.

Skehel, J., (1984) Proc. Natl. Acad. Sci. USA 81, 1179-1783.

Stunnenberg, H., Lange, H., Philipson, L., Miltenburg, R. & van der Vliet, R. (1988) Nucl.

- 20 Acids Res. 16, 2431-2444.
 - Stuyver, L., Van Arnhem, W., Wyseur, A., DeLeys, R. & Maertens, G. (1993a) Biochem. Biophys. Res. Commun. 192, 635-641.
 - Stuyver, L., Rossau, R., Wyseur, A., Duhamel, M., Vanderborght, B., Van Heuverswyn, H., & Maertens, G. (1993b) J. Gen. Virol. 74, 1093-1102.
- Stuyver, L., Van Arnhem, W., Wyseur, A., Hernandez, F., Delaporte, E., Maertens, G.
 (1994) Proc. Natl. Acad. Sci. USA 91, 10134-10138.
 Takimoto M, Ohkoshi S, Ichida T, Takeda Y, Nomoto M, Asakura H, Naito A, Mori S,

Hata K, Igarashi K, Hara H, Ohta H, Soga K, Watanabe T, Kamimura T (2002) Dig Dis Sci. 47(1):170-176.

30 Weil, L. & Seibler, S. (1961) Arch. Biochem. Biophys. 95, 470.

Yokosuka, O., Ito, Y., Imazeki, F., Ohto, M. & Omata, M. (1992) Biochem. Biophys. Res. Commun. 189:565-571.

WO 96/04385 (PCT/EP95/03031) - Purified Hepatitis C Virus Envelope Proteins for

. WO 03/051912 PCT/EP02/14480 * 121

Diagnostic and Therapeutic Use.

All references cited herein are incorporated in their entirety by reference.

We claim:

5

15

- A therapeutic HCV vaccine composition for reducing liver disease in a chronic HCVinfected mammal.
 - 2. A therapeutic HCV vaccine composition for reducing liver fibrosis progression in a chronic HCV-infected mammal.
- A therapeutic HCV vaccine composition for reducing liver fibrosis in a chronic HCVinfected mammal.
 - 4. A therapeutic HCV vaccine composition for reducing liver disease by at least 2 points according to the overall Ishak score in a chronic HCV-infected mammal.
 - 5. A therapeutic HCV vaccine composition for reducing liver disease by at least 1 point according to the Ishak fibrosis score in a chronic HCV-infected mammal.
- A therapeutic HCV vaccine composition for reducing serum ALT levels in a chronic
 HCV-infected mammal.
 - 7. A therapeutic HCV vaccine composition for reducing steatosis in a chronic HCV-infected mammal.
- 8. A therapeutic HCV vaccine composition for reducing anti-E2 immunoreactivity in the liver of a chronic HCV-infected mammal.
 - 9. The therapeutic HCV vaccine composition according to any of claims 1 to 8 which comprises a HCV antigen and, optionally, a pharmaceutically acceptable adjuvant.
 - 10. The therapeutic HCV vaccine composition according to claim 9 wherein said HCV antigen is an E1 or E2 antigen, or an immunogenic part of an E1 or E2 antigen.

15

30

PCT/EP02/14480 WO 03/051912 123

- 11. The therapeutic HCV vaccine composition according to claim 9 wherein said pharmaceutically acceptable adjuvant is alum.
- 12. A method to predict changes in liver disease in a chronic HCV-infected mammal comprising
 - (i) determining the level of serum anti-E1 antibody level prior to therapeutic vaccination with a HCV vaccine composition comprising an E1 antigen;
 - (ii) determining the level of serum anti-E1 antibody level after therapeutic vaccination with a HCV vaccine composition comprising an E1 antigen;
- 10 (iii) inferring the difference in level of serum anti-E1 antibody level determined in (i) and (ii) and, therefrom, predicting the change in liver disease.
 - 13. A therapeutic HCV vaccine composition comprising a therapeutically effective amount of at least one purified HCV single or specific oligomeric recombinant envelope protein selected from the group consisting of an E1 protein, an E2 protein, a part of said E1 and E2 proteins, an E1/E2 protein complex formed from purified HCV single or specific oligomeric recombinant E1 or E2 proteins or parts thereof; and optionally a pharmaceutically acceptable adjuvant.
- 20 14. A therapeutic HCV vaccine composition comprising a therapeutically effective amount of a combination of at least two purified HCV single or specific oligomeric recombinant envelope proteins selected from the group consisting of E1 proteins derived from different HCV genotypes or subtypes, E2 proteins derived from different HCV genotypes or subtypes, parts of said E1 and E2 proteins, and E1/E2 protein 25 complexes formed from purified HCV single or specific oligomeric recombinant E1 or E2 proteins, or parts thereof, derived from different HCV genotypes or subtypes; and optionally a pharmaceutically acceptable adjuvant.
 - 15. A therapeutic HCV vaccine composition comprising a therapeutically effective amount of at least one of the following E1 and E2 peptides:
 - E1-31 spanning amino acids 181 to 200 of the Core/E1-V1 region (SEQ ID NO:56),
 - E1-33 spanning amino acids 193 to 212 of the E1 region (SEQ ID NO:57),
 - E1-35 spanning amino acids 205 to 224 of the E1 V2 region (SEQ ID NO:58),

E1-35A spanning amino acids 208 to 227 of the E1 V2 region (SEQ ID NO:59), 1bE1 spanning amino acids 192 to 228 of E1 regions V1, C1, and V2 regions (SEO ID NO:53), E1-51 spanning amino acids 301 to 320 of the E1 region (SEQ ID NO:66), 5 E1-53 spanning amino acids 313 to 332 of the E1 C4 region (SEQ ID NO:67), E1-55 spanning amino acids 325 to 344 of the E1 region (SEQ ID NO:68), Env 67 or E2-67 spanning amino acid positions 397 to 418 of the E2 region (SEQ ID NO:72), Env 69 or E2-69 spanning amino acid positions 409 to 428 of the E2 region (SEQ ID 10 NO:73), Env 23 or E2-23 spanning positions 583 to 602 of the E2 region (SEQ ID NO:86), Env 25 or E2-25 spanning positions 595 to 614 of the E2 region (SEQ ID NO:87), Env 27 or E2-27 spanning positions 607 to 626 of the E2 region (SEQ ID NO:88), Env 17B or E2-17B spanning positions 547 to 586 of the E2 region (SEQ ID NO:83), 15 Env 13B or E2-13B spanning positions 523 to 542 of the E2 region (SEQ ID NO:82), IGP 1626 spanning positions 192-211 of the E1 region (SEQ ID NO:112), IGP 1627 spanning positions 204-223 of the E1 region (SEQ ID NO:113), IGP 1628 spanning positions 216-235 of the E1 region (SEQ ID NO:114), IGP 1629 spanning positions 228-247 of the E1 region (SEQ ID NO:115), 20 IGP 1630 spanning positions 240-259 of the E1 region (SEQ ID NO:116), IGP 1631 spanning positions 252-271 of the E1 region (SEQ ID NO:117), IGP 1632 spanning positions 264-283 of the E1 region (SEQ ID NO:118), IGP 1633 spanning positions 276-295 of the E1 region (SEQ ID NO:119), IGP 1634 spanning positions 288-307 of the E1 region (SEQ ID NO:120), 25 IGP 1635 spanning positions 300-319 of the E1 region (SEQ ID NO:121) and IGP 1636 spanning positions 312-331 of the E1 region (SEQ ID NO:122);

16. A therapeutic HCV composition comprising a therapeutically effective amount of at

least one purified HCV single or specific oligomeric recombinant envelope protein

selected from the group consisting of an E1 protein, an E2 protein, a part of said E1 and

E2 protein, and an E1/E2 protein complex formed from purified HCV single or specific
oligomeric recombinant E1 or E2 proteins or parts thereof; and optionally a

and, optionally, a pharmaceutically acceptable adjuvant.

10

15

pharmaceutically acceptable adjuvant.

- 17. A therapeutic HCV composition comprising a therapeutically effective amount of a combination of at least two purified HCV single or specific oligomeric recombinant envelope proteins selected from the group consisting of E1 proteins derived from different HCV genotypes or subtypes, E2 proteins derived from different HCV genotypes or subtypes, parts of said E1 and E2 proteins, and E1/E2 protein complexes formed from purified HCV single or specific oligomeric recombinant E1 or E2 proteins, or parts thereof, derived from different HCV genotypes or subtypes; and optionally a pharmaceutically acceptable adjuvant.
- 18. A therapeutic HCV composition comprising a therapeutically effective amount of at least one of the following E1 and E2 peptides:

E1-31 spanning amino acids 181 to 200 of the Core/E1 V1 region (SEQ ID NO:56),

- E1-33 spanning amino acids 193 to 212 of the E1 region (SEQ ID NO:57),
 - E1-35 spanning amino acids 205 to 224 of the E1 V2 region (SEQ ID NO:58),
 - E1-35A spanning amino acids 208 to 227 of the E1 V2 region (SEQ ID NO:59),
 - 1bE1 spanning amino acids 192 to 228 of E1 regions V1, C1, and V2 regions (SEQ ID NO:53),
- E1-51 spanning amino acids 301 to 320 of the E1 region (SEQ ID NO:66),
 - E1-53 spanning amino acids 313 to 332 of the E1 C4 region (SEQ ID NO:67),
 - E1-55 spanning amino acids 325 to 344 of the E1 region (SEQ ID NO:68),
 - Env 67 or E2-67 spanning amino acid positions 397 to 418 of the E2 region (SEQ ID NO:72),
- Env 69 or E2-69 spanning amino acid positions 409 to 428 of the E2 region (SEQ ID NO:73),
 - Env 23 or E2-23 spanning positions 583 to 602 of the E2 region (SEQ ID NO:86),
 - Env 25 or E2-25 spanning positions 595 to 614 of the E2 region (SEQ ID NO:87),
 - Env 27 or E2-27 spanning positions 607 to 626 of the E2 region (SEQ ID NO:88),
- Env 17B or E2-17B spanning positions 547 to 586 of the E2 region (SEQ ID NO:83),
 - Env 13B or E2-13B spanning positions 523 to 542 of the E2 region (SEQ ID NO:82),
 - IGP 1626 spanning positions 192-211 of the E1 region (SEQ ID NO:112),
 - IGP 1627 spanning positions 204-223 of the E1 region (SEQ ID NO:113),

IGP 1628 spanning positions 216-235 of the E1 region (SEQ ID NO:114), IGP 1629 spanning positions 228-247 of the E1 region (SEQ ID NO:115), IGP 1630 spanning positions 240-259 of the E1 region (SEQ ID NO:116), IGP 1631 spanning positions 252-271 of the E1 region (SEQ ID NO:117), IGP 1632 spanning positions 264-283 of the E1 region (SEQ ID NO:118), IGP 1633 spanning positions 276-295 of the E1 region (SEQ ID NO:119), IGP 1634 spanning positions 288-307 of the E1 region (SEQ ID NO:120), IGP 1635 spanning positions 300-319 of the E1 region (SEQ ID NO:121) and IGP 1636 spanning positions 312-331 of the E1 region (SEQ ID NO:122); and, optionally, a pharmaceutically acceptable adjuvant.

19. The therapeutic HCV composition according to any of claims 13 to 18 for at least one of inducing HCV-specific antibodies, stimulating T-cell activity and stimulating cytokine secretion.

15

10

20. The therapeutic HCV composition according to any of claims 13 to 18 which is therapeutically effective in a HCV carrier infected with a HCV genotype different from the HCV genotype or HCV genotypes from which said E1, E2, or E1/E2 protein complexes are derived.

20

21. A composition comprising at least one of the following E1 and E2 peptides:

IGP 1626 spanning positions 192-211 of the E1 region (SEQ ID NO:112),

IGP 1627 spanning positions 204-223 of the E1 region (SEQ ID NO:113),

IGP 1628 spanning positions 216-235 of the E1 region (SEQ ID NO:114),

IGP 1629 spanning positions 228-247 of the E1 region (SEQ ID NO:115),

IGP 1630 spanning positions 240-259 of the E1 region (SEQ ID NO:116),

IGP 1631 spanning positions 252-271 of the E1 region (SEQ ID NO:117),

IGP 1632 spanning positions 264-283 of the E1 region (SEQ ID NO:118),

IGP 1633 spanning positions 276-295 of the E1 region (SEQ ID NO:119),

IGP 1634 spanning positions 288-307 of the E1 region (SEQ ID NO:120),

IGP 1635 spanning positions 300-319 of the E1 region (SEQ ID NO:121) and

IGP 1636 spanning positions 312-331 of the E1 region (SEQ ID NO:122);

and, optionally, a pharmaceutically acceptable adjuvant.

22. The composition according to any of claims 10 and 13 to 21 wherein the cysteines of said E1 or E2 antigen, of said recombinant HCV envelope proteins or of said E1 and E2 peptides are blocked.

5

23. The composition according to any of claims 10, 13, 14, 16, 17, 19, 20 and 22 wherein said E1 or E2 antigen or said recombinant HCV envelope proteins are added as virallike particles.

- 10 24. The composition according to any of claims 10, 13, 14, 16, 17, 19, 20 and 22 wherein said E1 antigen or said recombinant HCV E1 envelope protein is an E1s protein.
 - 25. The composition according to claim 24 wherein said E1 antigen or said E1s protein is defined by SEQ ID NO:123.

15

26. The composition according to any of claims 1-10, 13, 14, 16, 17, 19, 20 and 22 to 25 wherein said HCV antigen or said recombinant HCV envelope proteins are produced by recombinant mammalian cells, by recombinant yeast cells or by a recombinant virus.

20

- 27. The composition according to any of claims 15 and 18 to 25 wherein said peptides are recombinant peptides or synthetic peptides.
- 28. The composition according to any one of claims 1 to 11 and 13 to 27 for treating a mammal infected with HCV.
- 29. The composition according to any of claims 1 to 11 and 28 wherein said mammal is a human.
- 30 30. The method according to claim 12 wherein said mammal is a human.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11






Figure 12







15 / 69




Figure 15






Figure 16




Figure 17




Figure 18




Figure 19




Figure 20

- 5' GGCATGCAAGCTTAATTAATT 3' (SEQ ID NO 1)
- 3'ACGTCCGTACGTTCGAATTAATTAATCGA 5' (SEQ ID NO 94)

5'CCGGGGAGGCCTGCACGTGATCGAGGGCAGACACCATCACCACCATCACTAATAGTTA ATTAACTGCA 3' (SEQ ID NO 2) 3'CCTCCGGACGTGCACTAGCTCCCGTCTGTGGTAGTGGTAGTGATTATCAATTAAT TG 5' (SEQ ID NO 95)

SEQ ID NO 3 (HCC19A)

SEQ ID NO 5 (HCCl10A)

SEQ ID NO 7 (HCCl11A)

SEQ ID NO 9 (HCCl12A)

SEQ ID NO 11 (HCCl13A)

SEQ ID NO 13 (HCCl17A)

WO 03/051912 PCT/EP02/14480 •

23 / 69

ATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTTTCTGTTCCGCTATGTACGTG
GGGGATCTCTGCGGATCTGTCTCCTCGTCTCCCAGCTGTTCACCATCTCGCCTCGCCGG
CATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGTCACCGT
ATGGCTTGGGATATGATGATGAACTGGTACTAATAG
SEQ ID NO 15 (HCPr51)
ATGCCCGGTTGCTCTTTCTCTATCTT
SEQ ID NO 16 (HCPr52)
ATGTTGGGTAAGGTCATCGATACCCT

SEQ ID NO 17 (HCPr53)
CTATTAGGACCAGTTCATCATCATATCCCA

SEQ ID NO 18 (HCPr54)
CTATTACCAGTTCATCATCATATCCCA

SEQ ID NO 19 (HCPr107)
ATACGACGCCACGTCGATTCCCAGCTGTTCACCATC

SEQ ID NO 20 (HCPr108)
GATGGTGAACAGCTGGGAATCGACGTGGCGTCGTAT

SEQ ID NO 21 (HCCl37)

SEQ ID NO 23 (HCC138)

WO 03/051912 PCT/EP02/14480 •

24 / 69

GACATGATCATGCACACCCCGGGTGCGTGCCCTGCGTTCGGGAGAACAACTCTTCCCGC TGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCGTCCCCACCACGACA ATACGACGCCACGTCGATTCCCAGCTGTTCACCATCTCGCCTCGCCGGCATGAGACGGTG CAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGTCACCGTATGGCTTGGGAT ATGATGATGAACTGGTAATAG

SEQ ID NO 25 (HCC139)

SEQ ID NO 27 (HCC140)

SEQ ID NO 29 (HCC162)

ATGGGTAAGGTCATCGATACCCTTACGTGCGGATTCGCCGATCTCATGGGGTACATCCCG
CTCGTCGGCGCTCCCGTAGGAGGCGTCGCAAGAGCCCTTGCGCATGGCGTGAGGGCCCTT
GAAGACGGGATAAATTTCGCAACAGGGAATTTGCCCGGTTGCTCCTTTTCTATTTTCCTT
CTCGCTCTGTTCTCTTGCTTAATTCATCCAGCAGCTAGTCTAGAGTGGCGGAATACGTCT
GGCCTCTATGTCCTTACCAACGACTGTTCCAATAGCAGTATTGTGTACGAGGCCGATGAC
GTTATTCTGCACACACCCCGGCTGCATACCTTGTGTCCAGGACGGCAATACATCCACGTGC
TGGACCCCAGTGACACCTACAGTGGCAGTCAAGTACGTCGGAGCAACCACCGCTTCGATA
CGCAGTCATGTGGACCTATTAGTGGGCGCGCCACGATGTGCTCTGCGCTCTACGTGGGT
GACATGTGTGGGGCTGTCTTCCTCGTGGGACAAGCCTTCACGTTCAGACCTCGCCCAT

25 / 69

CAAACGGTCCAGACCTGTAACTGCTCGCTGTACCCAGGCCATCTTTCAGGACATCGAATG
GCTTGGGATATGATGATGAACTGGTAATAG

SEQ ID NO 31 (HCCl63)

ATGGGTAAGGTCATCGATACCCTAACGTGCGGATTCGCCGATCTCATGGGGTATATCCCG
CTCGTAGGCGGCCCCATTGGGGGCGTCGCAAGGGCTCTCGCACACGGTGTGAGGGTCCTT
GAGGACGGGGTAAACTATGCAACAGGGAATTTACCCGGTTGCTCTTTCTCTATCTTTATT
CTTGCTCTTCTCTCGTGTCTGACCGTTCCGGCCTCTGCAGTTCCCTACCGAAATGCCTCT
GGGATTTATCATGTTACCAATGATTGCCCAAACTCTTCCATAGTCTATGAGGCAGATAAC
CTGATCCTACACGCACCTGGTTGCGTGCCTTGTGTCATGACAGGTAATGTGAGTAGATGC
TGGGTCCAAATTACCCCTACACTGTCAGCCCCGAGCCTCGGAGCAGTCACGGCTCCTCTT
CGGAGAGCCGTTGACTACCTAGCGGGAGGGGCTGCCCTCTGCTCCGCGTTATACGTAGGA
GACGCGTGTGGGGCACTATTCTTGGTAGGCCAAATGTTCACCTATAGGCCTCGCCAGCAC
GCTACGGTGCAGAACTGCAACTGTTCCATTTACAGTGGCCATGTTACCGGCCACCGGATG
GCATGGGATATGATGATGAACTGGTAATAG

SEQ ID NO 33 (HCPr109) TGGGATATGATGATGAACTGGTC

SEQ ID NO 34 (HCPr72)
CTATTATGGTGGTAAKGCCARCARGAGCAGGAG

SEQ ID NO 35 (HCCL22A)

TGGGATATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTATCGCAGCTGCTCCGG ATCCCACAAGCTGTCGTGGACATGGTGGCGGGGCCCATTGGGGGAGTCCTGGCGGGCCTC GCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGATGCTACTCTTTGCC GGCGTCGACGGCATACCCGCGTGTCAGGAGGGCCAGCCTCCGATACCAGGGGCCTT GTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGT GCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGT CGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGC TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCG TCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACC GATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTC AACAACACGCGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGG TTCACCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACAACACCTTG ACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTCT GGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTACCCC TGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGGCGTGGAGCACAGG TTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACAGGGATAGA TCAGAGCTTAGCCCGCTGCTGTCTACAACAGAGTGGCAGATACTGCCCTGTTCCTTC

26 / 69

ACCACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCAGAACATCGTGGACGTG CAATACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTCATCAAATGGGAGTATGTC. CTGTTGCTCTTCCTCCTGGCAGACGCGCGCATCTGCGCCTGCTTATGGATGATGCTG CTGATAGCTCAAGCTGAGGCCGCCTTAGAGAACCTGGTGGTCCTCAATGCGGCGGCCGTG GCCGGGGCGCATGGCACTCTTTCCTTCCTTGTGTTCTTCTGTGCTGCCTGGTACATCAAG GGCAGGCTGGTCCCTGGTGCGGCATACGCCTTCTATGGCGTGTGCCGCTGCTCCTGCTT CTGCTGGCCTTACCACCACGAGCTTATGCCTAGTAA

SEQ ID NO 37 (HCC141)

GATCCCACAAGCTGTCGTGGACATGGTGGCGGGGCCCATTGGGGGAGTCCTGGCGGGCCT CGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGC CGGCGTCGACGGGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCT TGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAG CGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTG TCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAG CTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGC GTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGAC CGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCT CAACACACGCGGCCGCCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGG GTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACAACACCTT GACCTGCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTC TGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTACCC CTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCGTGGAGCACAG GTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACAGGGATAG ATCAGAGCTTAGCCCGCTGCTGTCTACAACAGAGTGGCAGAGTGGCAGAGCTTAATT **AATTAG**

SEQ ID NO 39 (HCC142)

27 / 69

GACCTGCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTC
TGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTACCC
CTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGGCGTGGAGCACAG
GTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACACGGATAG
ATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGGTGATCGAGGGCAGACACCATCACC
ACCATCACTAATAG

SEQ ID NO 41 (HCCl43)

ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGG CATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTT AGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAAC AGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTAC AAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGAC AAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGG CCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGTGC GGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTTTGGT GTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTCAACAACACGCGG CCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCACCAAGACG TGTGGGGGCCCCCGTGCAACATCGGGGGGGCCGGCAACACACCTTGACCTGCCCCACT GACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTG ACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAAC TTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCGTGGAGCACAGGTTCGAAGCCGCA TGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGC

SEQ ID NO 43 (HCC144)

28 / 69

CCGCTGCTGCTGTCTACAACAGGTGATCGAGGGCAGACACCATCACCACCATCACTAATA

SEQ ID NO 45 (HCCL64)

ATGGTGGCGGGGCCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGG AACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGC GTGTCAGGAGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGCCCCGGG TCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACTGCC CTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTACAAACACAAA TTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCGCT CAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGC TGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTG TATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTTTGGTGTCCCCACG TATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTCAACAACACGCGGCCGCCGCGA GGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCACCAAGACGTGTGGGGGC CGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGG TGTATGGTTCATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATC TTCAAGGTTAGGATGTACGTGGGGGGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGG ACTCGAGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTG CTGTCTACAACAGAGTGGCAGATACTGCCCTGTTCCTTCACCACCCTGCCGGCCCTATCC ACCGGCCTGATCCACCTCCATCAGAACATCGTGGACGTGCAATACCTGTACGGTGTAGGG GCAGACGCGCATCTGCGCCTGCTTATGGATGATGCTGCTGATAGCTCAAGCTGAGGCC GCCTTAGAGAACCTGGTGGTCCTCAATGCGGCGGCCGTGGCCGGGGCGCATGGCACTCTT TCCTTCCTTGTGTTCTTCTGTGCTGCCTGGTACATCAAGGGCAGGCTGGTCCCTGGTGCG GCATACGCCTTCTATGGCGTGTGGCCGCTGCTCCTGCTTCTGCTGGCCTTACCACCACGA **GCTTATGCCTAGTAA**

SEQ ID NO 47 (HCCl65)

29 / 69

GGCCTCGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTC TTTGCCGGCGTCGACGGCATACCCGCGTGTCAGGAGGGGCAGC AGCCTCCGATACCAG GGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAA CTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGC CAGCTGTCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCC TAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGT ACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGG GACGACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCT GATTCTCAACACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGG CACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACAA CACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATG CGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCA CTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGGCGTGGA GCACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACAG GGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGGCAGATACTGCCCTG TTCCTTCACCACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCAGAACATCGT GGACGTGCAATACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTCATCAAATGGGA GTATGTCCTGTTGCTCTTCTCCTGGCAGACGCGCGCATCTGCGCCTGCTTATGGAT GATGCTGCTGATAGCTCAAGCTGAGGCCGCCTTAGAGAACCTGGTGGTCCTCAATGCGGC GGCCGTGGCCGGGGCGCATGGCACTCTTTCCTTCCTTGTGTTCTTCTGTGCTGCCTGGTA CATCAAGGCCAGGCTGGTCCCTGGTGCGGCATACGCCTTCTATGGCGTGTGGCCGCTGCT CCTGCTTCTGCTGGCCTTACCACCACGAGCTTATGCCTAGTAAGCTT

SEQ ID NO 49 (HCC166)

ATGAGCACGAATCCTAAACCTCAAAGAAAAACCAAACGTAACACCAACCGCCGCCCACAG GACGTCAAGTTCCCGGGCGGTGGTCAGATCGTTGGTGGAGTTTACCTGTTGCCGCGCAGG GGCCCAGGTTGGGTGTGCGCGACTAGGAAGACTTCCGAGCGGTCGCAACCTCGTGGG AGGCGACAACCTATCCCCAAGGCTCGCCGACCCGAGGGTAGGGCCTGGGCTCAGCCCGGG TACCCTTGGCCCCTCTATGGCAATGAGGGCATGGGGTGGGCAGGATGGCTCCTGTCACCC CGCGGCTCTCGGCCTAGTTGGGGCCCTACAGACCCCCGGCGTAGGTCGCGTAATTTGGGT AAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACATTCCGCTCGTC GGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCGGGTTCTGGAGGAC GGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCTATCTTCCTCTTGGCT TTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCGCAACGTGTCCGGGATG TACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTATGAGGCAGCGGACATGATC ATGCACACCCCGGGTGCGTGCCCTGCGTTCGGGAGAACAACTCTTCCCGCTGCTGGGTA GCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCGTCCCCACCACGACAATACGACGC CACGTCGATTTGCTCGTTGGGGCGGCTGCTTTCTGTTCCGCTATGTACGTGGGGGACCTC TGCGGATCTGTCTTCCTCGTCTCCCAGCTGTTCACCATCTCGCCTCGCCGGCATGAGACG GTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGTCACCGTATGGCTTGG

GATATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTATCGCAGCTGCTCCGGATC CCACAAGCTGTCGTGGACATGGTGGCGGGGCCCATTGGGGAGTCCTGGCGGGCCTCGCC TACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGATGCTACTCTTTGCCGGC GTCGACGGCATACCCGCGTGTCAGGAGGGCCAGCCAGCCTCCGATACCAGGGGCCTTGTG TCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGG CTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGC TCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCG GACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCT CAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGAT CGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTCAAC AACACGCGGCCGCCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTC ACCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACAACACCTTGACC TGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTCTGGG CCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTACCCCTGC GAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCA GAGCTTAGCCCGCTGCTGTCTACAACAGAGTGGCAGATACTGCCCTGTTCCTTCACC ACCCTGCCGGCCTATCCACCGGCCTGATCCACCTCCATCAGAACATCGTGGACGTGCAA TACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTCATCAAATGGGAGTATGTCCTG TTGCTCTTCCTCCTGGCAGACGCGCGCATCTGCGCCTGCTTATGGATGATGCTGCTG ATAGCTCAAGCTGAGGCCGCCTTAGAGAACCTGGTGGTCCTCAATGCGGCGGCCGTGGCC GGGGCGCATGGCACTCTTTCCTTCCTTGTGTTCTTCTGTGCTGCCTGGTACATCAAGGGC AGGCTGGTCCCTGGTGCGGCATACGCCTTCTATGGCGTGTGGCCGCTGCTCCTGCTTCTG CTGGCCTTACCACCACGAGCTTATGCCTAGTAA

31 / 69

OD measured at 450nm construct

Fraction	Volume	dilution	39	40	62	63
			type 1b	type 1b	type 3a	type 5a
Start	23ml	1/20	2.517	1.954	1.426	1.142
Flow through	23ml	1/20	0.087	0.085	0.176	0.120
1	0.4ml	1/200	0.102	0.051	0.048	0.050
2			0.396	0.550	0.090	0.067
3			2.627	2.603	2.481	2.372
4			3	2.967	3	2.694
5			3	2.810	2.640	2.154
6			2.694	2.499	1.359	1.561
7			2.408	2.481	0.347	1.390
8			2.176	1.970	1.624	0.865
9 .			1.461	1.422	0.887	0.604
10			1.286	0.926	0.543	0.519
11			0.981	0.781	0.294	0.294
12			0.812	0.650	0.249	0.199
13			0.373	0.432	0.239	0.209
14			0.653	0.371	0.145	0.184
15			0.441	0.348	0.151	0.151
16			0.321	0.374	0.098	0.106
17			0.525	0.186	0.099	0.108
18			0.351	0.171	0.083	0.090
19			0.192	0.164	0.084	0.087
13			U. 132	0.104	0.004	0.007




Figure 23

33 / 69

WO 03/051912

OD measured at 450nm construct

Fraction	Volume	dilution	39 type 1b	40 type 1b	62 type 3a	63 type 5a
20	250µl	1/200	0.072	0.130	0.096	0.051
21		:	0.109	0.293	0.084	0.052
22			0.279	0.249	0.172	0.052
23			0.093	0.151	0.297	0.054
24			0.080	0.266	0.438	0.056
25			0.251	0.100	0.457	0.048
26			3	1.649	0.722	0.066
27			3	3	2.528	0.889
28			3	3	3	2.345
29			3	3	2.849	2.580
30			2.227	1.921	1.424	1.333
31			0.263	0.415	0.356	0.162
32			0.071	0.172	0.154	0.064
33			0.103	0.054	0.096	0.057
34	,		0.045	0.045	0.044	0.051
35			0.043	0.047	0.045	0.046
36			0.045	0.045	0.049	0.040
37			0.045	0.047	0.046	0.048
38			0.046	0.048	0.047	0.057
39			0.045	0.048	0.050	0.057
40			0.046	0.049	0.048	0.049




Figure 25




Figure 26




Figure 27







Figure 28



- Lane 1: Crude Lysate
- Lane 2: Flow through Lentil Chromatography
- Lane 3: Wash with EMPIGEN Lentil Chromatography
- Lane 4: Eluate Lentil Chromatography
- Lane 5: Flow through during concentration lentil eluate
- Lane 6: Pool of E1 after Size Exclusion Chromatography






Figure 30









Figure 32

40 / 69


Figure 33: Silver stain of purified E2



1. 30mM imidazole wash Ni-IMAC

2. 0.5µg E2

Figure 33



Ņo.	Ret (ml)	Peak start (ml)	Peak end (ml)	Dur (ml)	Area (ml*mAU)	Height (mAU)
1	-0.45	-0.46	-0.43	0.04	0.0976	4.579
2	1.55	0.75	3.26	2.51	796.4167	889.377
3	3.27	3.26	3.31	0.05	0.0067	0.224
4	3.33	3.32	3.33	0.02	0.0002	0.018

Total number of detected peaks = 4
Total Area above baseline = 0.796522 ml*AU
Total area in evaluated peaks = 0.796521 ml*AU
Ratio peak area / total area = 0.999999
Total peak duration = 2.613583 ml

Fig. 35A-6

42 / 69








Fig. 35A-5








44 / 69








































Relative Map Positions of anti-E2 monoclonal antibodies




Figure 38




Figure 39




Figure 40




Figure 42A




Figure 42B







Figure 43






Figure 44A




Figure 44B



Figure 45




Figure 46


weeks


0 3 6 9 12 15


59 / 69

	age (years)	HCV infection (years)	genotype
Marcel	17	9	1a
Peggy	21	16,5	1b
Femma	15	9	1a
Yoran	12	none	
Marti	12	none	

chronic carriers (strong T-cell adjuvant) $\downarrow \downarrow 50 \mu g E1 dose$ 0 3 6 9 12 15 26 29 32 35 38 41 weeks naive (alum) $\downarrow \downarrow \downarrow \downarrow \downarrow \downarrow \downarrow \downarrow \downarrow \qquad 50 \mu g E1 dose$








1: Femma, 2: Marcel, 3: Peggy

Figure 49








Figure 50




Figure 51





Figure 52






Figure 53




FIGURE 54






FIGURE 55







Sequence Listing

<110>	Innogenetics N.V.	
<120>	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use.	
<140> <160>	PCT/EP02/00219 123	
<170>	PatentIn 3.1	
<210>	1	
<211> <212> <213>		
<400>	1	
ggcato	gcaag cttaattaat t	21
<210>	2	
<211> <212> <213>		
<400>	2	
ccggg	gagge etgeaegtga tegagggeag acaceateae caceateaet aatagttaat	60
taacto	gca .	68
<210>	3	
<211> <212> <213>		
<220> <221> <222>	CDS 1639	
<220> <221>	<pre>mat_peptide 1636</pre>	
<400>	3	
	cc ggt tgc tct ttc tct atc ttc ctc ttg gct tta ctg tcc tgt co Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys 5 10 15	48
	oc att cca gct tcc gct tat gag gtg cgc aac gtg tcc ggg atg or Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Met 20 25 30	96

											gag Glu		144
											cgg Arg		192
											gca Ala		240
											gat Asp 95		288
	-			_	_	_	-	-			gat Asp		336
											cct Pro		384
											ggc Gly		432
											tcg Ser		480
											gct Ala 175		528
											ctc Leu		576
											atg Met		624
		gct Ala		taat	tag								642
<210)> 4									٠			
<21	1> 2: 2> PI 3> He		itis	C v:	irus								
<400)> 4						_					•	

Met Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys 1 5 10 15

Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala 40 Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu 55 Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala 70 75 Arg Asn Ala Ser Val Pro Thr Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Leu Cys Ser Ala Met Tyr Val Gly Asp Leu 105 Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile Ser Pro Arg 120 Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His 135 Ile Thr Gly His Arg Met Ala Trp Asp Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln Leu Leu Arg Ile Pro Gln Ala Val 170 Val Asp Met Val Ala Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Leu 210 <210> 5 <211> 795 <212> DNA <213> Hepatitis C virus <220> <221> CDS <222> 1..792 <220> <221> mat_peptide <222> 1..789 <400> 5 48 atg ttg ggt aag gtc atc gat acc ctt aca tgc ggc ttc gcc gac ctc Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu 96 gtg ggg tac att ccg ctc gtc ggc gcc ccc cta ggg ggc gct gcc agg Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg

			20				25				30		
	ctg Leu												144
	ggg Gly 50												192
_	tcc Ser	_	_	-		-		_		•	 -		 240
	ggg Gly												288
	gag Glu												336
	cgg Arg												384
	gca Ala 130	-		_	_	-			_		_	-	432
	gat Asp												480
	gac Asp												528
	cct Pro												576
	ggc Gly												624
	tcg Ser 210												672
	gct Ala												720
	ctc Leu												768
Val	atg Met					taat	ag	,					795
<210)> 6												

<211> 263

<212> PRT

<213> Hepatitis C virus

<400> 6

Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu

1 5 . 10 15

Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg 20 25 30

Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala 35 40 45

Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu 50 55 60

Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val 65 70 75 80

Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val 85 90 95

Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys 100 105 110

Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr 115 120 125

Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His 130 135 140

Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val 145 150 155 160

Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile 165 170 175

Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr 180 185 190

Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Asn 195 200 205

Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln Leu Leu Arg Ile Pro 210 215 220

Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly Val Leu Ala 225 230 235 240

Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val Leu Ile 245 250 255

Val Met Leu Leu Phe Ala Pro 260

<211> 633 <212> DNA <213> Hepatiti	s C virus			
<220> <221> CDS <222> 1630				
<220> <221> mat_pept <222> 1627 <400> 7	ide			
atg ttg ggt aa Met Leu Gly Ly l				48
atg ggg tac at Met Gly Tyr Il 2	e Pro Leu	a Pro Leu		. 96
gcc ctg gcg ca Ala Leu Ala Hi 35				144
aca ggg aat tt Thr Gly Asn Le 50				192
ctg tcc tgt ct Leu Ser Cys Le 65				240
tcc ggg atg ta Ser Gly Met Ty				288
tat gag gca gc Tyr Glu Ala Al 10	a Asp Met	Thr Pro		336
gtt cgg gag aa Val Arg Glu As 115				384
ctc gca gct ag Leu Ala Ala Ar 130	g Asn Ala			432
gtc gat ttg ct Val Asp Leu Le 145				480
ggg gat ctc tg Gly Asp Leu Cy				528
tcg cct cgc cg Ser Pro Arg Ar 18	g His Glu	Asp Cys		576

ccc ggc cac ata aca ggt cac cgt atg gct tgg gat atg atg aac 624 Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Asn 200 633 tgg taatag Trp 210 <210> 8 <211> 209 <212> PRT <213> Hepatitis C virus <400> 8 Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg 25 Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys 105 Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile 170 Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr 185 Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Asn 200

Trp

```
<210> 9
<211> 483
<212> DNA
<213> Hepatitis C virus
<220>
<221> CDS
<222> 1..480
<220>
<221> mat_peptide
<222> 1..477
<400> 9
atg occ ggt tgc tot ttc tot atc ttc ctc ttg gcc ctg ctg tcc tgt
                                                                        48
Met Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys
                                     10
ctg acc ata cca gct tcc gct tat gaa gtg cgc aac gtg tcc ggg gtg
                                                                        96
Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Val
tac cat gtc acg aac gac tgc tcc aac tca agc ata gtg tat gag gca
                                                                       144
Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala
gcg gac atg atc atg cac acc ccc ggg tgc gtg ccc tgc gtt cgg gag
                                                                       192
Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu
ggc aac too too ogt tgc tgg gtg gcg oto act ooc acg oto gcg gco
                                                                       240
Gly Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala
                                                                       288
agg aac gcc agc gtc ccc aca acg aca ata cga cgc cac gtc gat ttg
Arg Asn Ala Ser Val Pro Thr Thr Ile Arg Arg His Val Asp Leu
                                     90
ctc gtt ggg gct gct ttc tgt tcc gct atg tac gtg ggg gat ctc
                                                                       336
Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val Gly Asp Leu
            100
                                105
tgc gga tct gtt ttc ctt gtt tcc cag ctg ttc acc ttc tca cct cgc
                                                                       384
Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Phe Ser Pro Arg
        115
                            120
cgg cat caa aca gta cag gac tgc aac tgc tca atc tat ccc ggc cat
                                                                       432
Arg His Gln Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His
    130
                        135
gta toa ggt cac cgc atg gct tgg gat atg atg atg aac tgg too taatag
                                                                       483
Val Ser Gly His Arg Met Ala Trp Asp Met Met Asn Trp Ser
145
                    150
                                        155
```

<210> 10

<211> 159

<212> PRT

<213> Hepatitis C virus

<400> 10

Met Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Val 20 25 Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala 40 Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu 55 Gly Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala 70 Arg Asn Ala Ser Val Pro Thr Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val Gly Asp Leu 105 Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Phe Ser Pro Arg 120 Arg His Gln Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His 135 Val Ser Gly His Arg Met Ala Trp Asp Met Met Asn Trp Ser <210> 11 <211> 480 <212> DNA <213> Hepatitis C virus <220> <221> CDS <222> 1..477 <220> <221> mat_peptide <222> 1..474 <400> 11 atg tcc ggt tgc tct ttc tct atc ttc ctc ttg gcc ctg ctg tcc tgt 48 Met Ser Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys

10 ctg acc ata cca get tcc get tat gaa gtg cgc aac gtg tcc ggg gtg 96 Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Val 144 tac cat gtc acg aac gac tgc tcc aac tca agc ata gtg tat gag gca Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala 40 gcg gac atg atc atg cac acc ccc ggg tgc gtg ccc tgc gtt cgg gag 192 Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu

50				55					60						
ggc aac tcc Gly Asn Ser 65															240
agg aac gcc Arg Asn Ala	-	-			-			-	-		-	-	-		288
ctc gtt ggg Leu Val Gly															336
tgc gga tct Cys Gly Ser 115						Gln									384
cgg cat caa Arg His Gln 130															432
gta tca ggt Val Ser Gly 145 <210> 12		Arg I										taat	ag		480
<211> 158 <212> PRT	itic (C mi	rue											٠	
<213> Hepat	ICIS '	C V1.	Lus												
<400> 12	ICIS	C VI.	143												
-				Ser	Ile	Phe	Leu 10	Leu	Ala	Leu	Leu	Ser 15	Cys		
<400> 12 Met Ser Gly	Cys	Ser 1	Phe		,		10					15			
<400> 12 Met Ser Gly	Cys :	Ser 1 5 Ala 3	Phe Ser	Ala	Tyr	Glu 25	10 Val	Arg	Asn	Val	Ser 30	15 Gly	Val		
<400> 12 Met Ser Gly 1 Leu Thr Ile Tyr His Val	Cys :	Ser 1 5 Ala 3	Phe Ser Asp	Ala Cys	Tyr Ser 40	Glu 25 Asn	10 Val Ser	Arg Ser	Asn Ile	Val Val 45	Ser 30 Tyr	15 Gly Glu	Val Ala		
<400> 12 Met Ser Gly 1 Leu Thr Ile Tyr His Val 35 Ala Asp Met	Pro 20 Thr 2	Ser 1 5 Ala 3 Asn 4	Phe Ser Asp His	Ala Cys Thr 55	Tyr Ser 40 Pro	Glu 25 Asn Gly	10 Val Ser Cys	Arg Ser Val	Asn Ile Pro 60	Val Val 45 Cys	Ser 30 Tyr Val	15 Gly Glu Arg	Val Ala Glu		
<400> 12 Met Ser Gly 1 Leu Thr Ile Tyr His Val 35 Ala Asp Met 50 Gly Asn Ser	Pro 20 Thr 2	Ser 1 5 Ala 3 Asn 4 Met 1	Phe Ser Asp His Cys	Ala Cys Thr 55	Tyr Ser 40 Pro	Glu 25 Asn Gly	10 Val Ser Cys Leu	Arg Ser Val Thr 75	Asn Ile Pro 60 Pro	Val Val 45 Cys	Ser 30 Tyr Val	Gly Glu Arg	Val Ala Glu Ala 80		
<400> 12 Met Ser Gly 1 Leu Thr Ile Tyr His Val 35 Ala Asp Met 50 Gly Asn Ser 65	Pro 20 Thr 2 Ser 2	Ser 1 5 Ala 3 Asn 2 Met 1 Arg (Phe Ser Asp His Cys 70	Ala Cys Thr 55 Trp	Tyr Ser 40 Pro Val	Glu 25 Asn Gly Ala	10 Val Ser Cys Leu Ile 90	Arg Ser Val Thr 75 Arg	Asn Ile Pro 60 Pro	Val 45 Cys Thr	Ser 30 Tyr Val Leu	Gly Glu Arg Ala Asp 95	Val Ala Glu Ala 80 Leu		
<400> 12 Met Ser Gly 1 Leu Thr Ile Tyr His Val 35 Ala Asp Met 50 Gly Asn Ser 65 Arg Asn Ala	Pro 20 Thr 2 Ser 2 Ala 2	Ser 1 5 Ala 3 Asn 2 Met 1 Arg (Phe Ser Asp His Cys 70 Pro	Ala Cys Thr 55 Trp Thr	Tyr Ser 40 Pro Val Thr	Glu 25 Asn Gly Ala Thr	10 Val Ser Cys Leu Ile 90 Ala	Arg Ser Val Thr 75 Arg	Asn Ile Pro 60 Pro Arg	Val 45 Cys Thr His	Ser 30 Tyr Val Leu Val	Gly Glu Arg Ala Asp 95 Asp	Val Ala Glu Ala 80 Leu Leu		

Val Ser Gly His Arg Met Ala Trp Asp Met Met Asn Trp 150 <210> 13 <211> 636 <212> DNA <213> Hepatitis C virus <220> <221> CDS <222> 1..633 <220> <221> mat_peptide <222> 1..630 <400> 13 atg ctg ggt aag gcc atc gat acc ctt acg tgc ggc ttc gcc gac ctc 48 Met Leu Gly Lys Ala Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu 10 gtg ggg tac att ccg ctc gtc ggc gcc ccc cta ggg ggc gct gcc agg 96 Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg gcc ctg gcg cat ggc gtc cgg gtt ctg gaa gac ggc gtg aac tat gca 144 Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala aca ggg aat ttg cct ggt tgc tct ttc tct atc ttc ctc ttg gct tta 192 Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu 50 55 ctg tcc tgt cta acc att cca gct tcc gct tac gag gtg cgc aac gtg 240 Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val 70 tcc ggg atg tac cat gtc acg aac gac tgc tcc aac tca agc att gtg 288 Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val 85 tat gag gca gcg gac atg atc atg cac acc ccc ggg tgc gtg ccc tgc 336 Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys 100 105 gtt cgg gag aac aac tet tee ege tge tgg gta geg ete ace eec acg 384 Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr 115 120 ctc gcg gct agg aac gcc agc atc ccc act aca aca ata cga cgc cac 432 Leu Ala Ala Arg Asn Ala Ser Ile Pro Thr Thr Ile Arg Arg His 130 135 140 gtc gat ttg ctc gtt ggg gcg gct gct ttc tgt tcc gct atg tac gtg 480 Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val 145 150 ggg gat ctc tgc gga tct gtc ttc ctc gtc tcc cag ctg ttc acc atc 528 Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile 165

tcg cct cgc cgg Ser Pro Arg Arg 180	His Glu Thr		Cys Asn Cys S		6
ccc ggc cac ata Pro Gly His Ile 195					! 4
tgg tac taatag Trp Tyr 210		·		64	0
<210> 14					
<211> 210 <212> PRT <213> Hepatitis	C virus				
<400> 14					
Met Leu Gly Lys 1	Ala Ile Asp 5	Thr Leu Thr		la Asp Leu 15	
Val Gly Tyr Ile 20		Gly Ala Pro 25		la Ala Arg 30	
Ala Leu Ala His 35	Gly Val Arg	Val Leu Glu 40	Asp Gly Val A	sn Tyr Ala	
Thr Gly Asn Leu 50	Pro Gly Cys 55	Ser Phe Ser	Ile Phe Leu L 60	eu Ala Leu	
Leu Ser Cys Leu 65	Thr Ile Pro 70	Ala Ser Ala	Tyr Glu Val A 75	rg Asn Val 80	
Ser Gly Met Tyr	His Val Thr 85	Asn Asp Cys 90		er Ile Val 95	
Tyr Glu Ala Ala 100		Met His Thr 105		al Pro Cys 10	
Val Arg Glu Asn 115	Asn Ser Ser	Arg Cys Trp 120	Val Ala Leu T 125	hr Pro Thr	
Leu Ala Ala Arg 130	Asn Ala Ser 135		Thr Thr Ile A	rg Arg His	
Val Asp Leu Leu 145	Val Gly Ala 150	Ala Ala Phe	Cys Ser Ala M 155	et Tyr Val 160	
Gly Asp Leu Cys	Gly Ser Val 165	Phe Leu Val		he Thr Ile 175	
Ser Pro Arg Arg 180		Val Gln Asp 185	-	er Ile Tyr 90	
Pro Gly His Ile 195	Thr Gly His	Arg Met Ala 200	Trp Asp Met M 205	et Met Asn	٠
Trp Tyr					

2: <210>			
<211> <212> <213> <400>	DNA Hepatitis C virus		
atgcc	eggtt getetttete tatett		26
<210>	16		
<211> <212> <213>	•		
<400>	16		•
atgtt	gggta aggtcatcga taccct	· · .	26
<210>	17		
<211> <212> <213>			
	misc_feature /note="antisense"		
<400>	17		
ctatt	aggac cagttcatca tcatatccca		30
<210>	18		
<211> <212>	DNA		
<213> <400>	Hepatitis C virus		
	accag ttcatcatca tatccca		27
<210>	19		
<211> <212> <213> <400>	DNA Hepatitis C virus		
atacg	acgcc acgtcgattc ccagctgttc acc	catc	36
<210>	20		

	<212 <213 <220 <221)> .> mi	VA epati isc_i	featı	C vi ire isens												
	<400)> 20		•													
	gato	gtga	aac a	gct	gggaa	at co	gacgt	.ggcq	g tc	gtat					•		36
•	<210)> 21	·. L			•				•				•			
	<212	l> 72 !> Di !> He	NΑ	itis	C vi	irus											
		> CI	os 720)	-						*.		÷	:			
	<222	i> ma	at_pe 717 l		de											·	•
					gtc Val 5												48
					ccg Pro												96
					ggc Gly												144
					ccc Pro												192
					acc Thr											- ,	240
			_		cat His 85	_	_		-	-			_				288
					gac Asp												336
					aac Asn								Thr				384
					aac Asn												432

									cct Pro							480
									ggc Gly 170							528
									tcg Ser							576
									gct Ala							624
									ctc Leu							672
Gly 225		Trp							atg Met						taatag 240	723
<212	L> 23 2> PI 3> He	RТ	itis	C vi	irus											
<400)> 22	2														
Met 1	Leu	Gly	Lys	Val 5	Ile	Asp	Thr	Leu	Thr 10	Cys	Gly	Phe	Ala	Asp 15	Leu	
Val	Gly	Tyr	Ile 20	Pro	Leu	Val	Gly	Ala 25	Pro	Leu	Gly	Gly	Ala 30	Ala	Arg	
Ala	Leu	Ala 35	His	Gly	Val	Arg	Val 40	Leu	Glu	Asp	Gly	Val 45	Asn	Tyr	Ala	:
Thr '	Gly 50	Asn	Leu	Pro	Gly	Cys 55	Ser	Phe	Ser	Ile	Phe 60	Leu	Leu	Ala	Leu	
Leu 65	Ser	Cys	Leu	Thr	Val 70	Pro	Ala	Ser	Ala	Tyr 75	Glu	Val	Arg	Asn	Val 80	
Ser	Gly	Met	Tyr	His 85	Val	Thr	Asn	Asp	Cys 90	Ser	Asn	Ser	Ser	Ile 95	Val	
Tyr	Glu	Ala	Ala 100	Asp	Met	Ile	Met	His 105	Thr	Pro	Gly	Cys	Val 110	Pro	Cys	
Val	Arg	Glu 115	Asn	Asn	Ser	Ser	Arg 120	Cys	Trp	Val	Ala	Leu 125	Thr	Pro	Thr	
Leu	Ala 130	Ala	Arg	Asn	Ala	Ser 135	Val	Pro	Thr	Thr	Thr 140	Ile	Arg	Arg	His	

145	150	155	160
Gln Asp Cys Asn Cy	s Ser Ile Tyr Pro Gl	•	His Arg 175
Met Ala Trp Asp Me 180	t Met Met Asn Trp Se 185	r Pro Thr Thr Ala I 190	Leu Val
Val Ser Gln Leu Le 195	u Arg Ile Pro Gln Al 200	a Val Val Asp Met \ 205	Val Ala
Gly Ala His Trp Gl 210	y Val Leu Ala Gly Le 215	ı Ala Tyr Tyr Ser N 220	Met Val
Gly Asn Trp Ala Ly 225 <210> 23	s Val Leu Ile Val Me 230	Leu Leu Phe Ala I 235	?ro
12107 25		•	•
<211> 561 <212> DNA <213> Hepatitis C	virus		
<220> <221> CDS <222> 1558			•
<220> <221> mat_peptide <222> 1555 <400> 23			
	c atc gat acc ctt aca 1 Ile Asp Thr Leu Th 5	Cys Gly Phe Ala A	
	g ctc gtc ggc gcc ccc o Leu Val Gly Ala Pro 25		
gcc ctg gcg cat gc Ala Leu Ala His Gl 35	c gtc cgg gtt ctg gad y Val Arg Val Leu Glu 40	g gac ggc gtg aac t n Asp Gly Val Asn 1 45	at gca 144 Tyr Ala
	c ggt tgc tct ttc tco o Gly Cys Ser Phe Sen 55		, ,
	c gtt cca gct tcc gct r Val Pro Ala Ser Ala 70		
Ser Gly Met Tyr Hi	t gtc acg aac gac tgc s Val Thr Asn Asp Cys 5	Ser Asn Ser Ser I	
	c atg atc atg cac acc p Met Ile Met His Th - 105		
gtt cgg gag aac aa Val Arg Glu Asn As	c tot too ogo tgo tgo	gta gcg ctc acc c	

125 115 120 ctc gca gct agg aac gcc agc gtc ccc acc acg aca ata cga cgc cac 432 Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Ile Arg Arg His 135 gtc gat tcc cag ctg ttc acc atc tcg cct cgc cgg cat gag acg gtg 480 Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val cag gac tgc aat tgc tca atc tat ccc ggc cac ata acg ggt cac cgt 528 Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg 165⁄ 170 atg gct tgg gat atg atg atg aac tgg taatag 561 Met Ala Trp Asp Met Met Met Asn Trp 180 <210> 24 <211> 185 <212> PRT <213> Hepatitis C virus <400> 24 Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg

Met Ala Trp Asp Met Met Met Asn Trp

<210> 25			
<211> 606 <212> DNA <213> Hepatitis C virus	·)
<220> <221> CDS <222> 1603			
<220> <221> mat_peptide <222> 1600 <400> 25	and the second		
atg ttg ggt aag gtc atc Met Leu Gly Lys Val Ile 1 5			Leu
gtg ggg tac att ccg ctc Val Gly Tyr Ile Pro Leu 20			
gcc ctg gcg cat ggc gtc Ala Leu Ala His Gly Val 35			
aca ggg aat ttg ccc ggt Thr Gly Asn Leu Pro Gly 50			
ctg tcc tgt ctg acc gtt Leu Ser Cys Leu Thr Val 65 70			
tcc ggg atg tac cat gtc Ser Gly Met Tyr His Val 85			val
tat gag gca gcg gac atg Tyr Glu Ala Ala Asp Met 100			
gtt cgg gag aac aac tct Val Arg Glu Asn Asn Ser 115	Ser Arg Cys Trp 120	Val Ala Leu Thr Pro 125	Th <u>r</u>
ctc gca gct agg aac gcc Leu Ala Ala Arg Asn Ala 130	Ser Val Pro Thr 135	Thr Thr Ile Arg Arc	, His
gtc gat tcc cag ctg ttc Val Asp Ser Gln Leu Phe 145 150	Thr Ile Ser Pro	Arg Arg His Glu Thr 155	Val 160
cag gac tgc aat tgc tca Gln Asp Cys Asn Cys Ser 165	Ile Tyr Pro Gly 170	His Ile Thr Gly His	Arg
atg gct tgg gat atg Met Ala Trp Asp Met Met			

606

180 185 190

gta tcg cag ctg ctc cgg atc ctc taatag Val Ser Gln Leu Leu Arg Ile Leu 195 200

<210> 26

<211> 200

<212> PRT

<213> Hepatitis C virus

<400> 26

Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu 1 5 10 15

Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg 20 25 30

Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala 35 40 45

Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu 50 55 60

Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val 65 70 75 80

Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val 85 90 95

Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys 100 105 110

Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr 115 120 125

Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Ile Arg Arg His 130 135 140

Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val 145 150 155 160

Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg 165 170 175

Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val 180 185 190

Val Ser Gln Leu Leu Arg Ile Leu 195 200

<210> 27

<211> 636

<212> DNA

<213> Hepatitis C virus

<220>

<221> CDS

<222> 1..633

<220> <221> mat_peptide <222> 1630 <400> 27																
	ttg Leu															48
	ggg Gly															. 96
	ctg Leu															144
	ggg Gly 50															192
	tcc Ser															240
	ggg Gly															288
	gag Glu															336
	cgg Arg															384
	gca Ala 130															432
	gat Asp															480
	gac Asp															528
_	gct Ala		_	_	_	-			-			-	-	_		576
	tcg Ser															624
	cac His 210														636	

<210> 28

<211> 210

<212> PRT

<213> Hepatitis C virus

<400> 28

Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
1 10 15

Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg 20 25 30

Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala 35 40 45

Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu 50 55 60

Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val 65 70 75 80

Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val 85 90 95

Tyr Glu Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys 100 105 110

Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr 115 120 125

Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His 130 135 140

Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val 145 150 155

Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg 165 170 175

Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val 180 185 190

Val Ser Gln Leu Leu Arg Ile Val Ile Glu Gly Arg His His His 195 200 205

His His

210

<210> 29

<211> 630

<212> DNA

<213> Hepatitis C virus

<220>

<221> CDS

<222> 1..627

<220>

<221> mat_peptide

<222> 1..624 . <400> 29 .

<213> Hepatitis C virus

_		_	-		_			_	tgc Cys 10		_	_	_		48
									gta Val						96
									gac Asp						144
									att Ile					•	192
									cta Leu					÷.	240
			-				_	-	tcc Ser 90	_	-				288
									ccc Pro						336
•	-					-	-		acc Thr						384
									gct Ala						432
									tgc Cys						480
									gga Gly 170						528
									tgt Cys						576
									tgg Trp						624
taa:	tag 0> 30)												_	634
	1> 20 2> PF		م اد ماد ا	C		-	•								

<400> 30

Met Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met
1 5 10 15

Gly Tyr Ile Pro Leu Val Gly Ala Pro Val Gly Gly Val Ala Arg Ala 20 25 30

Leu Ala His Gly Val Arg Ala Leu Glu Asp Gly Ile Asn Phe Ala Thr 35 40 45

Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Phe 50 55 60

Ser Cys Leu Ile His Pro Ala Ala Ser Leu Glu Trp Arg Asn Thr Ser 65 70 75 80

Gly Leu Tyr Val Leu Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr 85 90 95

Glu Ala Asp Asp Val Ile Leu His Thr Pro Gly Cys Ile Pro Cys Val 100 105 110

Gln Asp Gly Asn Thr Ser Thr Cys Trp Thr Pro Val Thr Pro Thr Val 115 120 125

Ala Val Lys Tyr Val Gly Ala Thr Thr Ala Ser Ile Arg Ser His Val 130 135 140

Asp Leu Leu Val Gly Ala Ala Thr Met Cys Ser Ala Leu Tyr Val Gly 145 150 155 160

Asp Met Cys Gly Ala Val Phe Leu Val Gly Gln Ala Phe Thr Phe Arg 165 170 175

Pro Arg Arg His Gln Thr Val Gln Thr Cys Asn Cys Ser Leu Tyr Pro 180 185 190

Gly His Leu Ser Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp 195 200 205

<210> 31

<211> 630

<212> DNA

<213> Hepatitis C virus

<220>

<221> CDS

<222> 1..627

<220>

<221> mat_peptide

<222> 1..624

<400> 31

atg ggt aag gtc atc gat acc cta acg tgc gga ttc gcc gat ctc atg
Met Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met

1 10 15

						ggc Gly									96
						gtc Val									144
		Leu			_	tct Ser 55									192
						gcc Ala									240
						aat Asn									288
						cta Leu								* .	336
						aga Arg									384
	-	_	-			gca Ala 135	_	_	_		 _	-	_		432
						gct Ala									480
						ttc Phe									528
						gtg Val			Cys					•	576
						cgg Arg									624
taat	ag														630
<211 <212)> 32 l> 2(2> PE B> He	O8 RT	itis	C vi	irus										

<213> Hepatitis C virus

<400> 32

Met Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met 1 5 10 15

Gly	Tyr	Ile	Pro 20	Leu	Val	Gly	Gly	Pro 25	Ile	Gly	Gly	Val	Ala 30	Arg	Ala	
Leu	Ala	His 35	Gly	Val	Arg	Val	Leu 40	Glu	Asp	Gly	Val	Asn 45	Tyr	Ala	Thr	
Gly	Asn 50	Leu	Pro	Gly	Cys	Ser 55	Phe	Ser	Ile	Phe	Ile 60	Leu	Ala	Leu	Leu	
Ser 65	Cys	Leu	Thr	Val	Pro 70	Ala	Ser	Ala	Val	Pro 75	Tyr	Arg	Asn	Ala	Ser 80	
Gly	Ile	Tyr	His	Val 85	Thr	Asn	Asp	Cys	Pro 90	Asn	Ser	Ser	Ile	Val 95	Tyr	
Gļu	Ala	Asp	Asn 100	Leu	Ile	Leu	His	Ala 105	Pro	Gly	Cys	Val	Pro 110	Cys	Val	
Met	Thr	Gly 115	Asn	Val	Ser	Arg	Cys 120	Trp	Val	Gln	Ile	Thr 125	Pro	Thr	Leu	
Ser	Ala 130	Pro	Ser	Leu	Gly	Ala 135	Val	Thr	Ala	Pro	Leu 140	Arg	Arg	Ala	Val	
Asp 145	Tyr	Leu	Ala	Gly	Gly 150	Ala	Ala	Leu	Cys	Ser 155	Ala	Leu	Tyr	Val	Gly 160	
Asp	Ala	Cys		Ala 165	Leu	Phe	Leu	Val	Gly 170	Gln	Met	Phe	Thr	Tyr 175	Arg	
Pro	Arg	Gln	His 180	Ala	Thr	Val	Gln	Asn 185	Cys	Asn	Cys	Ser	Ile 190	Tyr	Ser	
	His)> 33	195	Thr	Gly	His	Arg	Met 200	Ala	Trp	Asp	Met	Met 205	Met	Asn	Trp	
<211 <212 <213	L> 23 2> DN	3 NA epati	ltis	C vi	irus											
tggg	jatat	ga t	gato	gaact	g gt	c ·	•	•						,		23
<210)> 34	1												•		
<212 <213	L> 3(2> DN 3> He 0> 34	NA epati	itis	C vi	irus											
ctat	tato	ggt g	gtaa	agcca	ac aç	gagca	aggaç	J								30
<210)> 35	5														
<212	l> 14 ?> DN 3> He		tis	C vi	rus	•										

<220> <221> CDS <222> 11473	
<220> <221> mat_peptide <222> 11470 <400> 35	
tgg gat atg atg aac tgg tcg cct aca acg gcc ctg gtg gta tcg Trp Asp Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser 1 5 10	48
cag ctg ctc cgg atc cca caa gct gtc gtg gac atg gtg gcg ggg gcc Gln Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala 20 25 30	96
cat tgg gga gtc ctg gcg ggc ctc gcc tac tat tcc atg gtg ggg aac His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn 35 40 45	144
tgg gct aag gtt ttg gtt gtg atg cta ctc ttt gcc ggc gtc gac ggg Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly 50 55 60	192
cat acc cgc gtg tca gga ggg gca gcc tcc gat acc agg ggc ctt His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu 65 70 75 80	240
gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa atc cag ctc gta aac Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn 85 90 95	288
acc aac ggc agt tgg cac atc aac agg act gcc ctg aac tgc aac gac Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp 100 105 110	336
tcc ctc caa aca ggg ttc ttt gcc gca cta ttc tac aaa cac aaa ttc Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe 115 120 125	384
aac tcg tct gga tgc cca gag cgc ttg gcc agc tgt cgc tcc atc gac Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp 130 135 140	432
aag ttc gct cag ggg tgg ggt ccc ctc act tac act gag cct aac agc Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser 145 150 155 160	, 480
tcg gac cag agg ccc tac tgc tgg cac tac gcg cct cga ccg tgt ggt Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly 165 170 175	528
att gta ccc gcg tct cag gtg tgc ggt cca gtg tat tgc ttc acc ccg Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro 180 185 190	576
agc cct gtt gtg gtg ggg acg acc gat cgg ttt ggt gtc ccc acg tat Ser Pro Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr 195 200 205	624

							tcg Ser 215											672
							ttc Phe											720
			_	-	-		ggc Gly		_	_					-			768
•						. =	ccc Pro	_	_									816
							ggt Gly											864
•	_	_					agg Arg 295						-		_			912
					-	-	agg Arg	-									٠	960
							tgg Trp											1008
	-		-	-			ctt Leu	_	_		_	_						1056
		-		•		-	tcc Ser				-	-	_					1104
			Ile		Leu	His	cag Gln 375	Asn					Gln					1152
							gtc Val											1200
							ctg Leu											1248
							gct Ala											1296
							gcc Ala											1344
	ttc	ctt	gtg	ttc	ttc	tgt	gct	gcc	tgg	tac	atc	aag	ggc	agg	ctg	gtc		1392

Phe	Leu 450	Val	Phe	Phe	Cys	Ala 455	Ala	Trp	Tyr	Ile	Lys 460	Gly	Arg	Leu	Val	
			gca Ala													1440
			tta Leu							tagt	caa					1476
<210)> 36	5 .	. ::	:	•	, .				: : 4						
<2,12	L> 49 2> PF 3> He	۲Ť	itis	C vi	irus	ė	:	•							٠.	
		- p							• .		٠					
<400)> 3 (5				•				*		,				• *
Ψrn	Λen.	Mo+	Mot	Mot	Acn.	· ·	50×		ሞb ×	 Th∞	λla	Lou	Va 1	Val	Sor	•
1	wsb	., ec	Met	5	ASII	irb	Ser	FIO	10	iii.	Ητά.	 Ten	vai	15	séř	2 ° 4 ° 1
Gln	Leu	Leu	Arg 20	Ile	Pro	Gln	Ala	Val 25	Val	Asp	Met	Val	Ala 30	Gly	Ala	
His	Trp	Gly 35	Val	Leu	Ala	Gly	Leu 40	Ala	Tyr	Tyr	Ser	Met 45	Val	Gly	Asn	
Trp	Ala 50	Lys	Val	Leu	Val	Val 55	Met	Leu	Leu	Phe	Ala 60	Gly	Val	Asp	Gly	
His 65	Thr	Arg	Val	Ser	Gly 70	Gly	Ala	Ala	Ala	Ser 75	Asp	Thr	Arg	Gly	Leu 80	
Val	Ser	Leu	Phe	Ser 85	Pro	Gly	Ser	Ala	Gln 90	Lys	Ile	Gln	Leu	Val 95	Asn	
Thr	Asn	Gly	Ser 100	Trp	His	Ile	Asn	Arg 105	Thr	Ala	Leu	Asn	Cys 110	Asn	Asp	
Ser	Leu	Gln 115	Thr	Gly	Phe	Phe	Ala 120	Ala	Leu	Phe	Tyr	Lys 125	His	Lys	Phe	a see
Äsn	Ser 130	Ser	Gly	Cys	Pro	Glu 135	Arg	Leu	Ala	Ser	Cys 140	Arg	Ser	Ile	Asp	4 1 (4) + 4 (4)
Lys 145	Phe	Ala	Gln	Gly	Trp 150	Gly	Pro	Ļeu	Thr	Tyr 155	Thr	Glu	Pro	Asn	Ser 160	
Ser	Asp	Gln	Arg	Pro 165	Tyr	Cys	Trp	His	Tyr 170	Ala	Pro	Arg	Pro	Cys 175	Gly	
Ile	Val	Pro	Ala 180	Ser	Gln	Val	Cys	Gly 185	Pro	Val	Tyr	Cys	Phe 190	Thr	Pro	
Ser	Pro	Val 195	Val	Val	Gly	Thr	Thr 200	Asp	Arg	Phe	Gly	Val 205	Pro	Thr	Tyr	
Asn	Trp 210	Gly	Ala	Asn	Asp	Ser 215	Asp	Val	Leu	Ile	Leu 220	Asn	Asn	Thr	Arg	
Pro	Pro	Arg	Gly	Asn	Trp	Phe	Gly	Cys	Thr	Trp	Met	Asn	Gly	Thr	Gly	

ter en e

225 230 235 240 Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly 250 Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu 265 Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn 290 295 Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg 310 Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Ser Thr Thr Glu Trp Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly Val Gly Ser Ala Val Val Ser Leu Val Ile Lys Trp Glu Tyr Val Leu Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu Trp Met Met Leu Leu Ile Ala Gln Ala Glu Ala Leu Glu Asn Leu Val Val Leu Asn Ala Ala Ala Val Ala Gly Ala His Gly Thr Leu Ser Phe Leu Val Phe Phe Cys Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val Pro Gly Ala Ala Tyr Ala Phe Tyr Gly Val Trp Pro Leu Leu Leu Leu Leu Ala Leu Pro Pro Arg Ala Tyr Ala <210> 37

<211> 1021

<212> DNA

<213> Hepatitis C virus

<220>

<221> CDS

<222> 2..1018

	<222	1> ma	at_p 10:	epti 15	de				•		٠									٠		
										al A				at to is T	rp G			46				
e ve e verte e														tgg Trp				94		•		
										Gly				cat His 45				142				· .
en e				Gly		Ala	Ala	Ser	Asp	Thr	Arg	Gly		gtg Val				190				sak er
	ttt Phe	agc Ser 65	ccc Pro	Gly	tcg Ser	gct Ala	cag Gln 70	aaa Lys	atc Ile	cag Gln	ctc Leu	gta Val 75	aac Asn	acc Thr	aac Asn	ggc Gly		238				
														tcc Ser				286				
														aac Asn				334				
														aag Lys 125				382				
* #				Gly					Thr					tcg Ser			. * .	430			*	·,
g se sek gesek et e genedag som et e Store en store green	agg Arg	ccc Pro 145	Tyr	tgc	tgg Trp	Cac	tac Tyr 150	gcg Ala	cct Pro	cga Arg	ccg Pro	tgt Cys 155	ggt Gly	att Ile	gta Val	ccc Pro	erri ve deski	478	k trebe gaši k		rr sgr	
	Ala 160	Ser	Gln	Val	Cys	Gly 165	Pro	Val	Tyr	Cys	Phe 170	Thr	Pro	agc Ser	Pro	Val 175		526				
	gtg Val	gtg Val	Gly	acg Thr	Thr 180	gat Asp	Arg	Phe	ggt Gly	yal 185	Pro	acg Thr	Tyr	aac Asn	tgg Trp 190	ggg		574				
														ccg Pro 205				622				
,														ttc Phe				670				
	acg	tgt	ggg	ggc	ccc	ccg	tgc	aac	atc	ggg	ggg	gcc	ggc	aac	aac	acc		718				

1111	Cys 225	Gly	Gly	Pro	Pro	Cys 230	Asn	Ile	Gly	Gly	Ala 235	Gly	Asn	Asn	Thr		
		tgc Cys															766
		tgc Cys															814
		tat Tyr															862
		gtt Val 290													gcc Ala		910
		aat Asn															958
-		gag Glu		_	_		-	-						_	-		1006
	aga Arg	gct Ala	taat	ta													1021
<21	0> 38	8															
<21	1> 3: 2> PI 3> He		itis	C vi	irus												
<40																	
	0> 38	8															
Ile 1		3 Gln	Ala	Val 5	Val	Asp	Met	Val	Ala 10	Gly	Ala	His	Trp	Gly 15	Val		
. 1	Pro			5		_			10			, .		15			
1 Leu	Pro Ala	Gln	Leu 20	5 Ala	Tyr	Tyr	Ser	Met 25	10 'Val	Gly	Àsn	Trp	Ala 30	15 Lys	Val		E * * . * *
Leu Leu	Pro Ala Val	Gln Gly Val	Leu 20 Met	5 Ala Leu	Tyr Leu	Tyr Phe	Ser Ala 40	Met 25 Gly	10 'Val Val	Gly	Asn Gly	Trp His 45	Ala 30 Thr	15 Lys Arg	Val Val		
Leu Leu Ser	Pro Ala Val Gly 50	Gln Gly Val 35	Leu 20 Met	5 Ala Leu Ala	Tyr Leu Ala	Tyr Phe Ser 55	Ser Ala 40 Asp	Met 25 Gly Thr	10 'Val Val Arg	Gly Asp Gly	Asn Gly Leu 60	Trp His 45 Val	Ala 30 Thr	15 Lys Arg Leu	Val Val Phe		
Leu Ser Ser 65	Pro Ala Val Gly 50 Pro	Gln Gly Val 35 Gly	Leu 20 Met Ala Ser	5 Ala Leu Ala Ala	Tyr Leu Ala Gln 70	Tyr Phe Ser 55	Ser Ala 40 Asp	Met 25 Gly Thr	10 Val Val Arg Leu	Gly Asp Gly Val 75	Asn Gly Leu 60 Asn	Trp His 45 Val	Ala 30 Thr Ser	Lys Arg Leu Gly	Val Val Phe Ser 80		
Leu Ser Ser 65	Pro Ala Val Gly 50 Pro	Gln Gly Val 35 Gly	Leu 20 Met Ala Ser	Ala Leu Ala Ala Arg 85	Tyr Leu Ala Gln 70	Tyr Phe Ser 55 Lys Ala	Ser Ala 40 Asp Ile Leu	Met 25 Gly Thr Gln Asn	Val Val Arg Leu Cys 90	Gly Gly Val 75 Asn	Asn Gly Leu 60 Asn Asp	Trp His 45 Val Thr	Ala 30 Thr Ser Asn	Lys Arg Leu Gly Gln 95	Val Val Phe Ser 80	•	

115 120 125

Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Ser Asp Gln Arg 130 135 140

Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile Val Pro Ala 145 150 155 160

Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val Val 165 170 175

Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn Trp Gly Ala 180 185 190

Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg Gly
195 200 205

Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys Thr 210 215 220

Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr Leu 225 230 235 240

Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr Ala 245 250 255

Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His Tyr 260 265 270

Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe 275 280 285

Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala 290 295 300

Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg 305 310 315 320

Ser Glu Leu Ser Pro Leu Leu Ser Thr Thr Glu Trp Gln Ser Gly 325 330 335

Arg Ala

<210> 39

<211> 1034

<212> DNA

<213> Hepatitis C virus

<220>

<221> CDS

<222> 2..1032

<220>

<221> mat_peptide

<222> 2..1029

<400> 39

g atc cca caa gct gtc gtg gac atg gtg gcg ggg gcc cat tgg gga

1	le Pi 1	ro G	ln A	la Va	al Va 5	al As	sp Me	et Va		la G. 10	ly A	la H	is T	-	ly 15		
								tcc Ser									94
								gcc Ala 40									142
			Gly		gca			gat Asp									190
		Pro						atc Ile		Leu						•	238
								ctg Leu								•	286
								tac Tyr									334
								tgt Cys 120									382
								act Thr									430
								cct Pro									478
			Val		Gly	Pro	Val	tat Tyr	Cys	Phe	Thr		Ser			** *** **	526
								ggt Gly									574
								ctc Leu 200									622
								atg Met									670
acg Thr	tgt Cys 225	ggg Gly	ggc Gly	ccc Pro	Pro	tgc Cys 230	aac Asn	atc Ile	ggg Gly	Gly Ggg	gcc Ala 235	ggc Gly	aac Asn	aac Asn	acc Thr	-	718
								cgg Arg									766

						ccc Pro										814	
						cac His			-		-					862	
			Arg			gtg Val										910	
						gga Gly 310										958	
						ctg Leu										1006	٠.
						tca Ser		at a	ag							1034	
<210)> 4()															
<212	L> 34 2> PI 3> He		itis	C v	irus												
<400)> 4()															
Ile 1	Pro	Gln	Ala	Val 5	Val	Asp	Met	Val	Ala 10	Gly	Ala	His	Trp	Gly 15	Val		
Leu	Ala	Gly	Leu 20	Ala	Tyr	Tyr	Ser	Met 25	Val	Gly	Asn	Trp	Ala 30	Lys	Val		
Leu	Val	Val 35	Met	Leu	Leu	Phe	Ala 40	Gly	Val	Asp	Gly	His 45	Thr	Arg	Val	***	
Ser	GIÿ 50			Ála	'Ala	Ser 55	Asp		Arg	-	Leu 60			Leu	Phe	888 - (Sec.) 8 8 8	
Ser 65	Pro	Gly	Ser	Ala	Gln 70	Lys	Ile	Gln	Ĺeu	Val 75	Asn	Thr	Asn	Gly	Ser 80		
Trp	His	Ile	Asn	Arg 85	Thr	Ala	Leu	Asn	Cys 90	Asn	Asp	Ser	Leu	Gln 95	Thr		
Gly	Phe	Phe	Ala 100	Ala	Leu	Phe	Tyr	Lys 105	His	Lys	Phe	Asn	Ser 110	Ser	Gly		
Cys	Pro	Glu 115	Arg	Leu	Ala	Ser	Cys 120	Arg	Ser	Ile	Asp	Lys 125	Phe	Ala	Gln		
Gly	Trp 130	Gly	Pro	Leu	Thr	Tyr 135	Thr	Glu	Pro	Asn	Ser 140	Ser	Asp	Gln	Arg		
Pro	Tyr	Cys	Trp	His	Tyr	Ala	Pro	Arg	Pro	Cys	Gly	Ile	Val	Pro	Ala		

Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala 1 5 10 15 ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc gat Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp 20 25 30		•																
Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg Gly 200 Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys Thr 210 Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr Leu 240 Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr Ala 245 Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His Tyr 260 Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe 275 Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala 290 Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg 305 Ser Glu Leu Ser Pro Leu Leu Ser Thr Thr Gly Asp Arg Gly Gln 328 Thr Pro Ser Pro Pro Ser Leu 340 <210> 41 <220> <221> Cys Mat peptide 222> 1.942 <220> <221> Cys mat peptide 222> 1.939 <400 41 atg gtg ggg aac tgg gct aag gtt ttg gtt gtg atg cts ctc ttt gcc Met Val Asp Thr Arg Gly His Thr Arg Val Lys Usl Val Ala Ala Ala 31 Ala 329 Ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc gat Gly Val Asp Gly Gly Val Asp Arg Asp Arg Asp Arg Asp Arg 310 Ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc gat Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ala Ser Asp 20 acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa atc 14			Gln	Val	Cys	_			Tyr	Cys		Thr		Ser	Pro		Val	
Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys Thr 210 Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr Leu 225 Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr Leu 225 Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr Ala 245 Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His Tyr 260 265 Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe 280 Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala 290 Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg 305 Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gly Asp Arg Gly Gln 325 Thr Pro Ser Pro Pro Ser Leu 340 <210 41 <220		Val	Gly	Thr		Asp	Arg	Phe	Gly		Pro	Thr	Tyr	Asn		Gly	Ala	
Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr Leu 225		Asn	Asp		Asp	Val	Leu	Ile		Asn	Asn	Thr	Arg			Arg	Gly	
Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr Ala 255 Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His Tyr 260 Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe 275 Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala 290 Cys Asn Trp Thr Arg Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg 305 Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gly Asp Arg Gly Gln 325 Thr Pro Ser Pro Pro Ser Leu 340 <210> 41 <221> DNA <2220> <222> 1.942 <220> <222> 1.942 <220> 41 atg gtg ggg aac tgg gct aag gtt ttg gtt gtg atg cta ctc ttt gcc Met Val Gly Asp Gly His Thr Arg Val Leu Val Val Met Leu Leu Phe Ala 1 1 ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc gat Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp 20 acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa atc 14	en e	Asn			Gly	Cys	Thr		Met	Asn	Gly	Thr			Thr	Lys	Thr	
Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His Tyr 260 Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe 275 280 Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala 290 Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg 305 Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gly Asp Arg Gly Gln 325 Thr Pro Ser Pro Pro Ser Leu 340 <210> 41 <211> 945 <222> <220> <221> CDS <222> 1942 <220> <221> mat peptide <222> 1942 <220> <221> mat peptide <222> 1942 <220> <221> mat peptide <222> 1942 <220> <221 mat peptide <222> 1942 <220> <221 mat peptide <222 mat peptide <222 mat peptide <221 mat peptide <222 mat peptide <222 mat peptide <222 mat peptide <221 mat peptide <222 mat peptide <221 mat peptide <222 mat peptide <223 mat peptide <224 mat petide <225 mat peptide <225 mat peptide <226 mat petide <227 mat peptide <227 mat peptide <228 mat peptide <229 mat peptide <229 mat peptide <221 mat petide <221 mat petide <221 mat petide <222 mat petide <222 mat petide <223 mat petide <224 mat petide <225 mat petide <226 mat			Gly	Gly	Pro				Ile	Gly	Gly			Asn	Asn	Thr		· · ·
Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe 275 Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala 290 Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg 305 Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gly Asp Arg Gly Gln 325 Thr Pro Ser Pro Pro Ser Leu 340 <210> 41 <2211> 945 <2212> DNA <213> Hepatitis C virus 2200 <2221> mat peptide <2222> 1942 <220> <221> mat gdg ggg aac tgg gct aag gtt ttg gtt gtg atg cta ctc ttt gcc Met Val Gly Asp Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala 1	e de la composition della comp	Thr	Cys	Pro	Thr		Cys	Phe	Arg	Lys		Pro	Glu	Ala	Thr		Ala	
Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala 290 Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg 305 Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gly Asp Arg Gly Gln 325 Thr Pro Ser Pro Pro Ser Leu 340 <210> 41 <221> 945 <221> DNA <213> Hepatitis C virus <220> <221> mat peptide <222> 1939 <400> 41 atg gtg ggg aac tgg gct aag gtt ttg gtt gtg atg cta ctc ttt gcc Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala 1 5 ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc gat Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp 20 acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gcc cag aaa atc 14	and the second s	Arg	Суя	Gly			Pro	Trp	Leu		Pro	Arg	Cys	Met		His	Tyr	
Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg 305 Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gly Asp Arg Gly Gln 325 Thr Pro Ser Pro Pro Ser Leu 340 <210> 41 <221> 945 <212> DNA <213> Hepatitis C virus <220> <221> cos <222> 1942 <220> <221> mat peptide <222> 1939 <400> 41 atg gtg ggg aac tgg gct aag gtt ttg gtt gtg atg cta ctc ttt gcc Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala 1 f ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc gat Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp 20 acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa atc 14		Pro	Tyr		Leu	Trp	His	Tyr		Cys	Thr	Val	Asn		Thr	Ile	Phe	
Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gly Asp Arg Gly Gln 325 Thr Pro Ser Pro Pro Ser Leu 340 <210> 41 <221> 945 <212> DNA <213> Hepatitis C virus 220> <221> CDS <222> 1.942 <220> <221> mat_peptide <222> 1.939 <400> 41 atg gtg ggg aac tgg gct aag gtt ttg gtt gtg atg cta ctc ttt gcc Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala 1 1 5 10 ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc gat Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp 20 acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa atc 14		Lys		Arg	Met	Tyr	Val		Gly	Val	Glu	His			Glu	Ala	Ala	
Thr Pro Ser Pro Pro Ser Leu 340 <210> 41 <211> 945 <212> DNA <213> Hepatitis C virus 220> <221> CDS <222> 1.942 <220> <221> mat_peptide <222> 1.939 <400> 41 atg gtg ggg aac tgg gct aag gtt ttg gtt gtg atg cta ctc ttt gcc Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Phe Ala 1 5 10 ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc gat Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp 20 25 30 acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa atc 14			Asn	Trp	Thr	Arg		Glu	Arg	Cys	Asp		Glu	Asp	Arg	Asp	_	
340 <210> 41 <211> 945 <212> DNA <213> Hepatitis C virus <220> <221> CDS <222> 1942 <220> <221> mat_peptide <222> 1939 <400> 41 atg gtg ggg aac tgg gct aag gtt ttg gtt gtg atg cta ctc ttt gcc Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala 1 5 10 ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc gat Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp 20 acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa atc 14		Ser	Glu	Leu	Ser		Leu	Leu	Leu	Ser		Thr	Gly	Asp	Arg		Gln	
<pre> <212> DNA <213> Hepatitis C virus 220> <221> CDS <222> 1942 <220> <221> mat_peptide <222> 1939 <400> 41 atg gtg ggg aac tgg gct aag gtt ttg gtt gtg atg cta ctc ttt gcc Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala 1 5 10 15 ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc gat Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp 20 25 30 acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa atc 14</pre>						Pro	Ser	Leu										
<pre> <220> <221> CDS <222> 1942 <220> <221> mat_peptide <222> 1939 <400> 41 atg gtg ggg aac tgg gct aag gtt ttg gtt gtg atg cta ctc ttt gcc Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Phe Ala 1 5 10 ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc gat Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp 20 25 30 acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa atc 14</pre>	e san de la companya	<212	2> DN	JA	ítís	Ć v:	irus		٠			-	دره محر	1 - 1 - 1	. •			
<pre><221> mat_peptide <222> 1939 <400> 41 atg gtg ggg aac tgg gct aag gtt ttg gtt gtg atg cta ctc ttt gcc Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala</pre>	Employed the control of the section	<221	l> CI			•1≈ s•	e var	ejPSrw. v [†] #	**************************************	translava	•	en des	meter e d	1 14. 1 14. 1 14.				American Carlos
Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala 1 5 10 15 ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc gat 9 Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp 20 25 30 acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa atc 14		<221 <222	l> ma 2> 1.	. 939		de				•	. •	·		,			• .	
Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp 20 25 30 acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa atc 14		Met				Trp					Val					Phe		48
					Gly					Ser					Ala			96
																		144

40 45 35 cag ctc gta aac acc aac ggc agt tgg cac atc aac agg act gcc ctg 192 Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu 55 aac tgc aac gac tcc ctc caa aca ggg ttc ttt gcc gca cta ttc tac 240 Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr 75 aaa cac aaa ttc aac tcg tct gga tgc cca gag cgc ttg gcc agc tgt 288 Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys 85 90 cgc tcc atc gac aag ttc gct cag ggg tgg ggt ccc ctc act tac act 336 Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr 100 105 384 gag cct aac agc tog gac cag agg ccc tac tgc tgg cac tac gcg cct Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro 115 120 cga ccg tgt ggt att gta ccc gcg tct cag gtg tgc ggt cca gtg tat 432 Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr 130 tgc ttc acc ccg agc cct gtt gtg gtg gtg acg acc gat cgg ttt ggt 480 Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly gtc ccc acg tat aac tgg ggg gcg aac gac tcg gat gtg ctg att ctc 528 Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu 576 aac aac acg cgg ccg ccg cga ggc aac tgg ttc ggc tgt aca tgg atg Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met 180 185 aat ggc act ggg ttc acc aag acg tgt ggg ggc ccc ccg tgc aac atc 624 Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile 195 200 205 ggg ggg gec ggc aac aac acc ttg acc tgc ccc act gac tgt ttt egg 672 Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg 215 720 aag cac ccc gag gcc acc tac gcc aga tgc ggt tct ggg ccc tgg ctg Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu 225 230 768 aca cct agg tgt atg gtt cat tac cca tat agg ctc tgg cac tac ccc Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro 250 816 tgc act gtc aac ttc acc atc ttc aag gtt agg atg tac gtg ggg ggc Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly 265 gtg gag cac agg ttc gaa gcc gca tgc aat tgg act cga gga gag cgt 864

Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg

285

	Cys tct Ser 305		Leu aca Thr	Glu gag	Asp tgg	Arg cag	Asp 295 agc	Arg tta	Ser att	Glu aat								912 945
	<21	1> 3: 2> PI 3> He	RT epat:	itis									- '					
	<40	0> 42	2			,	, ,											
t di series di se		Val	•		_	•	14	Val		Val 10	Val	Met	Leu	Leu	Phe 15	Ala	•	
and the second second second	Gly	Val	Asp	Gly 20	His	Thr	Arg	Val	Ser 25	Gly	Gly	Ala	Ala	Ala 30	Ser	Asp		
	Thr	Arg	Gly 35	Leu	Val	Ser	Leu	Phe 40	Ser	Pro	Gly	Ser	Ala 45	Gln	Lys	Ile		
	Gln	Leu 50	Val	Asn	Thr	Asn	Gly 55	Ser	Trp	His	Ile	Asn 60	Arg	Thr	Ala	Leu		
	Asn 65	Cys	Asn	Asp	Ser	Leu 70	Gln	Thr	Gly	Phe	Phe 75	Ala	Ala	Leu	Phe	Tyr 80		
	Lys	His	Lys	Phe	Asn 85	Ser	Ser	Gly	Суз	Pro 90	Glu	Arg	Leu	Ala	Ser 95	Суѕ		•
	Arg	Ser	Ile	Asp 100	Lys	Phe	Ala	Gln	Gly 105	Trp	Gly	Pro	Leu	Thr 110	Tyr	Thr		
	Glu	Pro	Asn 115	Ser	Ser	Asp	Gln	Arg 120	Pro	Tyr	Суѕ	Trp	His 125	Tyr	Ala	Pro		
The speed from the contract of	Arg	130	Cys	_	Ile		135	Ala		Gln	Val	Cys 140		Pro	Val	Tyr		***
					Ser					Gly	Thr 155			Arg	Phe	Gly 160		
		Pro	Thr	Tyr	Asn 165	Trp	Gly	Ala	Asn	Asp 170	Ser	Asp	Val		Ile 175	Leu		
	Asn	Asn	Thr	Arg 180	Pro	Pro	Arg	Ģly	Asn 185	Trp	Phe	Gly	Cys	Thr 190	Trp	Met		
	Asn	Gly	Thr 195	Gly	Phe	Thr	Lys	Thr 200	Cys	Gly	Gly	Pro	Pro 205	Cys	Asn	Ile		
	Gly	Gly 210	Ala	Gly	Asn	Asn	Thr 215	Leu	Thr	Cys	Pro	Thr 220	Asp	Cys	Phe	Arg		
	Lys 225	His	Pro	Glu	Ala	Thr 230	Tyr	Ala	Arg	Суз	Gly 235	Ser	Gly	Pro	Trp	Leu 240		

in the second of the second of

\$ 2 2 5 2 5

Thr Pro Arg Cys Met 245	Val His Tyr Pro	Tyr Arg Leu Trp His Tyr 250 255	Pro
Cys Thr Val Asn Phe 260	Thr Ile Phe Lys 265	Val Arg Met Tyr Val Gly 270	Gly
Val Glu His Arg Phe 275	Glu Ala Ala Cys 280	Asn Trp Thr Arg Gly Glu 285	Arg
Cys Asp Leu Glu Asp 290	Arg Asp Arg Ser	Glu Leu Ser Pro Leu Leu 300	Leu
Ser Thr Thr Glu Trp	Gln Ser Leu Ile	Asn	
	· · · · · · · · · · · · · · · · · · ·	e de la companya de l	
<210> 43		en de la companya de	
<211> 961 <212> DNA	and the second second		
<213> Hepatitis C v	irus	· · · · · · · · · · · · · · · · · · ·	en e
<220> <221> CDS <222> 1958			
<220> <221> mat_peptide <222> 1955 <400> 43	·		
		gtt gtg atg cta ctc ttt Val Val Met Leu Leu Phe 10	
ggc gtc gac ggg cat Gly Val Asp Gly His 20	acc cgc gtg tca Thr Arg Val Ser 25	gga ggg gca gca gcc tcc Gly Gly Ala Ala Ala Ser 30	gat 96 Asp
		ccc ggg tcg gct cag aaa Pro Gly Ser Ala Gln Lys 45	
and the set of the set	e in a filograph was proportional and assistant as the con-	also from the minimum of the control	And the second of the second o
		cac atc aac agg act gcc His Ile Asn Arg Thr Ala 60	
		ttc ttt gcc gca cta ttc Phe Phe Ala Ala Leu Phe 75	
		cca gag cgc ttg gcc agc Pro Glu Arg Leu Ala Ser 90 95	
cgc tcc atc gac aag Arg Ser Ile Asp Lys 100	ttc gct cag ggg Phe Ala Gln Gly 105	tgg ggt ccc ctc act tac Trp Gly Pro Leu Thr Tyr 110	act 336 Thr
		tac tgc tgg cac tac gcg Tyr Cys Trp His Tyr Ala 125	

man in the Managara and the will entry section of the

							gcg Ala										432
							gtg Val										480
							gcg Ala										528
							ggc Gly		Trp							•	576
							acg Thr 200										624
							ttg Leu										672
							gcc Ala										720
			_	_	-		tac Tyr										768
							ttc Phe										816
							gca Ala 280										864
							aga Arg										912
							cag Gln								a		958
tag <210)> 44	1															961
<212	l> 31 2> PF 3> He	RT	itis	C vi	irus									,			
<400)> 44	1															
Met 1	Val	Gly	Asn	Trp 5	Ala	Lys	Val	Leu	Val 10	Val	Met	Leu	Leu	Phe 15	Ala		

Gly	Val	Asp	G1y 20	His	Thr	Arg	Val	Ser 25	Gly	Gly	Ala	Ala	30	Ser	Asp
Thr	Arg	Gly 35	Leu	Val	Ser	Leu	Phe 40	Ser	Pro	СĴУ	Ser	Ala 45	Gln	Lys	Ile

Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu

. 55

- Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr 65 70 75 80
- Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys 85 90 95
- Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr 100 105 110
- Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro 115 120 125
- Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr 130 140
- Cys Phe Thr Pro Ser Pro Val Val Gly Thr Thr Asp Arg Phe Gly 145 150 155 160
- Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu 165 170 175
- Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met 180 185 190
- Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile 195 200 205
- Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg 210 215 220
- Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu 225 230 235 240
- Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro 255 255
- Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly 260 265 270
- Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg 275 280 285
- Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu 290 295 300
- Ser Thr Thr Gly Asp Arg Gly Gln Thr Pro Ser Pro Pro Ser Leu 305 310 315

	<211> 1 <212> D <213> H	DNA	itis C	virus																
·	<220> <221> C <222> 1		∋ 2																	
	<220> <221> m <222> 1 <400> 4	1138			. ,		٠.						er .							
	atg gtg Met Val 1	l Ala		la His					Ala					Tyr		48				
Mariana di Salaharan da Salahar	tcc atg Ser Met												Leu			96			20 - S	
	gcc ggc Ala Gly															144			* * * * * * * * * * * * * * * * * * *	
	gat acc Asp Thr 50	r Arg									Ser					192				
	atc cag Ile Gln 65				Asn											240				
	ctg aac Leu Asn		Asn As						Phe					Phe		288				
	tac aaa Tyr Lys	s His				Ser		Cys					Ala			336				
and the second s	tgt cgc Cys Arg	c tcc g Ser 115	atc ga Ile A	ıc aag sp Lys	Phe	gct Ala 120	cag Gln	ggg	tgg Trp	Gly	ccc Pro 125	ctc Leu	act Thr	tac Tyr	, e = , e = =	384	e et voor e	N. et a	Salah Salah Salah Salah Salah Salah Salah Salah Salah	
ere spread of the	act gag Thr Glu 130	u Pro							Tyr						-	432	. %			
	cct cga Pro Arg 145				Val :											480				
	tat tgc Tyr Cys		Thr Pr				Val					Asp		Phe		528				
	ggt gtc Gly Val	l Pro'				Gly					Asp					576				
	ctc aac	; aac	acg cç	ld ccd	ccg	cga	ggc	aac	tgg	ttc	ggc	tgt	aca	tgg		624				

PCT/EP02/14480 WO 03/051912

	Leu	Asn	Asn 195	Thr	Arg	Pro	Pro	Arg 200	Gly	Asn	Trp	Phe	Gly 205	Cys	Thr	Trp					
			ggc Gly															672			
			ggg Gly															720	· .		
	cġg Arg	aag Lys	His	ccc Pro	Glu	gcc Ala	acc Thr	tac Tyr	gcc Ala	aga Arg 250	Cys	ggt Gly	tct Ser	GJ À âââ	ccc Pro 255	tgg Trp		768			
A second against the second of																tac Tyr		816			
execusive of the																ggg Gly		864	,		
			gag Glu															912			
			gac Asp															960			
			aca Thr															1008			
			cta Leu															1056			
Here is a second of the second	Val		Tyr 355		Tyr		Val		Ser	Ala	Val		Ser 365		Val	atc Ile		1104	e de la companya de La companya de la co	en e	10 (10 (10 (10 (10 (10 (10 (10 (10 (10 (
e de la companya de La companya de la companya de l			gag Glu														·	1152	· · · · · · · · · · · · · · · · · · ·		*
			gcc Ala															1200			
<i>;</i>			gag Glu															1248			
			act Thr															1296			
			agg Arg															1344			

435 440 445

ccg ctg ctc ctg ctt ctg ctg gcc tta cca cca cga gct tat gcc tagtaa 1395
Pro Leu Leu Leu Leu Leu Ala Leu Pro Pro Arg Ala Tyr Ala
450 455 460

<210> 46

<211> 463

<212> PRT

<213> Hepatitis C virus

at a contract of the property of the same and the same and

<400> 46

Met Val Ala Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr $1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15$

Ser Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe
20
25
30
Ala Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser

Ala Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser 35 40 45

Asp Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys
50 55 60

Ile Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala 65 70 75 80

Leu Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe
85 90 95

Tyr Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser 100 105 110

Cys Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr 115 120 125

Thr Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala 130 135 140

Pro Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val
145 150 155 160

Tyr Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe 165 170 175

Gly Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile 180 185 1-90

Leu Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp
195 200 205

Met Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn 210 215 220

Ile Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe 225 230 235 240

Arg Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp
245 250 255

					ccg Pro												96	
					gtc Val 5												48	
	<222	l> ma	20	eptio 76	de													
	<221	l> Ci	DS 20				•						. •			·		
The state of the s	<212 <213	2> Dì 3> Hè	082 NA epat				erite recues		oria segu	inger a nga katana n	*** ***********	te s Etgeske svægski	an dis Surso proc		. •		en e	
		450)> 4	7				455	Lance			- 4 40 5	460		િ <i>ાત્ર ક</i> ે ની		S. Agazaño (1812)		
	Pro		Leu		Leu	Leu	Leu			Pro	Pro	Arg		Tyr	Ala			
	Lys	Gly	Arg 435	Leu	Val	Pro	Gly	Ala 440	Ala		Ala	Phe	Tyr 445		Val	Trp		
	His	Gly	Thr	Leu 420	Ser	Phe	Leu	Val	Phe 425		Cys	Ala	Ala	Trp 430	Tyr	Ile		
	Ala	Leu	Glu	Asn	Leu 405	Val	Val	Leu	Asn	Ala 410	Ala	Ala	Val	Ala	Gly 415	Ala		
	Ile 385	Суз	Ala	Cys	Leu	Trp 390	Met	Met	Leu	Leu	Ile 395	Ala	Gln	Ala	Glu	Ala 400		
	Lys	Trp 370		Tyr	Val	Leu	Leu 375		Phe	Leu	Leu	Leu 380	Ala	Asp	Ala	Arg	* we	
	Val	Gln	Tyr 355		Tyr	Gly		Gly 360		Ala	Val	Val	Ser 365	Leu	Val	Ile	en e	
		Ala	Leu	Ser 340		Glŷ	Leu							Ile 350		Asp		
	Leu	Ser	Thr	Thr	Glu 325		Gln	Ile	Leu	Pro 330	Cys	Ser	Phe	Thr	Thr 335	Leu		
	305				Glu	310					Glu 315	Leu	Ser	Pro	Leu	Leu 320		
	Gly	Val 290		His	Arg	Phe	Glu 295		Ala	Cys	Asn	Trp 300	Thr	Arg	Gly	Glu	•	
	Pro	Cys	Thr 275	Val	Asn	Phe	Thr	Ile 280		Lys	Val	Arg	Met 285	Tyr	Val	Gly		
	Leu	Thr	Pro	Arg 260	Cys	Met	Val	His	Tyr 265		Tyr	Arg	Leu	Trp 270	His	Tyr		

ends where the real special control of the e

									ctg Leu								14	4			
									ttc Phe								19	2			
the second		Ser	Cys	Leu	Thr	Val	Pro	Ala	tcc Ser	Ala	Tyr						24	0			
•		Gly	Met	Tyr	His		Thr	Asn	gac Asp		Ser			Ser			28	8			-
	tat Tyr	gag Glu	gca Ala	gcg Ala 100	gac Asp	atg Met	atc Ile	atg Met	cac His 105	acc Thr	ccc Pro	ggg Gly	tgc Cys	gtg Val 110	Pro	tgc Cys	33	6			
er v a									tgc Cys							acg Thr	38	4	-		. \$
									ccc Pro								43	2			
									gct Ala								48	0			
									ctc Leu								52	8			
	tcg Ser	cct Pro	cgc Arg	cgg Arg 180	cat His	gag Glu	acg Thr	Val	cag Gln 185	gac Asp	tgc Cys	aat Asn	tgc Cys	tca Ser 190	atc Ile	tat Tyr	57	6	•		
Alaborat Santonia (1997) Santonia (1997) Santonia (1997)	Pro	ggc Gly	cac His 195	ata Ile	acg Thr	ggt Gly	cac His	cgt Arg 200	atg Met	gct Ala	tgg Trp	gat Asp	atg Met 205	atg Met	atg Met	aac Asn	62	4	ingr.	* * *	 43
Marian San San San San San San San San San S	tgg Trp	tcg Ser 210	cct	aca Thr	acg Thr	gcc Ala	ctg Leu 215	gtg Val	gta Val	tcg Ser	cag Gln	ctg Leu 220	ctc Leu	cgg Arg	atc	cca Pro	67	2			
									ggg Gly								72	0 '			
									ggg Gly			-	-	-	-	-	76	8			
									gac Asp 265								81	6			
	ggg	gca	gca	gcc	tcc	gat	acc	agg	ggc	ctt	gtg	tcc	ctc	ttt	agc	ccc	86	4			

	Gly	Ala	Ala 275	Ala	Ser	Asp	Thr	Arg 280	Gly	Leu	Val	Ser	Leu 285	Phe	Ser	Pro						
													ggc Gly					912				
													caa Gln					960				
er e						Tyr							tct Ser					1008				
	gag Glu	cgc Arg	ttg Leu	gcc Ala 340	Ser	tgt Cys	cgc Arg	tcc Ser	atc Ile 345	gac Asp	aag Lys	ttc Phe	gct Ala	cag Gln 350	Gly	tgg Trp		1056				.2++
en e													cag Gln 365					1104			٠.	
													ccc Pro					1152				
	Val 385	Cys	Gly	Pro	Val	Tyr 390	Cys	Phe	Thr	Pro	Ser 395	Pro	gtt Val	Val	Val	Gly 400		1200				
													Gly					1248				
													cga Arg					1296				
er og star e <mark>n sægendererer</mark> er er er Der ærte sinne er er er er er er	Phe	Gly	Cys 435	Thr	Trp	Met	Asn	Gly 440	Thr	Gly	Phe	Thr	445	Thr	Cys	Gly		1344	e e e e e e e e e e e e e e e e e e e	*** * * * * * * * * * * * * * * * * *	ga ga Saar A	्र दुव्य - एक्ट
 Ald Eq. (1) or extract probability for the control of the control of													acc Thr			tgc Cys	(S. W.	1392	, ,,,, ,,,	* * *	Saraj Saraj Saraj	
													tac Tyr					1440				
·													cat His					1488				
													atc Ile					1536				
													gcc Ala 525					1584				

		Thr												aga Arg				1632			
	ctt Leu 545	530 agc Ser	ccg Pro	ctg Leu	ctg Leu	ctg Leu 550	535 tct Ser	aca Thr	aca Thr	gag Glu	tgg Trp 555	540 cag Gln	ata Ile	ctg Leu	ccc Pro	tgt Cys 560		1680			
ere e e e e e e e e e e e e e e e e e e	tcc					ccg					ggc Gly			cac His		cat His	÷	1728	•		
														tcg Ser 590				1776			
i periodi														ttc Phe				1824			
														ctg Leu				1872			
														aat Asn			•	1920			
														ttc Phe				1968			
														gca Ala 670				2016			
رمدورا والمراجع والمر														tta Leu				2064	، يُفتِدِ	, f •1	- 107 - 107
	Arg	Ala 690	tat Tyr 8	Ala	tag	taa			era e		gas to the state of the state o		e e e e e e e e e e e e e e e e e e e	*/				2082	z i i i i		
	<212	1> 69 2> P1 3> He		itis	C v	irus						•			-						
	<400	0> 41	8 .																		
	Asn 1	Leu	Gly	Lys	Val 5	Ile	Asp	Thr	Leu	Thr 10	Cys	Gly	Phe	Ala	Asp 15	Leu					
	Val	Gly	Tyr	Ile 20	Pro	Leu	Val -	Gly	Ala 25	Pro	Leu	Gly	Gly	Ala 30	Ala	Arg					
	Ala	Leu	Ala 35	His	Gly	Val	Arg	Val 40	Leu	Glu	Asp	Gly	Val 45	Asn	Tyr	Ala					

	Thr	Gly 50	Asn	Leu	Pro	Gly	Cys 55	Ser	Phe	Ser	Ile	Phe 60	Leu	Leu	Ala	Leu							
	Leu 65	Ser	Cys	Leu	Thr	Val 70	Pro	Ala	Ser	Ala	Tyr 75	Glu	Val	Arg	Asn	Val 80							
	Ser	Glÿ	Met	Tyr	His 85	Val	Thr	Asn	Asp	Cys 90	Ser	Asn	Ser	Ser	Ile 95	Val							
A STATE OF THE STA	ŢŅr	Glu	Ala	Ala 100	Asp	Met	Ile	Met	His 105		Pro	Gly	Суs	Val 110	٠.,	CÀa		٠					•
en e	Vál	Arġ					Ser		Cys	Trp	Val	Ala	Leu 125	Thr	Pro	Thr							
ng digital and a second a second and a second a second and a second a second and a second and a second and a	Leu	Ala 130	Ala	Arg	Asn	Ala	Ser 135	Val	Pro	Thr	Thr	Thr 140		Arg	Arg	His							
en e	Val 145		Leu	Leu		Gly 150		Ala	Ala	Phe	Cys 155	Ser	Äla	Met	Tyr	Val 160		•		۰.	.* .	,	:
	Gly	Asp	Leu	Cys	Gly 165	Ser	Val	Phe	Leu	Val 170	Ser	Gln	Leu	Phe	Thr 175	Ile							
	Ser	Pro	Arg	Arg 180	His	Glu	Thr	Val	Gln 185	Asp	Суѕ	Àsn	Cys	Ser 190	Ile	Tyr							
	Pro	Gly	His 195	Ile	Thr	Gly	His	Arg 200	Met	Ala	Trp	Asp	Met 205	Met	Met	Asn							
	Trp	Ser 210	Pro	Thr	Thr	Ala	Leu 215	Val	Val	Ser	Gln	Leu 220	Leu	Arg	Ile	Pro							
	Gln 225	Ala	Val	Val	Asp	Met 230	Val	Ala	Gly	Ala	His 235	Trp	Gly	Val	Leu	Ala 240							
•	Gly	Leu	Ala	Tyr	Tyr 245	Ser	Met	Val	Gly	Asn 250		Ala	Lys	Val	Leu 255		•						
interpretation of the second o				260					265					270		Gly	 . des. y	 		Tugse 5			Autoritation of the
ing the second of the second o									Gly				285	FILE		FIO			. 7				
	Gly		Ala						Val			Asn 300	Gly	Ser	Trp	His							•
٠.	Ile 305	Asn	Arg	Thr	Ala	Leu 310	Asn	Cys	Asn	Asp	Ser 315	Leu	Gln	Thr	Gly	Phe 320							
	Phe	Ala	Ala	Leu	Phe 325	Tyr	Lys	His	Lys	Phe 330	Asn	Ser	Ser	Gly	Cys 335	Pro							
	Glu	Arg	Leu	Ala 340	Ser	Суѕ	Arg	Ser	Ile 345	Asp	Lys	Phe	Ala	Gln 350	Gly	Trp							
-	Gly	Pro	Leu 355	Thr	Tyr	Thr	Glu	Pro 360	Asn	Ser	Ser	Asp	Gln 365	Arg	Pro	Tyr		٠					
	Cys	Trp	His	Tyr	Ala	Pro	Arg	Pro	Cys	Gly	Ile	Val	Pro	Ala	Ser	Gln							

370 375 380 Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val Val Val Gly 395 Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp 425 Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly 435 440 Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys 455 Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr Ala Arg Cys 470 480 Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val "His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Ser Thr Thr Glu Trp Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly Val Gly Ser Ala Val 585 And the state of t Val Ser Leu Val Ile Lys Trp Glu Tyr Val Leu Leu Phe Leu Leu 595 Amore and the fire particles of the fire and a second of the fire and No. 1 Carlo Leu Ala Asp Ala Arg IIe Cys Ala Cys Leu Trp Met Met Leu Ile 615 620 Ala Gln Ala Glu Ala Ala Leu Glu Asn Leu Val Val Leu Asn Ala Ala 625 630 635 Ala Val Ala Gly Ala His Gly Thr Leu Ser Phe Leu Val Phe Phe Cys 645 650 Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val Pro Gly Ala Ala Tyr Ala 660 665 Phe Tyr Gly Val Trp Pro Leu Leu Leu Leu Leu Leu Ala Leu Pro Pro 675 680

> Arg Ala Tyr Ala 690

	<210)> 49	Ð															
	<212	l> 24 2> Di 3> He	ΙA	itis	C v	irus												
. :		> CI	os 24.	3.0		e e e e e e e e e e e e e e e e e e e	}.	• •	· .				*:					
	<222	L> ma	242	eptio 27	de				·.					•			-	
										aaa Lys 10							٠.	48
										ggc Gly								96
										ccc Pro								144
										cct Pro								192
										agg Arg								240
		Pro		Pro	Leu	Tyr	Gly	Asn	Glu	ggc Gly 90	Met	Gly		Ala				288
		Leu	Ser		Arg	Gly	Ser	Arg	Pro 105	agt Ser	Trp	Gly		Thr 110	Asp			336
				-					_	gtc Val		_				_		384
										ccg Pro								432
										ggc Gly								480
										ccc Pro 170								528
	ttc	ctc	ttg	gct	ttg	ctg	tcc	tgt	ctg	acc	gtt	сса	gct	tcc	gct	tat		576

	Phe	Leu	Leu	Ala 180		Leu	Ser	Cys	Leu 185		Val	Pro	Ala	Ser 190		Tyr					
		Val		Asn		tcc Ser	Gly		Tyr					Asp			624				
			Ser	Ile	Val	•	Glu 215	Ala	Ala	Asp	Met		Met				672			·	
		Cys	gtg	CCC	tgc	gtt Val 230	cgg Arg	gag		aac	tct	Ser					720		••••	•	
		Ļeu		Pro	Thr	ctc Leu					Ala					Thr	768				
					His	gtc Val				Val					Phe		816		* * * * * * * * * * * * * * * * * * *		
				Tyr		ggg Gly			Cys					Leu			864				
			Phe			tcg Ser		Arg					Val				912				
		Cys				ccc Pro 310	Gly					His					960				
·						tgg Trp					Ala					Gln	1008	·			
e de la companya de l	Leu	Leu	Arg	Ile 340	Pro	Gln	.Ala,	, Val	Val 345	Asp	Met,	yal	Ala	Gly 350	Ala	His		er sare ca			14
i en franke i kalendar i kalendar Maria kalendar i kalend Kalendar i kalendar i	tgg		gtc	Leu	gçg	ggc	ctc	gcc	tac Tyr	: tat	tçç	atg Met		"ggg. Gly			1104			· · · · · · · · · · · · · · · · · · ·	
			Val			gtg Val		Leu					Val				1152				
,		Arg				390 390	Ala					Thr					1200				
					Pro	Gly					Ile					Thr	1248				
						atc Ile											1296				

v				420					425					430				
							_	_	cta Leu									1344
									gcc Ala									1392
									act Thr									1440
									tac Tyr									1488
									cca Pro 505								•	1536
		-				_		_	cgg Arg			-		_				1584
									ctg Leu									1632
									aca Thr									1680
									tgc Cys									1728
ingenye fiyasa oleh Miliyasi ilaksisha ili ili Mili kani ili oleh ili ili ili ili ili ili ili ili ili il					-				tgt Cys 585			-				-		1776
engin kalan sakar Salah Salah kalan kalan salah	acc Thr			aga Arg					ccc Pro						tgt Cys	atg Met	•	1824
									cac His								:	1872
•									gtg Val								:	1920
				-				_	gga Gly		_	_	-	_		-		1968
			-				_	_	ctg Leu 665	_	_						:	2016

												acc Thr		2064
												tac Tyr		2112
				Val								gtc Val		2160
			Leu									tta Leu 735		2208
												ctg Leu		2256
												tcc Ser		2304
				-	-	-			_		 _	gtc Val		2352
												ctt Leu		2400
Leu	Ala	Leu			_	gct Ala	gcc Ala	tagt	aa					2433
<21	D> 5(L> 8(2> PI	09												
<21.		epāt:	• •	C v:			 anan area Caranas	•		a. 3e			egis week with the second of the second with the second of	* •
	0> 50		urin. ur		**					: 40			en e	

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro

Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly 65 70 75 80

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Met Gly Trp Ala Gly Trp

85 90 95

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys
115
120
125

Gly Phe Ala Asp Leu Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 180 185 190

Glu Val Arg Asn Val Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser 195 200 205

Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro 210 215 220

Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val 225 230 235 240

Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr 245 250 255

Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys 260 265 270

Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 275 280 285

Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys 290 · 295 300

Asn Cys Ser Ile Tŷr Pro Glŷ His Ile Thr Glŷ His Arg Met Ala Trp 305 310 315

Asp Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 325 330 335

Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His 340 345 350

Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 355 360 365

Ala Lys Val Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly His 370 375 380

Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu Val 385 390 395 400

Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr 405 410 415

	Asn	Gly	Ser	Trp 420	_	Ile	Asn	Arg	Thr 425	Ala	Leu	Asn	Cys	Asn 430	_	Ser		
	Leu	Gln	Thr 435	Gly	Phe	Phe	Ala	Ala 440	Leu	Phe	Tyr	Lys	His 445	Lys	Phe	Asn		
	Ser	Ser 450	Gly	Cys	Pro	Glu	Arg 455	Leu	Ala	Ser	Cys	Arg 460	Ser	Ile	Asp	Lys		
	Phe 465	Ala	Gln	Gly	Trp	Gly 470		Leu		Tyr	Thr 475	Glu	Pro	Asn	Ser	Ser 480	· ·	
e e e	Asp	Gln	Arg	Pro	Tyr 485	Cys	Trp	His	Tyr	Ala 490		Arg	Pro	Cys	Gly 495	Ile		
and the second second	Val	Pro	Ala	Ser 500		Val	Cys	Gly	Pro 505	Val	Tyr	Cys	Phe	Thr 510		Ser		
	Pro	Val	Val 515	Val	Gly	Thr	Thr	Asp 520	Arg	Phe	Gly	Val	Pro 525	Thr	Tyr	Asn		-
	Trp	Gly 530	Ala	Asn	Asp	Ser	Asp 535	Val	Leu	Ile	Leu	Asn 540	Asn	Thr	Arg	Pro		
	Pro 545	Arg	Gly	Asn	Trp	Phe 550	Gly	Cys	Thr	Trp	Met 555	Asn	Gly	Thr	Gly	Phe 560		
	Thr	Lys	Thr	Cys	Gly 565	Gly	Pro	Pro	Cys	Asn 570	Ile	Gly	Gly	Ala	Gly 575	Asn		
	Asn	Thr	Leu	Thr 580	Cys	Pro	Thr	Asp	Cys 585	Phe	Arg	Lys	His	Pro 590	Glu	Ala		
	Thr	Tyr	Ala 595	Arg	Cys	Gly	Ser	Gly 600	Pro	Trp	Leu	Thr	Pro 605	Arg	Cys	Met		
	Val	His 610	Tyr	Pro	Tyr	Arg	Leu 615	Trp	His	Tyr	Pro	Cys 620	Thr	Val	Asn	Phe		
i di kadi i 1929 ni ndi interesi ni ndi kaling ing ni ngangganggan saka	Thr 625	Ile	Phe	Lys	Val	Arg 630	Met	Tyr	Val	Gly	Gly 635	Val	Glu	His	Arg	Phe 640		vers.
grave per en	Glü	Ala	Ala	Cys	Asn 645	Trp		Arg	Gly	G1u 650	Arg	Cys	Asp	Leu	655	Asp	en e	· .
	Arg	Asp	Arg	Ser 660	Glu	Leu	Ser	Pro	Leu 665		Leu	Ser	Thr	Thr 670	Glu	Trp		
	Gln	Ile	Leu 675	Pro	Cys	Ser	Phe	Thr 680	Thr	Leü	Pro	Ala	Leu 685	Ser	Thr	Gly		
	Leu	Ile 690	His	Leu	His	Gln	Asn 695	Ile	Val	Asp	Val	Gln 700	Tyr	Leu	Tyr	Gly		
	Val 705	Gly	Ser	Ala	Val	Val 710	Ser	Leu	Val	Ile	Lys 715	Trp	Glu	Tyr	Val	Leu 720		
-	Leu	Leu	Phe	Leu	Leu 725	Leu	Ala	Asp	Ala	Arg 730	Ile	Cys	Ala	Cys	Leu 735	Trp		
	Met	Met	Leu	Leu	Ile	Ala	Gln	Ala	Glu	Ala	Ala	Leu	Glu	Asn	Leu	Val		

> 745 740 750

Val Leu Asn Ala Ala Ala Val Ala Gly Ala His Gly Thr Leu Ser Phe

Leu Val Phe Phe Cys Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val Pro

Gly Ala Ala Tyr Ala Phe Tyr Gly Val Trp Pro Leu Leu Leu Leu 785 790 795

Leu Ala Leu Pro Pro Arg Ala Tyr Ala 805

<210> 51 ...

<211> 17

<212> PRT <213> Hepatitis C virus

<220>

<221> Modified-site

<222> 1..17

<400> 51

Ser Asn Ser Ser Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys 10 5

Val

<210> 52

<211> 22

<212> PRT

<213> Hepatitis C virus

<220>

<221> Modified-site

<222> 1..22

<400> 52 Gly Gly Ile Thr Gly His Arg Met Ala Trp Asp Met Met Asn Trp 15

. Programme and the second control of the se Ser Pro Thr Thr Ala Leu 20

<210> 53

<211> 37

<212> PRT

<213> Hepatitis C virus

<221> Modified-site

<222> 1..37

<400> 53

Tyr Glu Val Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys

Ser Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr 25 Pro Gly Cys Gly Lys 35 <210> 54 <211> 25 <212> PRT <213> Hepatitis C virus <221> Modified-site <222> 1..25 <400> 54 Gly Gly Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Ala Thr 10 15 Gln Leu Arg Arg His Ile Asp Leu Leu <210> 55 <211> 25 <212> PRT <213> Hepatitis C virus <220> <221> Modified-site <222> 1..25 <400> 55 Gly Gly Thr Pro Thr Leu Ala Ala Arg Asp Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Leu Leu 20 и больши падамы не часть с намары стане станую польтый с десе десь достанования и было с с والمراويين والمراوي والمراوي والمراوية والمستعورة والمراوية والمراوية والمراوية والمراوية والمعك فيتناوها والم >211 20 1<212> PRT 1 <211> 20 <213> Hepatitis C virus <400> 56 Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Gln Val Arg Asn 10 Ser Thr Gly Leu 20 <210> 57

<211> 20 <212> PRT

```
<400> 57
    Gln Val Arg Asn Ser Thr Gly Leu Tyr His Val Thr Asn Asp Cys Pro
                                 10
    Asn Ser Ser Ile
              20
<210> 58
<211> 20
<212> PRT
<213> Hepatitis C virus
<400> 58
    Asn Asp Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala His Asp Ala Ile
            5 10 15
    Leu His Thr Pro
              20
<210> 59
<211> 20
<212> PRT
<213> Hepatitis C virus
<400> 59
     Ser Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr
  Pro Gly Cys Val
           20
<211> 19
<212> PRT
<213> Hepatitis C virus
<400> 60
    His Asp Ala Ile Leu His Thr Pro Gly Val Pro Cys Val Arg Glu Gly
    Asn Val Ser
```

<210> 61

<211> 20

<212> PRT

```
<400> 61
                              Cys Val Arg Glu Gly Asn Val Ser Arg Cys Trp Val Ala Met Thr Pro
                                                                                                                                                                                                                                                            10
                              Thr Val Ala Thr
                                                                                                       20
<211> 20
<212> PRT
<213> Hepatitis C virus
 <400> 62
                             Ala Met Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Ala Thr
                              Gln Leu Arg Arg
                                                                                                         20
<210> 63
<211> 20
<212> PRT
<213> Hepatitis C virus
<400> 63
                              Leu Pro Ala Thr Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser
Ala Thr Leu Cys
  A THE SECTION OF THE 
, and the control of the compagnetic of the control of the control
<210> 64
<211> 20
<212> PRT
<213> Hepatitis C virus
<400> 64
                              Leu Val Gly Ser Ala Thr Leu Cys Ser Ala Leu Tyr Val Gly Asp Leu
                              Cys Gly Ser Val
                                                                                                         20
<210> 65
```

<211> 20

```
<212> PRT
<213> Hepatitis C virus
```

<400> 65

Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Gly Cys
1 10 15

Asn Cys Ser Ile

<210> 66

<211> 20

<212> PRT

<213> Hepatitis C virus

<400> 66

Thr Gln Gly Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His 1 5 10 15

Arg Met Ala Trp 20

<210> 67

<211> 20

<212> PRT

<213> Hepatitis C virus

<400> 67

Thr Ala Ala Leu

20

<210> 68

<211> 20

<212> PRT

<213> Hepatitis C virus

<400> 68

Asn Trp Ser Pro Thr Ala Ala Leu Val Met Ala Gin Leu Leu Arg Ile 1 5 10 15

Pro Gln Ala Ile

<210> 69

```
<211> 20
      <212> PRT
      <213> Hepatitis C virus
      <400> 69
           Leu Leu Arg Ile Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His
           Trp Gly Val Leu
      <211> 20
      <212> PRT
      <213> Hepatitis C virus
      <400> 70
           Ala Gly Ala His Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met
                                             10
           Val Gly Asn Met
      <210> 71
      <211> 20
      <212> PRT
      <213> Hepatitis C virus
Val Val Leu Leu Phe Ala Gly Val Asp Ala Glu Thr Ile Val Ser
1 5 10 15
    Gly Gly Gln Ala
                       20
      <210> 72
      <211> 20
      <212> PRT
      <213> Hepatitis C virus
      <400> 72
           Ser Gly Leu Val Ser-Leu Phe Thr Pro Gly Ala Lys Gln Asn Ile Gln
                                              10
```

Leu Ile Asn Thr

20

<210> 73 <211> 20 <212> PRT <213> Hepatitis C virus <400> 73 Gln Asn Ile Gln Leu Ile Asn Thr Asn Gly Gln Trp His Ile Asn Ser Thr Ala Leu Asn <211> 21 <212> PRT <213> Hepatitis C virus <400> 74 Leu Asn Cys Asn Glu Ser Leu Asn Thr Gly Trp Trp Leu Ala Gly Leu 10 Ile Tyr Gln His Lys 20 <210> 75 <211> 20 <212> PRT <213> Hepatitis C virus and the contraction of the contr <400>75 Ala Gly Leu Ile Tyr Gln His Lys Phe Asn Ser Ser Gly Cys Pro Glu
1 5 10 15 Arg Leu Ala Ser <210> 76 <211> 20 <212> PRT <213> Hepatitis C virus

Gin Gly Trp Gly 20

<210> 77

<211> 20

<212> PRT <213> Hepatitis C virus

<400> 77

Thr Asp Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser 1 5 10 15

Gly Pro Asp Gln 20

<210> 78

<211> 20

<212> PRT

<213> Hepatitis C virus

<400> 78

Ala Asn Gly Ser Gly Pro Asp Gln Arg Pro Tyr Cys Trp His Tyr Pro 1 $$ 5 $$ 10 $$ 15

Pro Lys Pro Cys

<210> 79

<211> 20

<212> PRT

<213> Hepatitis C Virus

<400> 79

Trp His Tyr Pro Pro Lys Pro Cys Gly Ile Val Pro Ala Lys Ser Val 1 5 10 15

Control of the Control of the Section of the Association of the Control of the Co

and the second state of the contract of

Cys Gly Pro Val

<210> 80

<211> 20

<212> PRT

<213> Hepatitis C virus

<400> 80

PCT/EP02/14480

WO 03/051912 Ala Lys Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr 20 <210> 81 <211> 20 <212> PRT <213> Hepatitis C virus <400> 81 Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Ser Gly Ala Pro Thr 1 5 10 15 Tyr Ser Trp Gly <210> 82 <211> 20 <212> PRT <213> Hepatitis C virus <400> 82 Gly Ala Pro Thr Tyr Ser Trp Gly Glu Asn Asp Thr Asp Val Phe Val Leu Asn Asn Thr 20 <210> 83 <212> PRT <213> Hepatitis C virus <400> 83 Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe Thr Lys Val Cys Gly Ala

<210> 84

<211> 20

<212> PRT

```
<400> 84
```

Gly Phe Thr Lys Val Cys Gly Ala Pro Pro Val Cys Ile Gly Gly Ala 10

Gly Asn Asn Thr 20

<210> 85

<211> 19

<212> PRT

<213> Hepatitis C virus

<400> 85

Ile Gly Gly Ala Gly Asn Asn Thr Leu His Cys Pro Thr Asp Cys Arg
1 10 15

Lys His Pro

<210> 86

<211> 20

<212> PRT

<213> Hepatitis C virus

<400> 86

Thr Asp Cys Phe Arg Lys His Pro Asp Ala Thr Tyr Ser Arg Cys Gly

Ser Gly Pro Trp

<213> Hepatitis C virus

<400> 87

Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Leu Val Asp

Tyr Pro Tyr Arg 20

<210> 88

<211> 20

<212> PRT

<400> 88

Asn Tyr Thr Ile 20

<210> 89

<211> 20

<212> PRT

<213> Hepatitis C virus

<400> 89

Pro Cys Thr Ile Asn Tyr Thr Ile Phe Lys Ile Arg Met Tyr Val Gly
1 5 10 15

Gly Val Glu His

.<210> 90

<211> 20

<212> PRT

<213> Hepatitis C virus

<400> 90

Met Tyr Val Gly Gly Val Glu His Arg Leu Glu Ala Ala Cys Asn Trp 1 $$ 5 $$ 10 $$ 15

The second respectively and the second respectively. When the second respectively is the second respectively as the second respectively.

Thr Pro Gly Glu 20

<210>`91

<211> 20

<212> PRT

<213> Hepatitis C virus

<400> 91

Ala Cys Asn Trp Thr Pro Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp 1 5 10 15

Arg Ser Glu Leu

<210> 92

<211> 20

```
<212> PRT
<213> Hepatitis C virus
<400> 92
    Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Thr Thr Thr
                                      -10
    Gln Trp Gln Val
<210> 93
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> '93
    Tyr Gln Val Arg Asn Ser Thr Gly Leu
<210> 94
<211> 29
<212> DNA
<213> Hepatitis C virus
<400> 94
agctaattaa ttaagcttgc atgcctgca
                                                                  29
<210> 95
<211> 60
<212> DNA
<213> Hepatitis C virus
<400> 95
        Control Carrier & Control Control Control Control Control
gttaattaac tattagtgat ggtggtgatg gtgtctgccc tcgatcacgt gcaggcctcc
<210> 96
<211> 19
<212> DNA
<213> Hepatitis C virus
<400> 96
gtttaaccac tgcatgatg
                                                                    19
<210> 97
```

<211> 20

	· ·	
	<212> DNA <213> Hepatitis C virus	
	<400> 97	
	gtcccatcga gtgcggctac	. 20
	<210> 98	
	<211> 45 <212> DNA <213> Hepatitis C virus	
minute of the second	<400> 98	
Lar es	cgtgacatgg tacattccgg acacttggcg cacttcataa gcgga	45
	<210> 99	•
*****	<211> 42 <212> DNA <213> Hepatitis C virus	•
	<400> 99	
	tgcctcatac acaatggagc tctgggacga gtcgttcgtg ac	42
	<210> 100	
	<211> 42 <212> DNA <213> Hepatitis C virus	
	<400> 100	
	tacccagcag cgggagctct gttgctcccg aacgcagggc ac	42
and the second of the second o		
The section of the se	<211> 42 <212> DNA <213> Hepatitis C virus	
	<400> 101	
	tgtcgtggtg gggacggagg cctgcctagc tgcgagcgtg gg	42
	<210> 102	
	<211> 48 <212>	
	<400> 102	
	cqttatqtqq cccqqqtaqa ttqaqcactq qcaqtcctqc accqtctc	48

cgttatgtgg cccgggtaga ttgagcactg gcagtcctgc accgtctc

PCT/EP02/14480

WO 03/051912

	<210> 103			
	<211> 42			
•	<211> 42 <212> DNA			
	<213> Hepatitis C virus			
	<400> 103			
	cagggccgtt ctaggcctcc actgcatcat catatcccaa gc		42	٠.
•			•	
	<210> 104		•	
•	<211> 26			
	<212> DNA			
	<213> Hepatitis C virus			t estern
1				
	<400> 104	4	•	
	ccggaatgta ccatgtcacg aacgac		26	·
	<210> 105			
	<211> 24			
	<212> DNA			
	<213> Hepatitis C virus			
	<400> 105			
	gctccattgt gtatgaggca gcgg		24	
	2010\ 10C			
	<210> 106			
	<211> 23		-	
A Marie of Frankrick Com	<212> DNA <213> Hepatitis C virus	e seeks ke		and the second
The state of the s	• • •	Vite to 1		***
			• 4 •	
	<400> 106		•	
•	gagetecege tgetgggtag ege		23	
				•
	<210> 107			
	<211> 25			
	<212> DNA			
	<213> Hepatitis C virus			
	<400> 107			
	cctccgtccc caccacgaca atacg		25	
	<210> 108			

,	WO Q3/051912	PCT/EP02/14480
	<211> 27 <212> DNA <213> Hepatitis C virus	
	<400> 108	
	ctacccgggc cacataacgg gtcaccg	27
	<210> 109	
e e e gas como e	<211> 24 <212> DNA <213> Hepatitis C virus	
er e	<400> 109	
	ggaggcctac aacggccctg gtgg	24
	<210> 110	
	<211> 22 <212> DNA <213> Hepatitis C virus	
	<400> 110	
	ttctatcgat taaatagaat tc	22
	<210> 111	
The state of the s	<211> 23 <212> DNA <213> Hepatitis C virus	, w
And the second of the second o	and the control of th	
	gccatacgct cacagoogat occ	23
	<210> 112	
	<211> 20 <212> PRT <213> Hepatitis C virus	
	<400> 112	
	Tyr Glu Val Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys 1 5 10 15	s

Ser Asn Ser Ser 20 <210> 113

<211> 20 <212> PRT

<213> Hepatitis C virus

<400> 113

Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp 1 5 10 15

A STATE OF THE STA

Met Ile Met His Thr 20

<212> PRT

<213> Hepatitis C virus

<400> 114

Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val 1 5 . 10 15

Arg Glu Asn Asn Ser 20

<210> 115

<211> 20

<212> PRT

<213> Hepatitis C virus

<400> 115

Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu 1 5 10 15

Thr Pro Thr Leu Ala

<210> 116

and commended the in-

<211> 20

<212> PRT

<213> Hepatitis C virus

<400> 116

Val Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro 1 5 10 15

Thr Thr Thr Ile Arg

<210> 117

```
<211> 20
    <212> PRT
    <213> Hepatitis C virus
    <400> 117
    Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Leu Leu Val
 Gly Ala Ala Ala Phe
           20
    <211> 20
    <212> PRT
    <213> Hepatitis C virus
    <400> 118
    Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val Gly
    Asp Leu Cys Gly Ser
     <210> 119
    <211> 20
     <212> PRT
     <213> Hepatitis C virus
     <400> 119
     Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu
The Sel Pro Control of the Selection of 
    Phe Thr Ile Ser Pro
     <210> 120
    <211> 20
    <212> PRT
    <213> Hepatitis C virus
     <400> 120
    Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val Gln
                                                                                                                               10
    Asp Cys Asn Cys Ser
                                                             20
    <210> 121
    <211> 20
    <212> PRT
```

<213> Hepatitis C virus

<400> 121

Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr

Gly His Arg Met Ala

<210> 122

<211> 20

<212> PRT

<213> Hepatitis C virus

<400> 122

His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Asn Trp 1 5. 10 Ser Pro Thr Thr Ala 20

<210> 123

<211> 135 <212> PRT <213> hepatitis C virus

<400> 123

Tyr Glu Val Arg Asn Val Ser Gly Met Tyr His Val Thr Asn Asp Cys

Ser Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr 20 25

Pro Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp

Val Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr 50 55 60

Thr Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe 70

Cys Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val 90 85

Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val Gln Asp 100 110 105

Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala

115

120

125

Trp Asp Met Met Met Asn Trp
130 135